<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2457581-B1" country="EP" doc-number="2457581" kind="B1" date="20140108" family-id="43499204" file-reference-id="318283" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588383" ucid="EP-2457581-B1"><document-id><country>EP</country><doc-number>2457581</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-10802352-A" is-representative="YES"><document-id mxw-id="PAPP154850575" load-source="docdb" format="epo"><country>EP</country><doc-number>10802352</doc-number><kind>A</kind><date>20100723</date><lang>JA</lang></document-id><document-id mxw-id="PAPP196397369" load-source="docdb" format="original"><country>EP</country><doc-number>10802352.4</doc-number><date>20100723</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140547219" ucid="JP-2009172589-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2009172589</doc-number><kind>A</kind><date>20090723</date></document-id></priority-claim><priority-claim mxw-id="PPC140549259" ucid="JP-2010062459-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2010062459</doc-number><kind>W</kind><date>20100723</date></document-id></priority-claim><priority-claim mxw-id="PPC140549258" ucid="JP-2010134600-A" load-source="docdb"><document-id format="epo"><country>JP</country><doc-number>2010134600</doc-number><kind>A</kind><date>20100611</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130716</date></intention-to-grant-date><search-report-dispatch-date><date>20121114</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989325463" load-source="docdb">A61K   9/10        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325464" load-source="docdb">A61K   9/12        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325465" load-source="docdb">A61K   9/70        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325466" load-source="docdb">A61K  38/22        20060101AFI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325467" load-source="docdb">A61P  17/06        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325468" load-source="docdb">A61Q  17/04        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325469" load-source="docdb">A61Q  19/00        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325470" load-source="docdb">A61K   9/08        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325471" load-source="docdb">A61K   8/64        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325472" load-source="docdb">A61K   9/06        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325473" load-source="docdb">A61P  17/00        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325474" load-source="docdb">A61P  17/04        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325475" load-source="docdb">A61P  17/08        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325476" load-source="docdb">A61P  37/08        20060101ALI20121108BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325477" load-source="docdb">A61Q   1/00        20060101ALI20121108BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1898988222" load-source="docdb" scheme="CPC">A61Q  19/10        20130101 LI20160901BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1898988223" load-source="docdb" scheme="CPC">A61Q  17/04        20130101 LI20160901BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1898988224" load-source="docdb" scheme="CPC">A61Q   1/02        20130101 LI20160901BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1898988225" load-source="docdb" scheme="CPC">A61K  38/2242      20130101 FI20160906BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1898988226" load-source="docdb" scheme="CPC">A61K  38/22        20130101 LI20160906BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1976568297" load-source="docdb" scheme="CPC">A61Q  19/00        20130101 LI20160203BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1976571586" load-source="docdb" scheme="CPC">A61K   9/06        20130101 LI20160203BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1976579579" load-source="docdb" scheme="CPC">A61K   8/64        20130101 LI20160203BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1976580172" load-source="docdb" scheme="CPC">A61K   9/0014      20130101 LI20160203BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369782" lang="DE" load-source="patent-office">ZUSAMMENSETZUNG ENTHALTEND CNP ODER BNP FÜR EIN EXTERNES HAUTPRÄPARAT ZUR BEHANDLUNG VON DERMATITIS</invention-title><invention-title mxw-id="PT132369783" lang="EN" load-source="patent-office">COMPOSITION COMPRISING CNP OR BNP  FOR EXTERNAL PREPARATION FOR SKIN FOR THE TREATMENT OF DERMATITIS</invention-title><invention-title mxw-id="PT132369784" lang="FR" load-source="patent-office">COMPOSITION COMPRENANT DU CNP OU DU BNP DESTINÉE À UNE PRÉPARATION EXTERNE POUR LA PEAU POUR LE TRAITEMENT DE LA DERMATITE</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919541159" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>IGISU CO LTD</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919533599" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>IGISU CO., LTD.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919507846" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ENDO KYOKO</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919505050" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ENDO, KYOKO</last-name></addressbook></inventor><inventor mxw-id="PPAR919022868" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>ENDO, KYOKO</last-name><address><street>2-26, Kamisugi 6-chome, Aoba-ku,</street><city>Sendai-shi Miyagi 980-0011</city><country>JP</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022870" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Igisu Co., Ltd.</last-name><iid>101287370</iid><address><street>R3204, Tokyo Twinparks, 1-10-2, Higashishinbashi,</street><city>Minato-ku, Tokyo 1050004</city><country>JP</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022869" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Zech, Stefan Markus</last-name><iid>100755512</iid><address><street>Meissner, Bolte &amp; Partner GbR Postfach 86 06 24</street><city>81633 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="JP-2010062459-W"><document-id><country>JP</country><doc-number>2010062459</doc-number><kind>W</kind><date>20100723</date><lang>JA</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2011010732-A1"><document-id><country>WO</country><doc-number>2011010732</doc-number><kind>A1</kind><date>20110127</date><lang>JA</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549802312" load-source="docdb">AL</country><country mxw-id="DS549869567" load-source="docdb">AT</country><country mxw-id="DS549892345" load-source="docdb">BE</country><country mxw-id="DS549923761" load-source="docdb">BG</country><country mxw-id="DS549784422" load-source="docdb">CH</country><country mxw-id="DS549892346" load-source="docdb">CY</country><country mxw-id="DS549878563" load-source="docdb">CZ</country><country mxw-id="DS549802313" load-source="docdb">DE</country><country mxw-id="DS549892347" load-source="docdb">DK</country><country mxw-id="DS549892348" load-source="docdb">EE</country><country mxw-id="DS549784996" load-source="docdb">ES</country><country mxw-id="DS549923762" load-source="docdb">FI</country><country mxw-id="DS549923763" load-source="docdb">FR</country><country mxw-id="DS549802314" load-source="docdb">GB</country><country mxw-id="DS549892353" load-source="docdb">GR</country><country mxw-id="DS549802315" load-source="docdb">HR</country><country mxw-id="DS549878564" load-source="docdb">HU</country><country mxw-id="DS549784423" load-source="docdb">IE</country><country mxw-id="DS549892354" load-source="docdb">IS</country><country mxw-id="DS549923764" load-source="docdb">IT</country><country mxw-id="DS549892355" load-source="docdb">LI</country><country mxw-id="DS549923765" load-source="docdb">LT</country><country mxw-id="DS549869568" load-source="docdb">LU</country><country mxw-id="DS549923766" load-source="docdb">LV</country><country mxw-id="DS549923767" load-source="docdb">MC</country><country mxw-id="DS549869569" load-source="docdb">MK</country><country mxw-id="DS549869590" load-source="docdb">MT</country><country mxw-id="DS549869591" load-source="docdb">NL</country><country mxw-id="DS549784424" load-source="docdb">NO</country><country mxw-id="DS549869592" load-source="docdb">PL</country><country mxw-id="DS549785001" load-source="docdb">PT</country><country mxw-id="DS549873018" load-source="docdb">RO</country><country mxw-id="DS549869593" load-source="docdb">SE</country><country mxw-id="DS549802316" load-source="docdb">SI</country><country mxw-id="DS549784437" load-source="docdb">SK</country><country mxw-id="DS549784438" load-source="docdb">SM</country><country mxw-id="DS549892356" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63960806" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>[Field of Invention]</b></heading><p id="p0001" num="0001">The present invention relates to a skin external-preparation composition comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as its active ingredient. In particular, the present invention relates to a therapeutic agent for skin disease comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as its active ingredient.</p><heading id="h0002"><b>[Background Art]</b></heading><heading id="h0003"><b>1. Dermatitis:</b></heading><p id="p0002" num="0002">Dermatitis is an inflammatory reaction of the skin, and is the most prevalent skin disease. Often in acute skin inflammations, clinically, edematous erythema is presented initially, followed by erythematous lesions with papules and serous papules, then formation of vesicles, pustules, erosions, crusts and scales, followed by healing process. When a skin inflammation becomes chronic, thickened skin, lichenification and pigmentations are observed, and they are often associated with itching.</p><p id="p0003" num="0003">Dermatitis includes contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular eczema, psoriasis, stasis dermatitis, dyshidrotic eczema, asteatotic eczema, autosensitization eczema, etc.</p><p id="p0004" num="0004"><!-- EPO <DP n="2"> --> Of these, atopic dermatitis is induced by hypersensitive reaction to a foreign protein antigen, a substance derived from other organisms which exists as house dust in the environment, as well as the involvement of various other non-specific stimulatory responses and specific allergic reactions. It is characterized by pruritic eczema over wide areas of the body accompanied by dryness and abnormal barrier function of the skin, and many patients have atopic diathesis. Atopic dermatitis is an intractable, chronic inflammatory disease, which relapses between remission and exacerbation. It has been known that delayed reactions associated with infiltration of eosinophils and lymphocytes, and production of various cytokines at the site of inflammation are involved in the onset and chronicity of atopic dermatitis.</p><heading id="h0004"><b>2. Treatment of dermatitis:</b></heading><p id="p0005" num="0005">Current treatments for atopic dermatitis involve elimination of onset/exacerbation factors and skin care, in combination with pharmacotherapy appropriate for symptoms, while steroid external preparations are most commonly used for treating dermatitis. Recently, tacrolimus, an immunosuppressive drug, has also been used for treating atopic dermatitis.</p><p id="p0006" num="0006">Despite their dramatic clinical effectiveness, however, steroid external preparations are drugs that elicit numerous side effects. Steroid external preparations are not always satisfactory due to their side effects, including skin thinning, atrophy, so-called "moon face"<!-- EPO <DP n="3"> --> which results from fat deposition in the face, skin flush, hirsutism, and skin striae, etc. In particular, since affected areas in the face and neck have higher absorbability of drugs than other areas, when a steroid external preparation is applied to the face, etc., they are more susceptible to steroid dermatitis such as steroid-induced rosacea. Moreover, further application of steroid external preparations to control the redness of the skin in steroid dermatitis means that the patients suffer from a vicious cycle of continuous steroid use. This explains why many patients avoid application of steroid drugs to the face and neck. In addition to these adverse side effects and concerns with regard to the use of steroid external preparations, there are further complications with the use of steroid drugs on patients with fairly sensitive skin, including infants, children, women and the patients with concomitant diseases, with whom eczema and dermatitis are found frequently. In addition, the repeated and long-term use of steroid external preparations, which is necessary due to the chronic nature of inflammation in atopic dermatitis developed with a background of atopic diathesis, may result in steroid resistance, in which the steroid external preparations become less effective against dermatitis. Furthermore, patients who withdraw from long-term use of steroid external preparations often suffer from what is known as a "rebound phenomenon" characterized by aggressive recurrence of a worsened symptoms than prior to the treatment.</p><p id="p0007" num="0007"><!-- EPO <DP n="4"> --> Other concerns with long-term use of steroid external preparations are skin flush and desquamation of the skin over the whole body, which often occur with the comorbidity of hair loss and swollen lymph nodes. In such conditions of erythroderma posteczematosa, the patients' social lives are severely disrupted.</p><p id="p0008" num="0008">Generally, steroids used for treating atopic dermatitis are classified as the "strongest", "very strong", "strong", "medium" and "weak" in order of their efficacy, and the choice depends on factors such as the body region, severity of the rash, age and the period of use. For atopic dermatitis treatment using steroids, it is recommended that a steroid of a rank that is sufficiently strong to suppress the inflammatory symptoms of atopic dermatitis is prescribed initially, which is then replaced by progressively weaker ranks of steroids once the symptoms are controlled, allowing the earliest withdrawal from the steroid use.</p><p id="p0009" num="0009">The "strongest" rank steroids include: clobetasol propionate and diflorasone diacetate, and "very strong" steroids include mometasone furoate, betamethasone butyrate propionate, fluocinonide, betamethasone dipropionate, difluprednate, budesonide, amcinonide, diflucortolone valerate, and hydrocortisone butyrate propionate. In addition, the "strong" rank steroids includes: deprodone propionate, dexamethasone propionate, dexamethasone valerate, halcinonide, betamethasone valerate, beclomethasone propionate, fluocinolone acetonide, etc.; and "medium" rank steroids include: prednisolone valerate<!-- EPO <DP n="5"> --> acetate, triamcinolone acetonide, flumethasone pivalate, alclometasone propionate, clobetasone butyrate, and hydrocortisone butyrate. The "weak" rank steroids include: predonisolone and hydrocortisone acetate.</p><p id="p0010" num="0010">Patients with chronic atopic dermatitis due to repeated recurrence are often found to have a history of use of multiple steroids belonging to either the "strongest" or "very strong" rank.</p><p id="p0011" num="0011">On the other hand, the alternative external preparation available, i.e., tacrolimus, is an immunosuppressive agent, and hence it is not applicable to children with 6 years old of age or younger, women who are or may be pregnant, and patients with renal disorders. The application of tacrolimus also significantly increases the risk of complication of herpes virus infection. This is thought to be due to the effect of the disturbance in the barrier function of the skin suffering from dryness, combined with the steroid-induced depression in the local immune functions. More seriously, incidence of malignant tumors has been recently reported in infants and children, making the safety of tacrolimus questionable. In addition, some patients find some of the local strong irritative side effects including burning sensation and itching, which inevitably occur upon external application of tacrolimus, unbearable.</p><p id="p0012" num="0012">For the reasons above, a safe, effective, adverse effect-free therapeutic agent for dermatitis, which is not only applicable without irritation to affected areas of<!-- EPO <DP n="6"> --> higher absorbability of drugs with high density of hair follicles such as the face and the neck, but also safe to apply to patients having sensitive skins, such as females and children, is much hoped for.</p><heading id="h0005"><b>3. Natriuretic peptides:</b></heading><p id="p0013" num="0013">Natriuretic peptides (NPs) are classified into three known families, named atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP); their well-known members are composed of 28, 32, and 22 amino acid residues, respectively.</p><heading id="h0006">(1) ANP and BNP:</heading><p id="p0014" num="0014">ANP and BNP are synthesized mainly by the atria and the ventricles, respectively, and released from the heart into the whole body. It is thought that nearly 100% of the circulating ANP and BNP in the blood originate from the heart. These ANP and BNP are reported to be deeply involved in numerous diseases, including hypertension, cardiomegaly, cardiac failure, myocardial infarction, valvular heart disease, cardiac dysrhythmia, and pulmonary hypertension.</p><p id="p0015" num="0015">Human ANP is a peptide produced and released by atrial cardiocytes, and is composed of 28 amino acids, of which the 7<sup>th</sup> cysteine and the 23<sup>rd</sup> cysteine are bonded by a disulfide bond to form a ring structure. ANP has been shown to have diuretic effects in the kidneys and relaxes/dilates vascular smooth muscle cells in the blood vessels. In contrast, human BNP is a peptide produced and<!-- EPO <DP n="7"> --> released by ventricular cells, and is composed of 32 amino acids, of which the 10<sup>th</sup> cysteine and the 26<sup>th</sup> cysteine are bonded by a disulfide bond to form a ring structure. BNP also possesses both diuretic and vasodilatory effects. BNP was originally isolated and identified in the porcine brain in Japan in 1988, and is also called B-type natriuretic peptide.</p><p id="p0016" num="0016">Both ANP and BNP bind to the receptor NPR-A (also called GC-A) having a guanylate cyclase domain, and exert their effects stated above, by stimulating the production of cGMP. In fact, secretion of ANP is stimulated in response to an increase in the atrial pressure by its distension in congestive heart failure, etc., and through its action stated above, ANP relieves the symptoms of congestive heart failure, etc. Likewise, BNP's release is stimulated during certain conditions including myocardial infarction, and BNP, through its action mentioned above, relieves the symptoms associated with myocardial infarction, etc. (Refer to non-patent literature 1). Although most of the circulating BNP derives from the ventricles, some BNP is released by the atria. In cardiac failure, the level of expression of both ANP and BNP increases to as much as 100 times more the normal level, but the increase of BNP expression is reported to be both greater and faster than that of ANP. While ANP (hANP) is marketed as a prescription drug for treating acute cardiac failure in Japan, BNP is clinically used in the United States.</p><heading id="h0007">(2) CNP:</heading><!-- EPO <DP n="8"> --><p id="p0017" num="0017">CNP, which was once thought to function only as a brain peptide because it was first found in the brain, has now been clarified to exist in the periphery as well. In the vessel walls, in particular, CNP specific receptors were found to be abundant in smooth muscle cells, and CNP is produced by cells of the monocyte/macrophage lineage and the endothelial cells. For those reasons, CNP is speculated to function in the vascular walls as a local mediator involved in inhibition of growth of vascular smooth muscle cells. Its clinical application is currently being investigated for possible prevention of restenosis by CNP administration, which occurs with a certain frequency after percutaneous transluminal coronary angioplasty (PTCA) performed on patients with ischemic heart failure.</p><p id="p0018" num="0018">Recently it has been reported that intravenous administration of CNP remarkably improves cardiomegaly and fibrosis associated with myocardial infarction, and improves cardiac functions in animal experiments. Cardiac fibrosis is known to cause diastolic ventricular failure and cardiac dysrhythmia. Since CNP possesses a powerful action to suppress fibroblast proliferation, the potential of CNP as an anti-fibrotic medication for the heart is under investigation. Since CNP is a hormone naturally occurring in the body, there is only little concern of it having adverse side effects; accordingly clinical application of CNP as a therapeutic agent for arteriosclerotic diseases and heart diseases is expected. Here, examples of CNP include CNP-22 composed of 22 amino<!-- EPO <DP n="9"> --> acids, and CNP-53 wherein 31 amino acid residues are attached to the N-terminal of CNP-22.</p><heading id="h0008">(3) Natriuretic peptide receptors:</heading><p id="p0019" num="0019">Natriuretic peptide receptors are classified into three subtypes; NPR-A receptor (also called GC-A) and NPR-B receptor (also called GC-B) both of which contain a guanylate cyclase domain, and NPR-C receptor which lacks a guanylate cyclase domain. It is known that ANP can bind to NPR-A and NPR-C receptors, BNP can bind to NPR-A and NPR-C receptors, and CNP can bind to NPR-B and NPR-C receptors.</p><p id="p0020" num="0020">It is suggested that the activation of NPR-A receptors induces vasodilatory action, diuretic action, and cell growth inhibitory action, while NPR-B receptors are abundant in vascular smooth muscle cells and thought to be involved in the growth inhibition of vascular smooth muscle cells.</p><heading id="h0009">(4) Relationship between natriuretic peptides and immune system:</heading><p id="p0021" num="0021">Historically, natriuretic peptide was first discovered as a peptide released from the atria, later named ANP, and its vasodilatory and diuretic actions gathered attention. BNP and CNP were then discovered as peptides similar to ANP. This historical background offers an explanation to why any attention to the relationship between natriuretic peptides and the immune system has been focused on those related to the cardiovascular system. CNP knock-out mice demonstrated impaired growth of cartilage resulting in a dwarfism-like<!-- EPO <DP n="10"> --> phenotype (refer to Non-patent literature 2), which directed some interest to the relationship between arthritis and natriuretic peptides.</p><p id="p0022" num="0022">ANP is implicated in playing a role in arthritis and sepsis as it inhibits the release of inflammatory cytokines including tumor necrosis factor (TNF-α) and interleukin 1β (IL-1β) by macrophages (refer to Non-patent literature 3). This literature, however, does not mention ANP's relationship with the skin.</p><p id="p0023" num="0023">Similarly, the blood concentration of BNP has been reported to increase with the rejection response following heart transplant, and therefore it is suggested that it is associated with the immune regulation in the cardiovascular system (refer to Non-patent literature 4). However, this literature does not describe any connection between BNP and the skin.</p><p id="p0024" num="0024">Taking into account the observation that there is an increase in the blood concentration of BNP during the heart graft rejection, Kuroski de Bold et al. have investigated the immunoregulatory action of natriuretic peptides, and have demonstrated that both ANP and BNP inhibit the lymphocyte growth (refer to Non-patent literature 5). However, there is no connection between natriuretic peptides and the skin mentioned in this literature.</p><p id="p0025" num="0025">Chiurchiu et al. on the other hand have investigated the immunoregulatory action of BNP focusing on its<!-- EPO <DP n="11"> --> association with the heart diseases and sepsis, and showed that BNP promotes the release by macrophages of pro-inflammatory cytokines such as arachidonic acid, prostaglandin E2 (PGE2), and leukotriene B4 (LTB4), and also promotes the release of anti-inflammatory cytokines including interleukin 10 (IL10). Thus, while BNP is indicated to have some action in the regulation of inflammatory responses, whether BNP acts overall to suppress or promote inflammatory responses remains inconclusive in the literature (refer to Non-patent literature 6). This literature also does not mention any connection between BNP and the skin.</p><p id="p0026" num="0026">Similarly, CNP is reported to be released by macrophages (refer to Non-patent literature 7), and while investigating the roles of CNP in cardiac ischemia and myocardial damage after reperfusion, Scotland et al. report that CNP suppresses platelet aggregation and lymphocyte migration (refer to Non-patent literature 8). The connection between CNP and the skin, however, is not described in this literature.</p><p id="p0027" num="0027">Likewise, Obata et al. examined the roles played by CNP in myocarditis using a rat myocarditis model generated by injecting pig myosin. They reported that continuous administration of CNP for 1 week had suppressed necrosis and inflammation of the cardiac tissues, while at the same time promoted the regeneration of blood vessels, thereby preventing functional loss of the heart (refer to Non-patent literature 9). Nevertheless, there is nothing in<!-- EPO <DP n="12"> --> this literature to suggest a connection between CNP and the skin.</p><p id="p0028" num="0028">In addition, based on the observation that CNP knock-out mice show a dwarfism-like phenotype, attention has been paid to the potential connection between CNP and cartilage growth. Agoston et al. demonstrated that when incubated with Dexamethasone, the primary cultured chondrocytes extracted from the tibial bones of mouse embryos had significantly increased the expression of CNP genes (refer to Non-patent literature 10). This literature, however does not describe any connections between CNP and the skin.</p><p id="p0029" num="0029">It is evident that the connections between natriuretic peptides and the immune system have drawn increasing attention in recent years, but it is limited only to the inflammation of the cardiovascular system and arthritis, and the relationship between dermatitis or more specifically atopic dermatitis and natriuretic peptides has never been reported.</p><heading id="h0010">(5) Reports on the application of natriuretic peptides:</heading><p id="p0030" num="0030">Following are some examples of a number of applications of CNP, BNP and ANP.</p><p id="p0031" num="0031">Toshiko Koide and her colleagues have proposed a preparation for repair/regeneration of tissues and organs, comprising a composition that comprises ANP, BNP, CNP and urodilatin (P-Uro), and their precursors and derivatives,<!-- EPO <DP n="13"> --> or combinations thereof as an active ingredient, and that may comprise pharmaceutically commonly-used diluents, excipients, fillers, and auxiliary agents (refer to Patent Literature 1).</p><p id="p0032" num="0032">However, specific examples of repair and regeneration of tissues and organs relate only to the regeneration of myocardiocytes, hypodermal tissue, hair, and improvement of cracked, rough skin due to wet work; they all correspond to ANP administration. There is no statement which implies therapeutic agents for treating skin disease or skin texture-improving agents by means of administration of CNP or BNP.</p><p id="p0033" num="0033">Masaharu Tanaka and his colleagues have proposed a C-type natriuretic peptide exhibiting a growth inhibitory action of vascular smooth muscle cells, as well as a growth inhibitory preparation for vascular smooth muscle cells containing such peptides as its active ingredient (refer to Patent Literature 2).</p><p id="p0034" num="0034">This, however, relates to the use of CNP in a growth inhibitory agent of vascular smooth muscle cells but does not imply application of CNP or BNP to therapeutic agents for dermatitis.</p><p id="p0035" num="0035">Katsuhiko Nakada and his colleagues proposed an eye drop for promoting lacrimal secretion or for treating keratoconjunctival disorder, containing as its active ingredient a natriuretic peptide, and they list ANP, BNP<!-- EPO <DP n="14"> --> and CNP as examples of usable natriuretic peptide (refer to Patent Literature 3).</p><p id="p0036" num="0036">This, however, only relates to the application of the property of ANP, CNP and BNP to promote lacrimal secretion in an eye drop for treating keratoconjunctival disorder, and does not indicate the use of CNP or BNP in a therapeutic agent to treat dermatitis.</p><p id="p0037" num="0037">Kazuwa Nakao and his colleagues proposed a composition for increasing the body length containing a guanyl cyclase B (GC-B) activator as the active ingredient, which is to be administered to an individual without FGFR3 abnormality (refer to Patent Literature 4).</p><p id="p0038" num="0038">This indicates an application of CNP in a composition for increasing the body height based on the finding that the nose-anus length in transgenic mice which over-expressed CNP was larger than that in normal litters, but dose not imply the use of CNP or BNP in a therapeutic agent for dermatitis.</p><p id="p0039" num="0039">Kazuwa Nakao and his colleagues also proposed a prophylactic agent or therapeutic agent for inflammation of the joints containing a guanyl cyclase B (GC-B) activator such as CNP as an active ingredient (refer to Patent Literature 5).</p><p id="p0040" num="0040">However, this relates only to the application of CNP in a therapeutic agent or prophylactic agent for<!-- EPO <DP n="15"> --> inflammation of the joints based on a study revealing that, compared to their litter mates, the articular cartilages grow thicker in the transgenic mice which over-express CNP, along with the observation that arthritis is repressed by the continuous administration of CNP to model animals of arthritis. Hence this does not imply the application of CNP or BNP in a therapeutic agent for dermatitis.</p><p id="p0041" num="0041">In addition, Masaharu Tanaka and his colleagues reported that CNP differs from ANP and BNP in the structure and function effects as stated below (refer to Patent Literature 2).</p><p id="p0042" num="0042">"At present, both ANP and BNP are thought to act as a hormone secreted by the heart into the blood, as well as a neurotransmission factor, and to play an important role in maintaining the amount of body fluid and homeostasis of blood pressure.... There are many unknown points in the physiological roles of CNP as a natriuretic peptide. Namely, since CNP has an amino acid primary sequence similar to that of ANP and BNP and shows a natriuretic action and a hypotensive action by in vivo administration, CNP was relegated to the natriuretic peptide family. However, because the natriuretic action and hypotensive action of CNP are significantly weaker than those of ANP and BNP (from 1/50 to 1/100) ..., CNP has held a unique position in the natriuretic peptide family, and has been presumed to be playing a role different from the maintenance of amounts of body fluid and homeostasis of blood pressure.... Comparing the structure of CNP with<!-- EPO <DP n="16"> --> that of ANP/BNP, CNP differs from ANP or BNP in the following points. Namely, the primary amino acid sequence of CNP differs from that of ANP or BNP at the exocyclic N-terminal domain; of the 17 amino acid residues in the endocyclic domain, 5 residues and 4 residues in CNP differ from those in ANP and BNP, respectively. In addition, the structure of the exocyclic C-terminal domain of CNP largely differs from that of ANP or BNP, and CNP does not have the tail structure which exists in ANP or BNP (in the cases of ANP and BNP, 5 amino acid residues and 6 amino acid resides, respectively, are attached to the C-terminal of the cyclic structure in ANP and BNP; this structure is called a tail structure for descriptive purposes). Thus-described structural differences between CNP and ANP/BNP are obviously involved in the manifestation of the above-mentioned characteristic pharmacological effects of CNP."</p><heading id="h0011">[Reference List]</heading><heading id="h0012">Patent Literature</heading><p id="p0043" num="0043"><ul><li>Patent Literature 1: <patcit id="pcit0001" dnum="JP2008162987A"><text>JP A 2008-162987</text></patcit></li><li>Patent Literature 2: <patcit id="pcit0002" dnum="JP6009688A"><text>JP A 6-9688</text></patcit></li><li>Patent Literature 3: <patcit id="pcit0003" dnum="JP2000169387A"><text>JP A 2000-169387</text></patcit></li><li>Patent Literature 4: <patcit id="pcit0004" dnum="WO2005094890A"><text>WO 2005/094890</text></patcit></li><li>Patent Literature 5: <patcit id="pcit0005" dnum="WO2005094889A"><text>WO 2005/094889</text></patcit></li></ul></p><heading id="h0013">Non-patent Literature</heading><p id="p0044" num="0044"><ul><li>Non-patent Literature 1: <nplcit id="ncit0001" npl-type="s"><text>European J. Endocrinology, Vol. 135, p. 265, 1996</text></nplcit>.<!-- EPO <DP n="17"> --></li><li>Non-patent Literature 2: <nplcit id="ncit0002" npl-type="s"><text>Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 7, p. 4016, 2001</text></nplcit>.</li><li>Non-patent Literature 3: <nplcit id="ncit0003" npl-type="s"><text>Annals of the Rheumatic Disease, Vol. 60, Suppl 3, iii, p. 68, 2001</text></nplcit>.</li><li>Non-patent Literature 4: <nplcit id="ncit0004" npl-type="s"><text>The Journal of Heart and Lung Transplantation, Vol. 27, p. 31, 2008</text></nplcit>.</li><li>Non-patent Literature 5: <nplcit id="ncit0005" npl-type="s"><text>The Journal of Heart and Lung Transplantation, Vol. 29, No. 3, p. 323, 2010</text></nplcit>.</li><li>Non-patent Literature 6: <nplcit id="ncit0006" npl-type="s"><text>Regulatory Peptides, Vol. 148, p. 26, 2008</text></nplcit>.</li><li>Non-patent Literature 7: <nplcit id="ncit0007" npl-type="s"><text>Experimental Hematology, Vol. 29, p. 609, 2001</text></nplcit>.</li><li>Non-patent Literature 8: <nplcit id="ncit0008" npl-type="s"><text>Proceedings of the National Academy of Sciences, Vol. 102, No. 40, p. 14452, 2005</text></nplcit>.</li><li>Non-patent Literature 9: <nplcit id="ncit0009" npl-type="s"><text>Biochemical and Biophysical Research Communications, Vol. 356, p. 60, 2007</text></nplcit>.</li><li>Non-patent Literature 10: <nplcit id="ncit0010" npl-type="s"><text>BMC Musculoskeletal Disorders, Vol. 7, p. 87, 2006</text></nplcit>.</li></ul></p><heading id="h0014"><b>[Disclosure of Invention]</b></heading><heading id="h0015"><b>Summary of Invention</b></heading><heading id="h0016"><b>Problems to Be Solved by the Invention</b></heading><p id="p0045" num="0045">The chronic nature of dermatitis, a representative skin disease, and in particular atopic dermatitis, makes continuous use of drugs necessary. While steroid external preparations produce satisfactory clinical effects as stated above, they also have many adverse local effects, including skin thinning and atrophy, moon face, skin flush, hirsutism, and skin striae, hence their application to<!-- EPO <DP n="18"> --> areas of high drug absorbability such as the face, and to patients with sensitive skin, children and females, has been difficult. In addition to the problem of adverse local effects, the repeated and long-term use of topical steroids, which is necessary in many cases due to the chronic nature of atopic dermatitis, can lead to rebound phenomena induced by discontinuation of external application. In other words, an acute exacerbation, which is worse than the state before the application, occurs upon abrupt discontinuation of external application. In addition, as more serious complications, erythroderma posteczematosa with whole-body skin flush and desquamation can result from continuous inappropriate external application. These severe symptoms induced by a long-term use of steroids have been a serious problem.</p><p id="p0046" num="0046">Hence, the aim of the present invention is to provide an effective and safe skin external preparation composition for patients with dermatitis, atopic dermatitis in particular, which is not only effective against severe conditions which are intractable with the currently available external preparations, but also safely applicable to affected areas of the face and neck, and also safely applicable to patients with sensitive skin, children and females. Furthermore, the invention also aims to provide a skin texture-improving agent to enhance the skin barrier functions important for prevention of recurrence, to improve the texture and moisture retention ability of the skin, which has an anti-inflammatory effect and effects of care for the horny cell layer, care for the epidermis, and care for the basal membrane.<!-- EPO <DP n="19"> --></p><heading id="h0017"><b>Means for Solving Problems</b></heading><p id="p0047" num="0047">Through extensive research, the inventors of the present invention discovered that C-type natriuretic peptide (CNP) and B-type natriuretic peptide (BNP) are safe and effective as a therapeutic agent for dermatitis, especially atopic dermatitis, and that they are also applicable to the face and neck, and patients who have sensitive skins, children and females. The present invention was thus made.</p><p id="p0048" num="0048">The present invention discloses the following.</p><p id="p0049" num="0049"><ol><li>1. A skin external-preparation composition comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) for use in the treatment of dermatitis.</li><li>2. The skin external-preparation composition according to the item 1, wherein the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is a chimeric peptide of CNP and BNP, in which CNP is CNP-22, CNP-53, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence having deletion, substitution, or addition of any amino acid in the amino acid sequence of CNP-22 or CNP-53, and in which BNP is BNP-26, BNP-32, BNP-45, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence having deletion, substitution, or addition of any amino acid in the amino acid sequence of BNP-26, BNP-32 or BNP-45, and wherein the chimeric peptide forms a ring structure by an intramolecular disulfide bond, and<!-- EPO <DP n="20"> --> wherein the chimeric peptide has CNP activity or BNP activity; or derivative(s) of the chimeric peptide.</li><li>3. The skin external-preparation composition according to the item 1, wherein the C-type natriuretic peptide (CNP) is CNP-22, CNP-53, or a CNP derivative in which any amino acid in the amino acid sequence of CNP-22 or CNP-53 is deleted, substituted or added, and which has CNP activity.</li><li>4. The skin external-preparation composition according to the item 3, wherein the C-type natriuretic peptide (CNP) is CNP-22.</li><li>5. The skin external-preparation composition according to the item 1, wherein the B-type natriuretic peptide (BNP) is BNP-26, BNP-32, BNP-45, or a BNP derivative in which any amino acid in the amino acid sequence of BNP-26, BNP-32, or BNP-45 is deleted, substituted or added, and which has BNP activity.</li><li>6. The skin external-preparation composition according to the item 5, wherein the B-type natriuretic peptide (BNP) is BNP-32.</li><li>7. The skin external-preparation composition according to the item 1, comprising 1-500 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).</li><li>8. The skin external-preparation composition according to the item 1, comprising 20-200 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).</li><li>9. The skin external-preparation composition according to the item 1, comprising 30-100 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).<!-- EPO <DP n="21"> --></li><li>10. The skin external-preparation composition according to the item 1, wherein the skin external-preparation composition is a therapeutic agent for dermatitis.</li><li>11. The skin external-preparation composition according to the item 10, wherein the skin external-preparation composition is a therapeutic agent for dermatitis, and the dermatitis is atopic dermatitis, dermatitis that led up to steroid dermatitis, steroid-resistant dermatitis, dermatitis to which tacrolimus is not applicable, chronic dermatitis, erythroderma, eczema, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, stasis dermatitis, urticaria, drug eruption, dermal vasculitis, prurigo, pruritus cutaneus, erythema, psoriasis, rosacea, rosacea-like dermatitis, lichen planus, or follicular keratosis.</li><li>12. The skin external-preparation composition according to the item 11, wherein the dermatitis is atopic dermatitis</li><li>13. The skin external-preparation composition according to the item 11, wherein the dermatitis is dermatitis that led up to steroid dermatitis.</li><li>14. The skin external-preparation composition according to the item 11, wherein the dermatitis is steroid-resistant dermatitis.</li><li>15. The skin external-preparation composition according to the item 11, wherein the dermatitis is the one for which tacrolimus is not applicable.</li><li>16. The skin external-preparation composition according to the item 11, wherein the dermatitis is chronic dermatitis.<!-- EPO <DP n="22"> --></li><li>17. The skin external-preparation composition according to the item 11, wherein the dermatitis is eczema.</li><li>18. The skin external-preparation composition according to the item 11, wherein the dermatitis is erythroderma.</li><li>19. The skin external-preparation composition according to the item 11, wherein the dermatitis is rosacea.</li><li>20. The skin external-preparation composition according to the item 11, wherein the dermatitis is rosacea-like dermatitis.</li><li>21. The skin external-preparation composition according to the item 11, wherein the dermatitis is psoriasis.</li><li>22. The skin external-preparation composition according to the item 10, wherein the skin external-preparation composition is a therapeutic agent for dermatitis, and the dermatitis is an inflammation associated with at least one rash symptom selected from erythema, infiltrative erythema, lichenified lesion, scales, adhesion of crusts, eczema, abrasion, excoriation, prurigo nodularis, papule, erosion, infiltration, vesicle, and edema.</li><li>23. The skin external-preparation composition according to the item 10, wherein the skin external-preparation composition is a therapeutic agent for dermatitis, and the dermatitis shows an immune reaction to at least one allergen selected from house dust, mite, cedar pollen, orchard grass pollen, ragweed pollen, egg white, and egg yolk.</li><li>24. The skin external-preparation composition according to the item 10, wherein the skin external-preparation composition is a therapeutic agent for dermatitis, and the<!-- EPO <DP n="23"> --> dermatitis occurs in at least one region selected from the face, neck, back, and arms.</li><li>25. The skin external-preparation composition according to the item 1, wherein the dosage form of the external preparation is selected from ointment, gel, cream, lotion, solution, spray, and patch.</li><li>26. The skin external-preparation composition according to the item 25, wherein the dosage form is ointment, gel, cream, or solution.</li><li>27. The skin external-preparation composition according to the item 1, wherein the skin external-preparation composition is a skin texture-improving agent.</li><li>28. The skin external-preparation composition according to the item 27, wherein the skin external-preparation composition is a skin texture-improving agent for improving dry skin, rough skin, sensitive skin and fine wrinkles.</li><li>29. The skin external-preparation composition according to the item 27, wherein the skin texture-improving agent is a skin care product or a quasi drug.</li><li>30. The skin external-preparation composition according to the item 27, wherein the dosage form is cream, foam, skin lotion, facial mask, skin-softening water, skin emulsion, foundation, makeup base, essence, soap, liquid cleanser, bath agent, sun-block cream, suntan oil or spray-type liquid preparation.</li></ol></p><heading id="h0018"><b>Effects of the Invention</b></heading><p id="p0050" num="0050">As described in the examples given below, a skin external-preparation composition comprising CNP or BNP as its active ingredient can greatly<!-- EPO <DP n="24"> --> improve erythema, papules and scales associated with severe swelling/edema/infiltration or lichenification, thereby achieving either remission, mild conditions mainly characterized by dry skin with mild erythema and scales, or minor rash having little inflammatory symptoms with dryness of the skin as its main symptom. Hence, the therapeutic agent for dermatitis of the present invention is expected to be applicable and extremely effective against atopic dermatitis, which develops resistance to the conventional steroid external drugs. In particular, it is possible to dramatically improve erythema, infiltration, scales or lichenification and burning sensation on the adult face without producing irritative symptom, which interfere with many aspects of social life. Remarkable improvements are also made in the other parts of the body including the upper limbs and back. The effects are not limited to adults but are similar with infants.</p><p id="p0051" num="0051">Conventionally and widely used steroid external preparations have the drawbacks of, upon discontinuation of the external application, relapsing to the severity of pre-treatment conditions, or worse, the rebound phenomena mainly characterized by the recurrence of worsened condition. In contrast, the present invention not only completely lacks these problems, but also results in moisturized, fine-textured skin. The effects of the therapeutic agent for dermatitis lasted 5 days to 2 weeks after its application was terminated, and the improved skin conditions were sustained throughout. Even in cases, which did not result in the<!-- EPO <DP n="25"> --> prominent effect, the therapeutic goals of atopic dermatitis were achieved, namely, the main symptoms were improved to dryness, minor or mild severity of erythema, and scales, etc. Furthermore, minor erythema, edema, papules and scales, which recurred after the treatment in some cases, did not worsen to the pre-treatment conditions and remained stable. This could not be attained by the steroid external preparations, the former therapeutic option, and is therefore worthy of special mention. In addition, when re-applied to the rashes that had relapsed, CNP or BNP preparations required a smaller number of applications than that of the initial time to reduce the severity of symptoms to either mild or minor rash. In terms of manifestation of effects, the patients experienced subjective awareness of burning sensation subsiding approximately 10 min after the application, and this was followed by the improvements of observable symptoms including erythema, infiltration, edema, papules, scales and excoriations after approximately 30 min. When application was further continued from 2 days to 4 days, erythema and infiltration improved remarkably and the skin became near-normal in condition with a fine texture in many cases. These findings were astonishing even for the inventor of the present invention who is a dermatologist. CNP preparations demonstrated especially remarkable effects.</p><p id="p0052" num="0052">Given that both BNP and ANP belong to the same family and share the same receptors, it was formerly assumed that BNP and ANP preparations possessed equivalent effects. When they were actually tested on patients with<!-- EPO <DP n="26"> --> inflammatory disease, in particular atopic dermatitis, however, BNP preparations were revealed to have much more intense pharmacological effects than ANP preparations. That is to say that BNP preparations are faster-acting than ANP preparations, and lead to better improvements of the clinical symptoms and the effects lasted longer. On the other hand, ANP preparations unexpectedly resulted in much poorer improvements in the local dermal symptoms of erythema, infiltration, scale and lichenification compared to BNP preparations, and in many cases, the symptoms showed no improvements or worsened. In cases where a little improvement was observed with ANP preparations, manifestation of the effects was slow and even 7 consecutive days of external application did not result in complete remission of erythema, while both erythema and dryness of the skin remained in all cases. The finding that BNP as a skin external-preparation composition had more intense pharmacological effects than ANP belonging to the same family of natriuretic peptide was surprising.</p><p id="p0053" num="0053">The active ingredients, CNP and BNP, are hormones which naturally occur in the body. Side effects are less expected and with adequate dosage, they are thought to have only a minor effect on the hemodynamic status and hence they are safe to apply to patients with low or unstable blood pressure, allowing long-term administration to chronic dermatitis patients. They show a potency to dermatitis greater than that of conventional steroid external preparations and are also rapid-acting to a greater degree and lead to longer-lasting effects, or more precisely, 5 days to 2 week remission<!-- EPO <DP n="27"> --> periods were observed even in the severe cases. Moreover, the skin external-preparation composition is safely applicable to patients with sensitive skin, children and females, and to the face and neck region, etc. without irritation symptoms, and this makes the present invention an unprecedented, important therapeutic agent for dermatitis.</p><p id="p0054" num="0054">In addition, when a skin texture-improving agent comprising CNP or BNP was applied, effects such as improvement of the texture, dryness and roughness of the skin while enhancing the softness and moisture retention, as well as obscuring fine wrinkles were confirmed. The present invention can therefore be intended as both a therapeutic agent for dermatitis.</p><heading id="h0019"><b>[Brief Description of Drawings]</b></heading><p id="p0055" num="0055"><ul><li>[<figref idrefs="f0001">Fig. 1] Figure 1</figref> is a photograph showing the effects of a CNP gel preparation when it was applied to a patient who had severe swelling, infiltration and erythema on the upper limbs. A and B show the state before application. C shows the state after application of the CNP gel preparation with 30 µg/g concentration three times at 20 min intervals, while D shows the state after application of a gel preparation without the addition of CNP 3 times at 20 min intervals. (Refer to Case 10 of the CNP gel preparation; subject 5: Tables 3 and 4)<!-- EPO <DP n="28"> --></li><li>[<figref idrefs="f0002">Fig. 2] Figure 2</figref> is a photograph showing the effects of a CNP aqueous-solution preparation when it was applied to a patient who had a rash mainly characterized by severe swelling, infiltration, erythema with lichenification, papules, erosions, and numerous excoriations on the face. A shows the state before application, and B shows the state after application of the CNP aqueous-solution preparation with a concentration of 100 µg/ml twice a day for 4 days. (Refer to Case 2 of the CNP aqueous-solution preparation; subject 6; Tables 5 and 6)</li><li>[<figref idrefs="f0002">Fig. 3] Figure 3</figref> is a photograph showing the effects of a CNP aqueous-solution preparation when it was applied to a patient who had a rash mainly characterized by erythema with lichenification, papules, erosions, scales and numerous excoriations on the face. A shows the state before application, and B shows the state after application of the CNP aqueous-solution preparation with a concentration of 100 µg/ml twice a day for 4 days. (Refer to Case 7 of CNP aqueous-solution preparation; subject 7; Tables 5 and 6)</li><li>[<figref idrefs="f0003">Fig. 4] Figure 4</figref> is a photograph showing the effects of a CNP gel-base preparation when it was applied to the arm of a patient who presented with erythema associated with lichenification, infiltrative erythema, severe scales, adhesion of crusts, vesicles, and erosions throughout the whole body. A shows the state before application, and B shows the state after application of the CNP gel-base preparation with a concentration of 30<!-- EPO <DP n="29"> --> µg/g, twice a day for 2 days. (Refer to CNP gel-base preparation; subject 17; Tables 9 and 10)</li><li>[<figref idrefs="f0004">Fig. 5] Figure 5</figref> is a photograph showing the effects of a CNP gel-base preparation when it was applied to a patient who presented with a rash associated with severe swelling/edema/infiltration/erythema on the upper limbs. A shows the state before application, and B shows the state after application of the CNP gel-base preparation with a concentration of 50 µg/g, twice a day for 4 days. (Refer to CNP gel-base preparation; subject 20; Tables 9 and 10) [<figref idrefs="f0005">Fig. 6] Figure 6</figref> is a photograph showing the effects of a CNP ointment preparation, when it was applied to the face and neck of a patient who presented with infiltrative erythema, erythema, severe scales, adhesion of crusts, and numerous excoriations over the whole body, and particularly apparent on the face and neck. A shows the state before application, and B shows the state after application of the CNP ointment preparation with a concentration of 30 µg/g twice a day for 2 days. (Refer to CNP ointment preparation; subject 21; Tables 11 and 12)</li><li>[<figref idrefs="f0005">Fig. 7] Figure 7</figref> is a photograph showing the effects of a CNP ointment preparation when it was applied to the face of a patient who presented with infiltrative erythema with strong itching associated with sleep disturbance, erythema, excoriations on the face, neck, four limbs, and back, and had a rash mainly characterized by severe infiltrative erythema, scales, and numerous excoriations particularly on the face. A shows the state<!-- EPO <DP n="30"> --> before application, and B shows the state after application of the CNP ointment preparation with a concentration of 50 µg/g, twice a day for 3 days. (Refer to CNP ointment preparation; subject 23; Tables 11 and 12)</li><li>[<figref idrefs="f0006">Fig. 8] Figure 8</figref> is a photograph showing the effects of a CNP ointment preparation, when it was applied to the neck and back of a patient who presented with infiltrative erythema, lichenified lesions, erythema, adhesion of crusts, and numerous excoriations on the body trunk, and had a rash forming a plaque associated with erythema with severe infiltration/lichenification, severe scales, and adhesion of crusts on the back. A shows the state before application, and B shows the state after application of the CNP ointment preparation with a concentration of 50 µg/g twice a day for 3 days. (Refer to CNP ointment preparation; subject 29; Tables 13 and 14)</li><li>[<figref idrefs="f0006">Fig. 9] Figure 9</figref> is a photograph showing the effects of a CNP ointment preparation, when it was applied to the upper limb of a patient suffering from the condition of erythroderma posteczematosa who presented infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, numerous excoriations over the whole body, and who had a rash mainly characterized by erythema associated with severe swelling and infiltration on the upper limbs. A shows the state before application, and B shows the state after application of the CNP ointment preparation with a concentration of 50 µg/g, twice a day for 2 days. (Refer to CNP ointment preparation; subject 30; Tables 13 and 14)<!-- EPO <DP n="31"> --></li><li>[<figref idrefs="f0007">Fig. 10] Figure 10</figref> is a photograph showing the effects of a CNP ointment preparation when it was applied to the face of a patient who presented a rash consisting of infiltration/severe scales, adhesion of crusts, erosions and numerous excoriations on the face, and also infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations over the whole body. A shows the state before application, and B shows the state after application of the CNP ointment preparation with a concentration of 50 µg/g twice a day for 3 days. (Refer to CNP ointment preparation; subject 27; Tables 13 and 14)</li><li>[<figref idrefs="f0007">Fig. 11] Figure 11</figref> is a photograph showing the effects of a CNP ointment preparation when it was applied to the face of a patient suffering from the condition of erythroderma posteczematosa who presented a rash mainly characterized by infiltrative erythema with swelling and erosions on the face and neck, and infiltrative erythema, lichenified lesions, erythema, severe scales, and adhesion of crusts throughout the whole body. A shows the state before application, and B shows the state after application of the CNP ointment preparation with a concentration of 50 µg/g twice a day for 3 days. (Refer to CNP ointment preparation; subject 28; Tables 13 and 14)</li><li>[<figref idrefs="f0008">Fig. 12] Figure 12</figref> is a photograph showing the effects of a BNP gel-base preparation when it was applied to a patient who had a rash mainly characterized by severe edema, infiltration, erythema, erosions, scales and numerous excoriations on the neck. A<!-- EPO <DP n="32"> --> shows the state before application, and B shows the state after application of the BNP gel-base preparation with a concentration of 50 µg/g twice a day for 5 days. (Refer to Case 1 of BNP gel-base preparation; subject 41; Tables 19 and 20)</li><li>[<figref idrefs="f0009">Fig. 13] Figure 13</figref> is a photograph showing the effects of a BNP gel-base preparation when it was applied to a patient who had a rash on the forearms, characterized by infiltration, erythema, severe scales and crusts. A shows the state before application, and B shows the state after application of the BNP gel-base preparation with a concentration of 50 µg/g twice a day for 5 days. (Refer to Case 4 of BNP gel-base preparation; subject 42; Tables 19 and 20)</li><li>[<figref idrefs="f0010">Fig. 14] Figure 14</figref> is a photograph showing the effects of a BNP gel-base preparation when it was applied to a patient who had a rash on the face and neck, mainly characterized by erythema with edema, erosions, scales and numerous excoriations. A shows the state before application, and B shows the state after application of the BNP gel-base preparation with a concentration of 50 µg/g twice a day for 2 days. (Refer to Case 5 of BNP gel-base preparation; subject 40; Tables 17 and 18)</li><li>[<figref idrefs="f0011">Fig. 15] Figure 15</figref> is a photograph showing the effects of a BNP aqueous-solution preparation when it was applied to a patient who had a rash on the face, mainly characterized by infiltrative erythema, many papules, scales and excoriations. A shows the state before application, and B shows the state after application of the<!-- EPO <DP n="33"> --> BNP aqueous-solution preparation with a concentration of 50 µg/ml twice a day for 5 days. (Refer to Case 8 of BNP aqueous-solution preparation; subject 43; Tables 19 and 20)</li><li>[<figref idrefs="f0012">Fig. 16] Figure 16</figref> is a photograph showing the effects in a comparative case when an ANP gel-base preparation was applied to a patient who had a rash on the face, mainly characterized by severe lichenified infiltration, erythema and scales. A shows the state before application, and B shows the state after application of the ANP gel-base preparation with a concentration of 50 µg/g twice a day for 7 days. (Refer to Case 2 of ANP gel-base preparation; subject 46; Tables 21 and 22)</li><li>[<figref idrefs="f0013">Fig. 17] Figure 17</figref> is a photograph showing the effects in a comparative case when an ANP gel-base preparation was applied to a patient who had a rash on the face, neck and the four limbs, characterized by severe swelling, skin flush and edema. A shows the state before application, and B shows the state after application of the ANP gel-base preparation with a concentration of 50 µg/g twice a day for 7 days. (Refer to Case 3 of ANP gel-base preparation; subject 45; Tables 21 and 22)</li><li>[<figref idrefs="f0014">Fig. 18] Figure 18</figref> is a photograph showing the effects in a comparative case when an ANP gel-base preparation was applied to a patient who had a rash on the back, characterized by severe infiltration, erythema, numerous excoriations, papules and lichenification. A shows the state before application, and B shows the state after application of the ANP gel-base preparation with a concentration of 50 µg/g twice a day for 5 days. (Refer to<!-- EPO <DP n="34"> --> Case 5 of ANP gel-base preparation; subject 48; Tables 21 and 22)</li><li>[<figref idrefs="f0015">Fig. 19] Figure 19</figref> is a graph showing the changes in the severity of the rashes evaluated using SCORAD before and after application of the skin external-preparation compositions comprising CNP or BNP. The white bars represent severity levels before application, while the black bars represent severity levels after application. The length of the bars represents the average, and the lines extending from the end of the bars represent the standard deviation. The number of cases in each group is as follows: 5 cases in the CNP gel preparation (30 µg/g) group, 5 cases in the CNP aqueous-solution preparation (100 µg/ml) group, 7 cases in the CNP gel-base preparation (30 µg/g) group, 3 cases in the CNP gel-base preparation (50 µg/g) group, 1 case in the CNP ointment preparation (30 µg/g) group, 9 cases in the CNP ointment preparation (50 µg/g) group, 5 cases in the CNP ointment preparation (100 µg/g) group, 2 cases in the BNP gel-base preparation (30 µg/g) group, 5 cases in the BNP gel-base preparation (50 µg/g) group, 3 cases in the BNP aqueous-solution preparation (50 µg/ml) group, and 5 cases in the ANP gel-base preparation (50 µg/g) group.</li><li>[<figref idrefs="f0016">Fig. 20] Figure 20</figref> is a graph showing the changes in the itching sensation subjectively evaluated by the participants using visual analogue scale method, before and after application of the skin external-preparation compositions comprising CNP or BNP. The white bars represent the levels before application,<!-- EPO <DP n="35"> --> while the black bars represent the levels after application. The length of the bars represents the average, and the lines extending from the end of the bars represent the standard deviation. The number of cases in each group is as follows: 5 cases in the CNP gel preparation (30 µg/g) group, 5 cases in the CNP aqueous-solution preparation (100 µg/ml) group, 7 cases in the CNP gel-base preparation (30 µg/g) group, 3 cases in the CNP gel-base preparation (50 µg/g) group, 1 case in the CNP ointment preparation (30 µg/g) group, 9 cases in the CNP ointment preparation (50 µg/g) group, 5 cases in the CNP ointment preparation (100 µg/g) group, 2 cases in the BNP gel-base preparation (30 µg/g) group, 5 cases in the BNP gel-base preparation (50 µg/g) group, 3 cases in the BNP aqueous-solution preparation (50 µg/ml) group, and 5 cases in the ANP gel-base preparation (50 µg/g) group.</li></ul></p><heading id="h0020"><b>Embodiments for Carrying out the Invention</b></heading><p id="p0056" num="0056">The active ingredient of the skin external-preparation compositions is 1-500 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).</p><p id="p0057" num="0057">Here, the CNP means: CNP-22 composed of 22 amino acids, and CNP-53 composed of 53 amino acids in which 31 amino acid residues are attached to the N-terminal of the CNP-22, or derivatives thereof without any particular limitations provided that they possess CNP activity. These CNP-22, CNP-53, and their derivatives are all heretofore known, and can be manufactured by chemical synthesis or genetic manipulations.<!-- EPO <DP n="36"> --></p><p id="p0058" num="0058">There are no particular limitations to the origin of CNP-22 and CNP-53, provided that they possess CNP activity, but the CNP derived from mammals including humans or birds is preferred, and more preferably, the CNP derived from humans, monkeys, mice, rats or pigs, and particularly preferably, the CNP derived from humans.</p><p id="p0059" num="0059">The CNP derivatives means those having, in the amino acid sequences of the CNP-22 or CNP-53, deletion(s), substitution(s) or addition(s) of 1-5 amino acids, more preferably 1-3 amino acids, and furthermore preferably 1 or 2 amino acids, while possessing CNP activity, or alternatively, those having a sequence with a homology of 85% or more, preferably 90% or more, and more preferably 95% or more with the amino acid sequence of the CNP-22 or CNP-53, while possessing CNP activity.</p><p id="p0060" num="0060">Replaceable amino acids are ideally substituted by conservative amino acid substitution with amino acids having similar polarities and charges. For example, nonpolar uncharged amino acids include glycine, alanine, valine, leucine, isoleucine, proline, etc.; aromatic amino acids include phenylalanine, tyrosine, tryptophan; polar uncharged amino acids include serine, threonine, cysteine, methionine, asparagine, glutamine, etc.; negatively-charged amino acids include asparaginic acid, glutamic acid; positively-charged amino acids include lysine, arginine, histidine. Thus, preferably amino-acid substitution is carried out between conservative amino acids belonging to the same group. Here, when proline is to be replaced by another nonpolar uncharged amino acid, or when proline is<!-- EPO <DP n="37"> --> to replace another nonpolar uncharged amino acid, then it should be noted that proline is not flexible in its spatial orientation. Similarly, when cysteine is to be replaced by another polar uncharged amino acid, or when cysteine is to replace another polar uncharged amino acid, then it should be noted that cysteine may form a disulfide bond with another cysteine.</p><p id="p0061" num="0061">CNP derivatives may include those amidated or methoxylated at a C-terminal, CNP modified with addition of polyethylene glycol or fatty acids, and, glycosylated or alkylated CNP, given that they have CNP activity.</p><p id="p0062" num="0062">Thus, any heretofore known CNPs with CNP activity can be used in the present invention. Examples may include CNP derivatives disclosed in <patcit id="pcit0006" dnum="JP6009688A"><text>JP A 6-9688</text></patcit>, CNP derivatives disclosed in <patcit id="pcit0007" dnum="US5583108A"><text>US Patent No. 5583108</text></patcit>, and CD-NP disclosed in <patcit id="pcit0008" dnum="US6818619B"><text>US Patent No. 6818619</text></patcit>. It is possible to easily test the presence/absence of CNP activities using heretofore known procedures, such as by testing a growth inhibitory action on the vascular smooth muscle cells, or by examining the activity of cGMP production in the cells expressing NPR-B receptors.</p><p id="p0063" num="0063">While any of CNP-22, CNP-53 and their derivatives can be used as the active ingredient of the present invention, CNP-22 with a smaller molecular weight is more preferable in terms of absorbability. CNP-22 can be manufactured by chemical synthesis or genetic manipulations using human CNP genes, and is also available from, for example, Peptide Institute Inc. as CNP-22 (human).</p><p id="p0064" num="0064"><!-- EPO <DP n="38"> --> CNP that can be used in the present invention includes: purified naturally occurring CNP, genetically engineered CNP manufactured using known genetic engineering procedures, CNP manufactured using known chemical synthetic procedures (such as solid-phase peptide synthesis by a peptide synthesis machine). Basic methods including genetic engineering techniques, site-specific mutagenesis, and PCR, are commonly known or heretofore known, and are described in, for example, <nplcit id="ncit0011" npl-type="b"><text>Current Protocols In Molecular Biology; John Wiley &amp; Sons (1998</text></nplcit>), and <patcit id="pcit0009" dnum="JP5207891A"><text>JP A 5-207891</text></patcit>.</p><p id="p0065" num="0065">Here, the BNP refers to: BNP-26 composed of 26 amino acids, BNP-32 composed of 32 amino acids, BNP-45 composed of 45 amino acids, or their derivatives without any particular limitations provided that they possess BNP activity. BNP can also be high molecular weight γ-BNP (molecular weight of approximately 13,000) which is formed by the removal of the signal peptide from a BNP precursor. BNP-32 and their derivatives are preferred. BNP-26, BNP-32, BNP-45, and their derivatives are heretofore known, and can be manufactured by chemical synthesis or genetic manipulations.</p><p id="p0066" num="0066">There are no particular limitations to the origin of the BNP-26, BNP-32 and BNP-45, provided that they possess BNP activity, but the CNP derived from mammals including humans or birds is preferred, and the CNP derived from humans, monkeys, mice, rats or pigs is more preferred, and the CNP derived from humans is particularly preferred.</p><p id="p0067" num="0067"><!-- EPO <DP n="39"> --> The BNP derivatives means, those having, in the amino acid sequences of BNP-26, BNP-32 or BNP-45, deletion(s), substitution(s) or addition(s) of 1-5 amino acids, more preferably 1-3 amino acids, and furthermore preferably 1 or 2 amino acids, while possessing BNP activity, or alternatively, those having a sequence with a homology of 85% or more, preferably 90% or more, and more preferably 95% or more with the amino acid sequence of BNP-26, BNP-32 or BNP-45, while possessing BNP activity.</p><p id="p0068" num="0068">Replaceable amino acids are ideally substituted by conservative amino acid substitution with amino acids having similar polarities and charges. For example, nonpolar uncharged amino acids include glycine, alanine, valine, leucine, isoleucine, proline, etc.; aromatic amino acids include phenylalanine, tyrosine, tryptophan; polar uncharged amino acids include serine, threonine, cysteine, methionine, asparagine, glutamine, etc.; negatively-charged amino acids include asparaginic acid, glutamic acid; positively-charged amino acids include lysine, arginine, histidine. Thus, preferably amino-acid substitution is carried out between conservative amino acids belonging to the same group. Here, when proline is to be replaced by another nonpolar uncharged amino acid, or when proline is to replace another nonpolar uncharged amino acid, then it should be noted that proline is not flexible in its spatial orientation. Similarly, when cysteine is to be replaced by another polar uncharged amino acid, or when cysteine is to replace another polar uncharged amino acid, then it should<!-- EPO <DP n="40"> --> be noted that cysteine may form a disulfide bond with another cysteine.</p><p id="p0069" num="0069">BNP derivatives may include those amidated or methoxylated at a C-terminal of BNP, BNP modified with addition of polyethylene glycol or fatty acids, and, glycosylated or alkylated BNP, provided that they have BNP activity.</p><p id="p0070" num="0070">Thus, any heretofore known BNP with BNP activity can be used in the present invention. Examples may include BNP derivatives disclosed in <patcit id="pcit0010" dnum="JP2007525213A"><text>JP A 2007-525213</text></patcit>, BNP derivatives disclosed in <patcit id="pcit0011" dnum="US6028055A"><text>US Patent No. 6028055</text></patcit>, BNP derivatives disclosed in <patcit id="pcit0012" dnum="US5114923A"><text>US Patent No. 5114923</text></patcit>, and BD-NP disclosed in <patcit id="pcit0013" dnum="US6818619B"><text>US Patent No. 6818619</text></patcit>.</p><p id="p0071" num="0071">It is possible to easily test the presence/absence of BNP activity using heretofore known procedures, such as an examination of the activity of cGMP production in the cells expressing NPR-A receptors.</p><p id="p0072" num="0072">While any of BNP-26, BNP-32, BNP-45 and their derivatives can be used as the active ingredient of the present invention, BNP-32 is preferable in terms of drug efficacy and availability.</p><p id="p0073" num="0073">BNP can be manufactured by chemical synthesis or genetic manipulations using human BNP genes (for example, refer to <patcit id="pcit0014" dnum="JP5207891A"><text>JP A 5-207891</text></patcit>, <patcit id="pcit0015" dnum="JP2007525957A"><text>JP A 2007-525957</text></patcit>, <patcit id="pcit0016" dnum="JP2007525213A"><text>JP A 2007-525213</text></patcit>), and BNP is also commercially<!-- EPO <DP n="41"> --> available since it has already been launched. Alternatively, it is available from, for example, Peptide Institute Inc. as BNP-32 (human).</p><p id="p0074" num="0074">BNP that can be used in the present invention includes: purified naturally occurring BNP, genetically engineered BNP manufactured using known genetic engineering procedures, BNP manufactured using known chemical synthesis procedures (such as solid-phase peptide synthesis by a peptide synthesis machine). Basic methods including genetic engineering techniques, site-specific mutagenesis, and PCR, are commonly known or heretofore known, and are described in, for example, <nplcit id="ncit0012" npl-type="b"><text>Current Protocols in Molecular Biology; John Wiley &amp; Sons (1998</text></nplcit>), and <patcit id="pcit0017" dnum="JP5207891A"><text>JP A 5-207891</text></patcit>.</p><p id="p0075" num="0075">When the term "CNP or BNP" is used herein, it refers to either CNP or BNP, as well as the chimeric peptides of CNP and BNP. That is, as used herein, the term "CNP or BNP" refers to "CNP or BNP" which may be: a chimeric peptide of CNP and BNP, in which CNP is CNP-22, CNP-53, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence having deletion, substitution, or addition of any amino acid in the amino acid sequence of CNP-22 or CNP-53, and in which BNP is BNP-26, BNP-32, BNP-45, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence having deletion, substitution, or addition of any amino acid in the amino acid sequence of BNP-26, BNP-32 or BNP-45, and wherein the chimeric peptide is the one that forms a ring structure by an intramolecular<!-- EPO <DP n="42"> --> disulfide bond, and wherein the chimeric peptide is the one that has CNP activity or BNP activity; or a derivative of the chimeric peptide.</p><p id="p0076" num="0076">Here, there are no particular limitations to the origin of CNP-22 and CNP-53, provided that they possess CNP activity, but the CNP derived from mammals including humans or birds are preferred, and more preferably, CNP derived from humans, monkeys, mice, rats or pigs, and most preferably, CNP derived from humans. Similarly, there are no particular limitations to the origin of BNP-26, BNP-32 and BNP-45, provided that they possess BNP activity, but the BNP derived from mammals including humans or birds is preferred, and the BNP derived humans, monkeys, mice, rats or pigs is more preferred, and the BNP derived from humans is particularly preferred.</p><p id="p0077" num="0077">The derivatives of chimeric peptide of CNP and BNP mean those which have, in the amino acid sequences of the chimeric peptide of CNP and BNP, a deletion, addition or substitution of preferably 1-5 amino acids, more preferably 1-3 amino acids, and furthermore preferably 1 or 2 amino acids, while possessing CNP or BNP activity.</p><p id="p0078" num="0078">Replaceable amino acids are ideally substituted by conservative amino acid substitution with amino acids having similar polarities and charges. For example, nonpolar uncharged amino acids include glycine, alanine, valine, leucine, isoleucine, proline, etc.; aromatic amino acids include phenylalanine, tyrosine, tryptophan; polar<!-- EPO <DP n="43"> --> uncharged amino acids include serine, threonine, cysteine, methionine, asparagine, glutamine, etc.; negatively-charged amino acids include asparaginic acid, glutamic acid; positively-charged amino acids include lysine, arginine, histidine. Thus, preferably amino-acid substitution is carried out between conservative amino acids belonging to the same group. Here, when proline is to be replaced by another nonpolar uncharged amino acid, or when proline is to replace another nonpolar uncharged amino acid, then it should be noted that proline is not flexible in its spatial orientation. Similarly, when cysteine is to be replaced by another polar uncharged amino acid, or when cysteine is to replace another polar uncharged amino acid, then it should be noted that cysteine may form a disulfide bond with another cysteine.</p><p id="p0079" num="0079">The derivatives of chimeric peptide of CNP and BNP may include those amidated or methoxylated at C terminal of the of chimeric peptide of CNP and BNP, those modified with addition of polyethylene glycol or fatty acids in the chimeric peptide of CNP and BNP, and, glycosylated or alkylated chimeric peptide of CNP and BNP, provided that they have CNP or BNP activity.</p><p id="p0080" num="0080">Thus, it is possible to use any heretofore known chimeric peptides of CNP and BNP or derivatives thereof in the present invention, on the condition that they possess CNP or BNP activity.</p><p id="p0081" num="0081"><!-- EPO <DP n="44"> --> Presence/absence of CNP or BNP activity can be easily tested using heretofore known procedures, such as an examination of the activity of cGMP production in the cells expressing NPR-A receptors or in the cells expressing NPR-B.</p><p id="p0082" num="0082">The chimeric peptides of CNP and BNP and their derivatives can also be manufactured by chemical synthesis or by genetic manipulations.</p><p id="p0083" num="0083">Dermatitis is an inflammation of the skin, characterized by common symptoms such as erythema, infiltrative erythema, lichenified lesions, scales, adhesion of crusts, eczema, abrasion, excoriations, prurigo nodularis, papules, erosions, infiltration, vesicles, edema, etc., and in particular, symptoms such as itching, blisters, reddening, swelling, feeling of oozing, scabs, scale formation, etc.</p><p id="p0084" num="0084">The skin external-preparation composition can be applied to dermatitis patients with inflammation, suffering from, atopic dermatitis, dermatitis that led up to steroid dermatitis, steroid-resistant dermatitis, dermatitis which cannot be treated with tacrolimus, chronic dermatitis, erythroderma, eczema, contact dermatitis, seborrheic dermatitis, autosensitization dermatitis, stasis dermatitis, urticaria, drug eruption, cutaneous angiitis, prurigo, pruritus cutaneus, erythema, psoriasis, rosacea, rosacea-like dermatitis, lichen planus, follicular<!-- EPO <DP n="45"> --> keratosis, and more preferably from atopic dermatitis, dermatitis that led up to steroid dermatitis, steroid-resistant dermatitis, dermatitis which cannot be treated with tacrolimus, chronic dermatitis, eczema, erythroderma, rosacea, rosacea-like dermatitis, and psoriasis, and even more preferably from atopic dermatitis, steroid-resistant dermatitis, chronic dermatitis, eczema, erythroderma, rosacea, rosacea-like dermatitis, and psoriasis, and most preferably from atopic dermatitis.</p><p id="p0085" num="0085">A skin external-preparation composition means a composition externally and directly applicable to the skin, and more specifically refers to a therapeutic agent for dermatitis. There are no particular limitations in its dosage form, but preferably it is an ointment, gel, cream, lotion, solution, spray, or patch, and more preferably, an ointment, gel, cream or solution. These dosage forms are particularly suited for therapeutic agents for dermatitis. When the skin external-preparation composition is to be used as a skin texture-improving agent, the preferred dosage forms are the following; cream, foam, skin lotion, facial mask, skin-softening water, skin emulsion, foundation, makeup base, essence, soap, liquid cleanser, bath agent, sun-block cream, suntan oil or spray-type liquid preparation. When the skin external-preparation composition is used as a skin texture-improving agent, it may be a skin-care cosmetic or a quasi drug.</p><p id="p0086" num="0086"><!-- EPO <DP n="46"> --> In terms of indication, the skin external-preparation composition as a therapeutic agent for dermatitis can be applied to dermatitis associated with at least one of the rash symptoms selected from: erythema, infiltrative erythema, lichenified lesions, scales, adhesion of crusts, eczema, abrasion, excoriations, prurigo nodularis, papules, erosions, infiltration, vesicles, and edema. These symptoms are the symptoms observed in patients with atopic dermatitis.</p><p id="p0087" num="0087">Atopic dermatitis mentioned above is defined by the Japanese Dermatological Association as a dermatitis for "which exacerbations and remissions recur, being mainly characterized by pruritic eczema, in which most of the patients have atopic diathesis".</p><p id="p0088" num="0088">That is to say, atopic dermatitis is a chronic eczema associated with itching that occurs in those who have an allergic predisposition. It is a typical inflammatory skin disease showing the conditions wherein the symptoms accompany itching, the rashes are eczematous lesions, which reddens as an acute lesion (erythema), oozing eruptions (papules and serous papules) are formed, then the skin peeled off and crusts are formed (scales and crusts). The chronic pathological lesions include thickening and hardening of the skin (lichenification), and formation of hard lumps (prurigo). Rashes have a tendency to develop on the forehead, around the eyes, around the mouth, on the neck, around the joints such as the elbows, knees and wrists, on the dorsal and abdominal regions, and they are<!-- EPO <DP n="47"> --> often characterized by a symmetrical distribution. In infantile atopic dermatitis, the lesions generally appear on the head and face first, and occasionally spread to the trunk and four limbs, whereas in puberty and adulthood, severe rashes tend to occur in the upper body (face, neck, chest and back). Atopic dermatitis also has a tendency to be chronic or recurrent lasting over 6 months, or 2 months in infants.</p><p id="p0089" num="0089">The skin external-preparation, in particular the therapeutic agent for dermatitis, is both safe and effective as a therapeutic agent for such atopic dermatitis which has conventionally been regarded as a difficult-to-treat disease.</p><p id="p0090" num="0090">Dermatitis that led up to steroid dermatitis refers to dermatitis, wherein it develops a group of adverse side effects due to the long-term continuous use of steroid external drugs. In particular, dermatitis in which a rebound phenomenon occurs upon withdrawal from steroid external drugs is called steroid dermatitis, and steroid rosacea is a typical example of steroid dermatitis.</p><p id="p0091" num="0091">Steroid-resistant dermatitis refers to dermatitis with decreased responsiveness to the steroid external preparations resulting from long-term use of the steroid external preparations. Steroid-resistant dermatitis tends to occur when steroid external preparations are used for a long time for the treatment of atopic dermatitis.</p><p id="p0092" num="0092"><!-- EPO <DP n="48"> --> Dermatitis to which tacrolimus is not applicable, means dermatitis suffered by pregnant women, infants below the age of 2, patients with oozing ulcerated regions or scratches, and women who are breast-feeding. In cases of dermatitis in immune-compromised patients and patients with a kidney disorder, caution needs to be taken with the use of tacrolimus. Hence, these dermatitides can also be regarded as the dermatitis to which tacrolimus is not applicable.</p><p id="p0093" num="0093">Chronic dermatitis is a dermatitis that has become chronic and intractable, and includes atopic dermatitis and contact dermatitis caused by an allergy or an irritation by the substance that contacts the skin.</p><p id="p0094" num="0094">Psoriasis is a chronic and repeatedly recurrent skin disease, characterized by one or several erythematous rashes (erythema) and silvery-white squamate scales.</p><p id="p0095" num="0095">Erythroderma, also called exfoliative dermatitis, commonly develops from atopic dermatitis or eczema in elderly patients, and it is a dermatitis characterized by skin flush over the whole body accompanied by desquamation. Diffuse erythema is observed over the whole body or on wide areas of the skin. Erythroderma includes erythroderma posteczematosa and erythroderma secondary to dermatoses, toxic erythroderma, infantile desquamative erythroderma, and paraneoplastic erythroderma. Of these, erythroderma posteczematosa refers to a state called erythroderma that shows skin flush and desquamation over the whole body,<!-- EPO <DP n="49"> --> caused by generalization of eczema due to long-term external application of inappropriate steroids or due to an increase of severity. Erythroderma is a significantly intractable disease with systemic symptoms, which is usually associated with itching, and as systemic symptoms, associated with failure of thermoregulation such as fever, chills, and shivering, hypoproteinemia and edema occurring with desquamation, electrolyte abnormality due to loss of water from the exfoliated skin, swelling of lymph nodes, a general feeling of malaise, and loss of body weight. Internal or external application of steroids is adopted for the treatment; however, because of its significantly intractable nature, symptoms may immediately relapse or even worsen as rebound phenomena upon discontinuation of medication.</p><p id="p0096" num="0096">Rosacea is a persistent skin disease, which typically produces conditions in which reddening and small pustules occur on the central area of the face, and in which blood vessels are fairly visible.</p><p id="p0097" num="0097">Rosacea-like dermatitis is characterized by many red papules, diffused skin flush and desquamation, and is often seen in adult females. Its major development factor is a long-term external application of steroids, and it is one of the representative side effects of steroid external preparations; for its treatment, rebound of symptoms is severe, and therapeutic technique and the patients' patience are required for getting over it.</p><p id="p0098" num="0098"><!-- EPO <DP n="50"> --> Prurigo often induces rashes as symptoms in addition to itching. Major causes of prurigo include parasites such as Sarcoptes scabiei, mites and lice, insect bites, urticaria, atopic dermatitis, allergic dermatitis and contact dermatitis, etc.</p><p id="p0099" num="0099">Erythema multiforme is a repeatedly recurrent dermatosis characterized by red raised skin lesions, presenting rashes that look like shooting targets. Symptoms of erythema multiforme often appear as a result of infection with herpes simplex viruses. In many cases, Erythema multiforme develops suddenly, and presents with red rashes (erythema) on the arms, legs and face as symptoms. Erythema presents with symptoms in a concentric fashion like a shooting target, sometimes associated with blisters.</p><p id="p0100" num="0100">Erythema nodosum is an inflammatory disease with tender red lumps (nodules) under the skin. Quite frequently it appears as a symptom of other diseases or as hypersensitivity to drugs. Young adults, in particular females are prone to erythema nodosum. It relapses repeatedly for several months to several years. Erythema nodosum may occur from infection with bacteria, fungi, or viruses.</p><p id="p0101" num="0101">Lichen planus is a skin disease with recurrent itching. Its symptoms include occurrence of small red or purple raised rashes. Initially the rashes are individually<!-- EPO <DP n="51"> --> separated, then in many cases, plural rashes are fused to form papules associated with rough, scaly and dry skin.</p><p id="p0102" num="0102">Lichen pilaris is also called as follicular keratosis. It is a disease in which the orifice of the hair follicle is clogged with dead cells (cuticle) that have been sloughed off from the upper layer of the skin.</p><p id="p0103" num="0103">Contact dermatitis includes irritant contact dermatitis and allergic contact dermatitis. The former is an inflammation of the skin caused by direct contact of the skin with a specific irritant, such as acid, alkali and solvent, etc. The rash is associated with strong itching, and affected regions are limited, often having a clear boundary with normal skin.</p><p id="p0104" num="0104">The therapeutic agent compositions for dermatitis can be formulated using widely used technologies. Examples of their formulation include external preparation, injectable preparation, oral preparation, and nasal preparation. In the case of oral preparation, enteric-coated preparations are preferred in order to avoid peptide degradation in the stomach. Examples of enteric-coated preparations include preparations wherein an enteric-substance is coated on capsules, tablets, or granules. In general, since peptide drugs are rapidly metabolized and easily excreted from the body, they can be modified with polyethylene glycol (PEGylation) in order to prolong their half life without<!-- EPO <DP n="52"> --> affecting the biological activities, and to decrease antigenicity.</p><p id="p0105" num="0105">The preferred dosage form of the therapeutic agent compositions for dermatitis is external preparations (transdermal absorption preparations) such as gel preparations, ointment preparations, liquid preparations, etc.</p><p id="p0106" num="0106">External preparations are not particularly limited as long as the present agent can be directly applied, sprayed, or attached to the desired region of the skin (affected area). The dosage form of the therapeutic agent composition for dermatitis of the present invention is preferably an external preparation such as an ointment preparation, gel preparation, cream preparation, lotion preparation, liquid preparation, spray preparation, or patch preparation, and particularly preferably, from the viewpoint of ease of application, an ointment preparation, gel preparation, cream preparation or liquid preparation, and more preferably a gel preparation, ointment preparation or liquid preparation consisting of an aqueous solution.</p><p id="p0107" num="0107">These external preparations can be easily obtained in accordance with heretofore known or well-known methods, by blending a pharmaceutically acceptable base and, as necessary, various additives, with CNP or BNP as an active ingredient or a principal agent.</p><p id="p0108" num="0108"><!-- EPO <DP n="53"> --> A gel preparation (suspension base) may be a hydrous gel, an anhydrous gel, or a gel with a low water content comprising a gel-forming material that can swell. It may also be a hydrogel base or a lyogel base, and preferably a transparent hydrogel having an inorganic or organic polymer as a base. Similar to those preparations comprising an oil or fat content, the gel itself is not absorbed by the skin. Hydrogel bases have no fat, have a consistency similar to that of ointment, and aim at increasing the transdermal absorbability of drugs. Lyogel bases are gelled by suspending stearyl alcohol, etc. in propylene glycol, and they have excellent transdermal absorbability and hygroscopicity.</p><p id="p0109" num="0109">The gel preparation may be a gel preparation manufactured by homogenously dispersing CNP or BNP as an active ingredient into a hydrophilic gel base comprising carboxy vinyl polymer, sodium polyacrylate, sodium polyacrylate, (vinyl methyl ether/ethyl maleate) copolymer, polymethacrylate, propylene glycol, etc. Examples of such gel preparations include gel preparations wherein ingredients are homogeneously dispersed in a commercially-available long-lasting water-retention agent, such as Lubrajel NP, Lubrajel CG, Lubrajel DV, Lubrajel MS, Lubrajel OIL, Lubrajel TW, Lubrajel DS, which are commercially-available products available from ISP Japan, Ltd., etc.</p><p id="p0110" num="0110">As used herein, "gel preparation" refers to gel preparations prepared in accordance with Example 2,<!-- EPO <DP n="54"> --> comprising dipotassium glycyrrhizinate, allantoin, pyridoxine hydrochloride, xanthan gum, and vitamin E. As used herein, "gel-base preparation" refers to gel preparations prepared in accordance with Examples 7, 13 or 14, which differ from the "gel preparation" in that the gel-base preparation does not comprise dipotassium glycyrrhizinate, allantoin, pyridoxine hydrochloride, xanthan gum, and vitamin E. The "gel preparations" of the present invention include both "gel preparations" and "gel-base preparations."</p><p id="p0111" num="0111">A liquid preparation means those wherein an active ingredient consisting of CNP or BNP is dissolved in a base such as alcohol, propylene glycol, polyethylene glycol or water. Preferably, it means a liquid preparation consisting of an aqueous solution wherein either CNP or BNP is dissolved in saline. In the aqueous solutions, a small amount of an organic base such as alcohol, propylene glycol, polyethylene glycol, etc. may be mixed, in addition to saline.</p><p id="p0112" num="0112">At this time, in order to ensure the extent of bioavailability and to provide more effective liquid preparations, in other words, with the aim of improving the extent of bioavailability upon subcutaneous injection of a bioactive peptide comprising CNP or BNP, it is possible to make the pH of the solution to be 3.0-7.0 by making an acid solution wherein one or more from the group consisting of butyric acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid,<!-- EPO <DP n="55"> --> benzoic acid, and salts thereof are combined with the bioactive peptide CNP or BNP as the active ingredient, or by making a polar organic solution wherein one or more from the group consisting of alcohols, and/or N-methyl-2-pyrrolidine, dimethylformamide, dimethyl sulfoxide, and methylparaben are combined with the bioactive peptide CNP or BNP as the active ingredient.</p><p id="p0113" num="0113">An ointment preparation may be either a grease base or a water-soluble base, and both can be easily obtained in accordance with heretofore known methods. A grease base such as vaseline has little irritation and is odorless, which is superior in protective action of the skin, softening action, crust-removal action, formation of granulation tissue, and epithelialization-stimulating action. A water-soluble base is an ointment having a macrogol base as the main ingredient, and has a strong action to absorb and remove aqueous secretions.</p><p id="p0114" num="0114">A cream preparation (emulsion base) may be an oil-in-water base (O/W) (vanishing cream) or a water-in-oil base (cold cream). An oil-in-water base has a smaller amount of oil-soluble component than water-soluble component. It has an advantage that the white color of a cream appears to disappear upon application. It extends well and feels good upon application to sweaty skin, thus it is cosmetically superior. In addition, it also has a good absorbability into the skin, thus is applicable to chronic hypertrophic lesions. A water-in-oil base has a smaller amount of water-soluble component than oil-soluble component, and is<!-- EPO <DP n="56"> --> also called a cold cream because it has a cooling action upon application by extending over the skin.</p><p id="p0115" num="0115">A lotion preparation means a liquid external preparation wherein CNP or BNP is dissolved or homogeneously dispersed in a liquid. Since ointments and creams tend to adhere to the hair, lotions are suitable for use on the head hair region, etc. The form of lotions may be any of a suspension lotion base, an emulsion lotion, and a solution-type lotion base.</p><p id="p0116" num="0116">In a patch preparation, a component comprising CNP or BNP is adsorbed to a patch, thereby stimulating absorption of the drug by utilizing the airtight characteristic of the patch. Upon application of the patch, scratching can be prevented.</p><p id="p0117" num="0117">A spray preparation refers to those wherein CNP or BNP is made into a solution, which is then sprayed by gas pressure. Sprays are convenient when applied to wide areas.</p><p id="p0118" num="0118">Thus, the therapeutic agent composition for dermatitis is a transdermal external preparation comprising an appropriate amount of CNP or BNP and various bases, as well as additives as necessary. To exert drug effects as an external preparation, it is important that the concentration of the active ingredient (CNP or BNP) applied to the skin surface can reach an effective concentration at affected lesions, and that the concentration can be maintained. Accordingly, dosage forms<!-- EPO <DP n="57"> --> and bases can be appropriately selected depending on the symptoms and patient.</p><p id="p0119" num="0119">Additives may be appropriately used depending on objectives. As additives, the following may be used.</p><p id="p0120" num="0120">Vaseline: Vaseline can be used as a base for ointment preparations. Viscosity and consistency vary with temperature, and its hardness differs between winter and summer. Vaseline is one of the safest bases. There are yellow vaseline, and white vaseline with a higher purity; both can be used.</p><p id="p0121" num="0121">Propylene glycol: Propylene glycol can be used as a solvent, solubilizing agent, or base for drugs.</p><p id="p0122" num="0122">Paraffin: Paraffin can be used when adjusting the viscosity/consistency of ointment preparations. Since its emulsification is relatively-easy, paraffin may also be used as an oil base for production of creams.</p><p id="p0123" num="0123">Bees wax (white beeswax): Bees wax is a processed wax of the honeycomb, which can be used as "Japanese Pharmacopoeia" simple ointment by blending with plant-derived fat and oil. White beeswax is a bleached product of bees wax to improve color and odor.</p><p id="p0124" num="0124">Macrogol: Macrogol is a mixture of polyethylene glycols with different molecular weights. It has good drug solubility and mixing characteristic, absorbs water well;<!-- EPO <DP n="58"> --> thus is suitable for adsorption and elimination of eluate from mucosa and affected area.</p><p id="p0125" num="0125">Stearyl alcohol: Stearyl alcohol can be used for emulsion lotions.</p><p id="p0126" num="0126">Isopropanol: Isopropanol can be used as a solvent or solubilizing agent, etc.</p><p id="p0127" num="0127">Benzyl alcohol: Benzyl alcohol can be used as a solubilizing agent and preservative, etc.</p><p id="p0128" num="0128">Parahydroxybenzoate esters (parabens): Parahydroxybenzoate esters can be used as an antiseptic agent, preservative, and stabilizer.</p><p id="p0129" num="0129">Gelled hydrocarbon: Gelled hydrocarbon is generally called "Plastibase", which is made by making liquid paraffin into a gelled (semi-solid) state using polyethylene.</p><p id="p0130" num="0130">Citric acid, sodium citrate: Citric acid and sodium citrate can be used as buffering agents or pH adjusters.</p><p id="p0131" num="0131">Squalene: Squalene is used as a base, and has slightly less oily feeling, being less sticky, than liquid paraffin. Similar to creams, squalene can also be used widely for emulsion lotions.</p><p id="p0132" num="0132"><!-- EPO <DP n="59"> --> Lanolins: Lanolins are fats and oils obtained from sheep's wool; although lanolins have drawbacks in terms of color and odor, they are effective for improving the softness of the skin.</p><p id="p0133" num="0133">Glycerin: Glycerin can be blended in creams, etc. as a moisturizing agent.</p><p id="p0134" num="0134">Polyoxyethylene hardened castor oil: This can be used as an emulsifying agent, solubilizing agent, etc.</p><p id="p0135" num="0135">Sorbitan fatty acid ester, glycerin fatty acid ester: They can be used as emulsifying agents, etc.</p><p id="p0136" num="0136">The therapeutic agent for dermatitis may further comprise moisturizing agents (skin softening agents) and symptom-relieving agents, etc. as described below.</p><p id="p0137" num="0137">Moisturizing agent (skin softening agent): Moisturizing agents provide moisture and oil content to the skin. Moisturizing agents are most effectively used when the skin is already moisturized, for example, just after taking a bath or shower. Components contained in moisturizing agents include glycerin, mineral oil, and vaseline, etc. The form and type of moisturizing agents include lotion preparations, cream preparations, ointment preparations and bathing oils, etc. Those comprising urea, lactic acid and glycolic acid have superior moisturizing effects.<!-- EPO <DP n="60"> --></p><p id="p0138" num="0138">Symptom-relieving agent: Skin diseases are often accompanied by itching. Itching and mild pain can be reduced by blending a sedative drug, specifically, chamomile, eucalyptus, camphor, menthol, zinc oxide, talc, glycerin, and calamine, etc. To suppress itching due to an allergy, antihistamine agents such as diphenhydramine may be comprised.</p><p id="p0139" num="0139">As such, when manufacturing the therapeutic agents for dermatitis, the following various agents may be arbitrarily blended in combination: base, moisturizing agent, ultraviolet absorbing agent, alcohols, chelates, pH adjuster, antiseptic agent, thickening agent, coloring agent, flavor, filling agent, excipient, disintegrating agent, filler, binding agent, coating agent, solubilizing agent, suspending agent, buffer, stabilizing agent, preservative, surfactant, antioxidative agent, dispersing agent, emulsifying agent, dissolving agent, solubilizer, etc. In addition to CNP or BNP, which is the principal agent, various drugs such as antiphlogistic analgetics, sterilizing agents, vitamins, skin softening agents, etc. may be appropriately blended as necessary.<!-- EPO <DP n="61"> --></p><p id="p0140" num="0140">Next, as representative examples of preparations of the therapeutic agent composition for dermatitis, production of aqueous-solution preparations as a liquid preparation and gel preparation will be described.</p><p id="p0141" num="0141">One of the preferred external preparations is an aqueous-solution preparation.</p><p id="p0142" num="0142">Such an aqueous-solution preparation, can be prepared for example, as a liquid preparation with a CNP or BNP concentration of 1-1000 µg/g, by dissolving 0.01-10 mg of human CNP-22 (Peptide Institute, Inc.) or human BNP-32 (Peptide Institute, Inc.) as the principal agent into 10 ml of saline. Here, since the specific gravity of water is 1, the CNP or BNP concentration in this case is 1-1000 µg/g by weight ratio. When the blending ratio is 1 µg/g or less, effects are not sufficient, and sufficient effects can be obtained with blending at a ratio of no more than 500 µg/g. Concentrations of CNP or BNP in an aqueous-solution preparation are preferably 1-500 µg/g, more preferably 10-500 µg/g, furthermore preferably 20-200 µg/g, and particularly preferably 30-100 µg/g.</p><p id="p0143" num="0143">Gel preparations can be obtained by, in accordance with heretofore known or well-known methods, dissolving an<!-- EPO <DP n="62"> --> appropriate amount of CNP or BNP into distilled water or saline to make an aqueous solution, and by mixing and stirring a heretofore known or well-known gelling agent with the solution. The final concentration of the CNP or BNP in the gel preparation is 1-500 µg/g, more preferably 10-500 µg/g, furthermore preferably 20-200 µg/g, and particularly preferably 30-100 µg/g.</p><p id="p0144" num="0144">Examples of the gelling agent consisting of macromolecular inorganic components include hydrous or water-absorbing silicates, such as aluminum silicate, bentonite, magnesium aluminum silicate, and colloid silica. As the gelling agent consisting of macromolecular organic substances, natural, semi-synthetic, or synthetic polymers may be used. Examples of natural and semi-synthetic polymers include, polysaccharides such as cellulose etc., starch, tragacanth, gum arabic, xanthan gum, agar, gelatin, alginic acid and its salts, for example, sodium alginate and its derivatives, lower alkyl cellulose, for example, methyl cellulose or ethyl cellulose, carboxy- or hydroxyl-lower-alkyl- cellulose, for example, carboxymethyl cellulose, or hydroxypropyl cellulose, etc. Examples of synthetic gelling agents include polyvinyl alcohols, polyvinyl pyrrolidones, polyacrylic acids or polymethacrylic acids, etc. Only one kind of these gelling agents, or a mixture of two or more kinds of these may be used.</p><p id="p0145" num="0145"><!-- EPO <DP n="63"> --> As necessary, a transdermal absorption aid may be added. Examples of the transdermal absorption aid include, for example, acetic acid, sodium acetate, limonene, menthol, salicylic acid, hyaluronic acid, oleic acid, N,N-diethyl-m-toluamide, n-butyl stearate, benzyl alcohol, isopropyl myristate, isopropyl palmitate, polypropylene glycol, crotamiton, diethyl sebacate, N-methyl pyrrolidone, N-ethyl pyrrolidone, lauryl alcohol, etc. In addition, an antiseptic agent and an antioxidant may be added as necessary.</p><p id="p0146" num="0146">The concentration of CNP or BNP in the therapeutic agent composition for use in treating dermatitis of the present invention may be appropriately selected according to symptoms, age, and dosage form, etc. The concentration of CNP or BNP is, for external preparations such as liquid preparations, gel preparations and lotion preparations, etc., 1-500 µg/g, more preferably 10-500 µg/g, furthermore preferably 20-200 µg/g, and particularly preferably 30-100 µg/g. For younger patients or patients with sensitive skin, the use of 20-100 µg/g concentration is preferred. The concentration of CNP or BNP in a gel preparation and ointment preparation is preferably 1-500 µg/g, more preferably 10-500 µg/g, and furthermore preferably 20-200 µg/g, and particularly preferably 30-100 µg/g. The concentration of CNP or BNP in a liquid preparation is preferably 1-500 µg/ml, more preferably 10-500 µg/ml, furthermore preferably 20-200 µg/ml, and particularly preferably 30-100 µg/ml. Here, since the specific gravity of the solution used in the liquid preparation<!-- EPO <DP n="64"> --> is almost 1, when the concentration of CNP or BNP in the liquid preparation is indicated in the units of µg/g, it is equivalent to the indication in the units of µg/ml for the concentration of CNP or BNP.</p><p id="p0147" num="0147">The administration of the therapeutic agent composition for dermatitis differs depending on symptoms, age and dosage form, etc.; however, administration is normally once or twice a day, and the duration of administration is from 1 to 10 days.</p><heading id="h0021"><b>Example 1</b></heading><heading id="h0022"><b>Diagnosis and evaluation of subjects</b></heading><p id="p0148" num="0148">First, prior to administration of the CNP preparation or BNP preparation, subjects were diagnosed and evaluated. The methods for diagnosis and evaluation of the subjects are as follows.</p><heading id="h0023">1. Diagnosis of subjects:</heading><p id="p0149" num="0149">All the subjects were patients for whom administration of existing external drugs such as steroids, etc. was ineffective. The diagnosis and treatment of these subjects were performed by the present inventor as a medical doctor.</p><heading id="h0024">2. Evaluation of symptoms:</heading><p id="p0150" num="0150">The evaluation of symptoms of atopic dermatitis was performed in accordance with, in principle, "2005 Guideline for the Treatment of Atopic Dermatitis by the Scientific Research Division of the Health and Welfare Ministry of Japan" (hereinafter, simply referred to as "Guideline<!-- EPO <DP n="65"> --> 2005") by the classification into four levels as shown in Table 1.</p><p id="p0151" num="0151"><tables id="tabl0001" num="0001"><table frame="all"><title>[Table 1]</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="69mm"/><colspec colnum="2" colname="col2" colwidth="97mm"/><thead><row><entry namest="col1" nameend="col2" align="left" valign="top">Evaluation of symptoms</entry></row></thead><tbody><row><entry>Mild</entry><entry>Only mild rash is observed regardless of size.</entry></row><row><entry>Moderate</entry><entry>Rash with severe inflammation is observed in less than 10% of the body surface area.</entry></row><row><entry>Severe</entry><entry>Rash with severe inflammation is observed over 10% or more and less than 30% of the body surface area.</entry></row><row><entry>Most severe</entry><entry>Rash with severe inflammation is observed over 30% or more of the body surface area.</entry></row><row><entry namest="col1" nameend="col2" align="left">"Mild rash": means lesions mainly characterized by mild erythema, dryness, and desquamation.</entry></row><row><entry namest="col1" nameend="col2" align="left">"Rash with severe inflammation": means lesions associated with erythema, papules, erosions, infiltration and lichenification, etc.</entry></row></tbody></tgroup></table></tables></p><p id="p0152" num="0152">In addition, the severity level of the rash at each region was determined in accordance with "Guidelines for Management of Atopic Dermatitis by the Japanese Dermatological Association" (hereinafter, simply referred to as the "Dermatological Association Guideline"), as shown in Table 2.</p><p id="p0153" num="0153"><tables id="tabl0002" num="0002"><table frame="all"><title>[Table 2]</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="18mm"/><colspec colnum="2" colname="col2" colwidth="148mm"/><thead><row><entry valign="top"/><entry valign="top">Severity level of rash</entry></row></thead><tbody><row><entry>Minor</entry><entry>Mainly characterized by dry symptoms with a little inflammation symptoms.</entry></row><row><entry>Mild</entry><entry>Mainly characterized by dryness and mild erythema and scales, etc.</entry></row><row><entry>Moderate</entry><entry>Mainly characterized by up to mild erythema, scales, a small number of papules and abrasion, etc.</entry></row><row><entry>Severe</entry><entry>Mainly characterized by erythema with severe swelling/edema/infiltration/or lichenification, many papules, severe scales, adhesion of crusts, vesicles, erosions, numerous excoriations, and prurigo nodularis, etc.</entry></row></tbody></tgroup><!-- EPO <DP n="66"> --></table></tables></p><p id="p0154" num="0154">The severity level of the rash of each region was also determined using SCORAD (SCORing of Atopic Dermatitis) index, which was proposed by the European Task Force on Atopic Dermatitis and is widely used throughout the world. With the SCORAD index, a severity level is determined by the summation of rating scores for each of (A) extent %, (B) intensity of rash, (C) subjective symptoms. In the evaluation of the present study, the intensity of rash (B) was evaluation with the following 4 levels: 0: none, 1: mild, 2: moderate, 3: severe, with respect to 6 items: erythema, edema/papulation, oozing/crusting, excoriation, lichenification, and dryness. Since the regions of application were limited to parts of the body instead of the whole body, the total score was not determined in accordance with a specified calculation formula of the severity-level classification by SCORAD. Instead, a score, which is a simple summation of the rating scores of the 6 items of intensity of rash at the region of application before and after the application, was used. Since choice of the external therapeutic method, which is a primary therapy, is determined based on the severity of each rash, the severity level of each rash is the most important factor in selecting external therapy as well as in predicting therapeutic outcomes. Details of the SCORAD index are described, for example, in <nplcit id="ncit0013" npl-type="s"><text>C. Gelmetti and C. Colonna, Allergy, Vol. 59, Supplement 78, p. 61, 2004</text></nplcit>.</p><heading id="h0025">3. Test method:</heading><!-- EPO <DP n="67"> --><p id="p0155" num="0155">In general, in order to evaluate the effects of external preparations on individual cases, a right/left comparative method is suitable. It is a method wherein, the therapeutic effects of active ingredients are identified by, for example, applying an external preparation comprising the active ingredient to be tested is applied to the left side of the affected region, and an external preparation without the active ingredient is applied to the right side. The preparations of the present invention were tested by right/left comparative method in preliminary tests. However, considering the medical ethics, preliminary tests by the right/left comparative method were limited to a minimum degree, and when preliminary tests were not performed, therapeutic effects were evaluated by the comparison between before and after application.</p><heading id="h0026"><b>Example 2</b></heading><heading id="h0027">1. Production of CNP gel preparation</heading><p id="p0156" num="0156">0.1 g of methyl parahydroxybenzoate (product name: Mekkins M, Ueno Fine Chemicals Industry), 0.2 g of phenoxyethanol, 3.0 g of 1,2-pentanediol, 6.0 g of concentrated glycerin, 0.1 g of dipotassium glycyrrhizinate, 0.1 g of allantoin, and 0.05 g of pyridoxine hydrochloride are added and dissolved in 75.72 g of purified water. Then 6.0 g of Lubrajel from Showa Denko K.K. (a mixture consisting of 4.674 g of purified water, 0.12 g of carboxy vinyl polymer, 0.006 g of sodium polyacrylate, and 1.2 g of glycerin), 0.44 g of carboxy vinyl polymer (product name: Carbopol 940, Lubrisol Advanced Materials, Inc.), and 8.00 g of 1% xanthan gum solution (product name: Keltrol T, CP<!-- EPO <DP n="68"> --> Kelco) were added to this solution and stirred and mixed, then 0.04 g of natural vitamin E was further added to make a homogenous mixed solution. Finally, 0.25 g of potassium hydroxide was added for neutralization, and the solution was sufficiently stirred to form a gelled state to obtain a gel preparation.</p><p id="p0157" num="0157">The CNP gel preparation was prepared as follows: 3 mg of human CNP-22 (Peptide Institute, Inc.) as the principal agent was dissolved in 3 ml of saline, and 100 µl of the resulting solution was diluted with 400 µl of saline to adjust the concentration to be 200 µg/ml, then 1.5 ml of the resulting solution was mixed and stirred in 8.5 g of the above gel preparation. The CNP concentration of thus-obtained gel preparation is 30 µg/g.</p><heading id="h0028"><b>Example 3</b></heading><heading id="h0029">2. Production of CNP aqueous-solution preparation</heading><p id="p0158" num="0158">The CNP aqueous-solution preparation was prepared as follows: 3 mg of human CNP-22 (Peptide Institute, Inc.) as the principal agent was dissolved in 3 ml of saline, and 100 µl of the resulting solution was diluted with 900 µl of saline to prepare the aqueous-solution preparation with a CNP concentration of 100 µg/ml. CNP aqueous-solution preparations with a CNP concentration of 50 µg/ml and 200 µg/ml were prepared similarly.</p><heading id="h0030"><b>Example 4</b></heading><heading id="h0031">3. Diagnosis of subjects:</heading><!-- EPO <DP n="69"> --><p id="p0159" num="0159">Prior to administration of the CNP gel preparation and CNP aqueous-solution preparation, history taking from the subjects, scratch tests for allergens, and a diagnosis were conducted. Table 3 (subjects 1-5) and Table 5 (subjects 6-10) show the results of the subjects' history taking and diagnosis, i.e., sex, age, onset and course of disease, family history, past history, scratch test results, diagnostic findings, and symptom evaluation based on "Guideline 2005" of the subject in each case.</p><heading id="h0032"><b>Example 5</b></heading><heading id="h0033">4. Therapeutic effects on subjects</heading><p id="p0160" num="0160">Therapeutic effects of the CNP gel preparation and CNP aqueous-solution preparation are shown in Table 4 (subjects 1-5) and Table 6 (subjects 6-10). In Tables 4 and 6, "itching sensation" represents a comparison of the itching sensation evaluated using the visual analogue scale method before and after treatment. Similarly, "non-recurrence period" refers to the period after discontinuation of the treatment by the preparation of the present invention subsequent to improvement of symptoms, in which relapse of the symptoms did not occur. In order to evaluate objectively, photographs before and after application of CNP preparations were taken for all cases. Of these, photographs of some cases are shown in the figures.<!-- EPO <DP n="70"> --></p><p id="p0161" num="0161"><tables id="tabl0003" num="0003"><table frame="all"><title>[Table 3]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="31mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="32mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP gel preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 1</entry><entry align="center" valign="top">Subject 2</entry><entry align="center" valign="top">Subject 3</entry><entry align="center" valign="top">Subject 4</entry><entry align="center" valign="top">Subject 5</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 1</entry><entry align="center">Case 6</entry><entry align="center">Case 5</entry><entry align="center">Case 9</entry><entry align="center">Case 10</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">21 years old</entry><entry align="center">39 years old</entry><entry align="center">24 years old</entry><entry align="center">9 months old</entry><entry align="center">32 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed in infancy, having recurrent eczema with itching.</entry><entry>Developed at 19 years of age, having recurrent eczema with itching. She is in the state of erythroderma posteczematosa presumably due to long period of steroid external therapy, and skin flush and desquamation are observed over the whole body.</entry><entry>Have repeated chronic recurrent dermatitis with itching from elementary school. Generalized type; symptoms on the face tend to worsen upon use of organic solvents and lack of sleep.</entry><entry>Developed at 10 days after birth; generalized-type recurrent eczema with itching. The face becomes occasionally full of excoriations due to scratching the skin all the time. Horse oil has been used for moisturization.</entry><entry>Developed in infancy, having recurrent eczema with itching, generalized type; he is in a state of erythroderma posteczematosa; chills, skin flush and scales are observed.</entry></row><row><entry>Family history</entry><entry>Mother and elder brother; Atopic dermatitis, allergic rhinitis</entry><entry>Mother; Atopic dermatitis</entry><entry>Mother; Bronchial asthma</entry><entry>Father; Atopic dermatitis</entry><entry>None</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis</entry><entry>Child asthma</entry><entry>Allergic rhinitis</entry><entry/><entry>Child asthma, Allergic rhinitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 5+</entry><entry>House dust: 3+</entry><entry>House dust: 2+</entry><entry>House dust: 1+</entry><entry>House dust: 2+</entry></row><row><entry rowsep="0">Mite: 5+</entry><entry rowsep="0">Mite: 2+</entry><entry rowsep="0">Mite: 2+</entry><entry rowsep="0">Mite: 2+</entry><entry rowsep="0">Mite: 3+</entry></row><row><entry rowsep="0"/><entry rowsep="0"/><entry rowsep="0">Cedar: 1+</entry><entry rowsep="0">Egg white: 2+</entry><entry rowsep="0"/></row><row><entry rowsep="0"/><entry rowsep="0"/><entry rowsep="0">Orchard grass: 2+</entry><entry rowsep="0">Egg yolk: 2+</entry><entry rowsep="0"/></row><row><entry/><entry/><entry>Ragweed: 1+</entry><entry/><entry/></row><!-- EPO <DP n="71"> --><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body.</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body. severe scales and infiltrative erythema with strong burning sensation are observed on the face.</entry><entry>Mild-to-severe level erythema, scales and excoriation are observed over the whole body.</entry><entry>Erythema, papules, scales and numerous excoriations are observed over the whole body.</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body. In particular on the upper limbs, infiltrative erythema with strong burning sensation is repeatedly worsened.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face and neck is mainly characterized by severe infiltration, and erythema with edema.</entry><entry>Rash on the face is mainly characterized by severe infiltration, erythema, and numerous excoriations.</entry><entry>Rash on the back is mainly characterized by severe swelling, erythema with edema, and scales.</entry><entry>Rash on the both forearms is mainly characterized by erythema, papules, scales, and numerous excoriations.</entry><entry>Rash on the forearms is mainly characterized by severe swelling, infiltration, erythema, scales, papules, erosions and numerous excoriations.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Steroid external drug had no effects on erythema, infiltrative erythema and scales on the face and neck.</entry><entry>She is in the state of erythroderma posteczematosa presumably due to steroid external therapy.</entry><entry>Steroid external therapy relieves the infiltrative erythema on the back and face only insufficiently, and the symptoms relapse soon.</entry><entry>(Parents) desire use treatment without steroids.</entry><entry>He is in the state of erythroderma posteczematosa presumably due to long-term steroid external therapy.</entry></row><!-- EPO <DP n="72"> --><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables></p><p id="p0162" num="0162"><tables id="tabl0004" num="0004"><table frame="all"><title>[Table 4]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP gel preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 1</entry><entry align="center" valign="top">Subject 2</entry><entry align="center" valign="top">Subject 3</entry><entry align="center" valign="top">Subject 4</entry><entry align="center" valign="top">Subject 5 (<figref idrefs="f0001">Fig. 1</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 1</entry><entry align="center">Case 6</entry><entry align="center">Case 5</entry><entry align="center">Case 9</entry><entry align="center">Case 10</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">21 years old</entry><entry align="center">39 years old</entry><entry align="center">24 years old</entry><entry align="center">9 months old</entry><entry align="center">32 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP gel preparation</entry><entry align="center">CNP gel preparation</entry><entry align="center">CNP gel preparation</entry><entry align="center">CNP gel preparation</entry><entry align="center">CNP gel preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice at 20-min interval</entry><entry align="center">Twice at 20-min interval</entry><entry align="center">3 times at 20-min interval</entry></row><row><entry align="center">Days of administration</entry><entry align="center">4 days</entry><entry align="center">3 days</entry><entry align="center">Only 1 day when visiting the clinic.</entry><entry align="center">Only 1 day when visiting the clinic.</entry><entry align="center">Only 1 day when visiting the clinic.</entry></row><row><entry align="center">Application region</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry><entry align="center">Back</entry><entry align="center">Forearm</entry><entry align="center">Upper limb</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: moderate</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: moderate</entry></row><row><entry morerows="1">Severity level evaluation of the rash</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry><entry>Erythema: 3</entry></row><row><entry>Edema/papulation : 3</entry><entry>Edema/papulation : 3</entry><entry>Edema/papulation : 3</entry><entry>Edema/papulation : 2</entry><entry>Edema/papulation : 3</entry></row><!-- EPO <DP n="73"> --><row><entry morerows="4">region by SCORAD (before application)</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 3</entry></row><row><entry>Lichenification: 2</entry><entry>Lichenification: 3</entry><entry>Lichenification: 1</entry><entry>Lichenification: 1</entry><entry>Lichenification: 3</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 13/18</entry><entry>Total: 16/18</entry><entry>Total: 13/18</entry><entry>Total: 11/18</entry><entry>Total: 18/18</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry></row><row><entry>Edema/papulation : 1</entry><entry>Edema/papulation : 0</entry><entry>Edema/papulation : 1</entry><entry>Edema/papulation : 1</entry><entry>Edema/papulation : 1</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification: 0</entry><entry>Lichenification: 0</entry><entry>Lichenification: 0</entry><entry>Lichenification: 0</entry><entry>Lichenification: 2</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 2</entry></row><row><entry>Total: 5/18</entry><entry>Total: 2/18</entry><entry>Total: 5/18</entry><entry>Total: 4/18</entry><entry>Total: 7/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 4 days of application of 30-µg/g CNP gel preparation to both sides of the face and neck twice a day, erythema was markedly reduced, scales disappeared and the skin texture became fine and softened.</entry><entry>After 3 days of application of 30-µg/g CNP gel preparation to both sides of the face and neck twice a day, remarkable effects were shown and erythema was almost disappeared, in addition, scales disappeared and the skin texture became fine.</entry><entry>After application of 30-µg/g CNP gel preparation to left side of the back twice at 20-min interval, erythema with swelling on the left side of the back was markedly improved 45 min, to a mild symptom characterized by mild erythema.</entry><entry>After application of 30-µg/g CNP gel preparation to the right forearm twice at 20-min interval, scaly erythema and infiltration on the right cubital fossa were reduced and erythema, papules and scales on the forearms were improved.</entry><entry>After application of 30-µg/g CNP gel preparation to the right upper limb at 20-min interval, subjective burning sensation on the right side (where CNP gel preparation was applied) subsided, and infiltration, scales and erythema on the right side were markedly improved compared to those on the left side.</entry></row><!-- EPO <DP n="74"> --><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">(Infant)</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 0</entry><entry align="center">After: 1</entry><entry align="center">After: 2</entry><entry align="center"/><entry align="center">After: 3</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">2 weeks</entry><entry align="center">7 days</entry><entry align="center">7 days</entry><entry align="center">2 weeks or more</entry><entry align="center">7 days</entry></row></tbody></tgroup></table></tables></p><p id="p0163" num="0163"><tables id="tabl0005" num="0005"><table frame="all"><title>[Table 5]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="32mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 6 (<figref idrefs="f0002">Fig. 2</figref>)</entry><entry align="center" valign="top">Subject 7 (<figref idrefs="f0002">Fig. 3</figref>)</entry><entry align="center" valign="top">Subject 8</entry><entry align="center" valign="top">Subject 9</entry><entry align="center" valign="top">Subject 10</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 2</entry><entry align="center">Case 7</entry><entry align="center">Case 8</entry><entry align="center">Case 3</entry><entry align="center">Case 4</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">41 years old</entry><entry align="center">29 years old</entry><entry align="center">36 years old</entry><entry align="center">38 years old</entry><entry align="center">32 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed at 7 years of age, having recurrent eczema with itching; in particular infiltrative erythema on the face tends to worsen acutely; herpes virus infection on the face as a complication has been repeated.</entry><entry>Developed in infancy; symptoms worsened since about a half year ago, showing severe infiltrative erythema on the four limbs and face.</entry><entry>Developed in infancy, having recurrent eczema with itching; she presents with severe infiltration and erythema over the whole body; without application of "the strongest" steroid external drugs, exudate leaks out.</entry><entry>Developed at 2 months after birth; she presents with generalized-type recurrent eczema with itching.</entry><entry>He presents with chronic recurrent dermatitis with itching repeatedly, which extended to the whole body since 2 years ago.</entry></row><row><entry>Family history</entry><entry>None</entry><entry/><entry>Elder brother; Atopic dermatitis</entry><entry>None</entry><entry>Mother; Atopic dermatitis</entry></row><!-- EPO <DP n="75"> --><row><entry>Past history</entry><entry>Child asthma</entry><entry>Allergic rhinitis</entry><entry>Child asthma</entry><entry>Bronchial asthma</entry><entry>Allergic rhinitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 3+</entry><entry>House dust: 2+</entry><entry>House dust: 3+</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 2+</entry></row><row><entry/><entry>Orchard grass: 2+</entry><entry>Cedar: 3+</entry><entry/><entry>Cedar: 2+</entry></row><row><entry/><entry>Ragweed: 1+</entry><entry>Orchard grass: 3+</entry><entry/><entry>Orchard grass: 2+</entry></row><row><entry/><entry/><entry>Ragweed: 2+</entry><entry/><entry>Ragweed: 1+</entry></row><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body. On the face; she presents with repeated exacerbation of infiltrative erythema with a strong burning sensation associated with capillary dilation.</entry><entry>Infiltrative erythema lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed on the four limbs and face.</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body; she is in the state of erythroderma posteczematosa.</entry><entry>Infiltrative erythema, scales, and numerous excoriations are observed over the whole body.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rashes on the face are mainly characterized by erythema with severe swelling, infiltration or lichenification, as well as papules, erosions and numerous excoriations.</entry><entry>Rashes on the face are mainly characterized by erythema with severe lichenification, as well as papules, erosions, scales and numerous excoriations.</entry><entry>Rashes on the face and neck are mainly characterized by severe infiltration, and erythema with edema.</entry><entry>Rashes on the face are mainly characterized by erythema with lichenification, as well as papules, erosions, scales, and numerous excoriations.</entry><entry>Rashes on the forearms are mainly characterized by erythema with severe swelling, as well as scales, and excoriations.</entry></row><!-- EPO <DP n="76"> --><row><entry>Effects of steroid external drug</entry><entry>Not reduced by steroid external therapy.</entry><entry>Although infiltrative erythema on the face is reduced by steroid external therapy, it easily relapses and tends to worsen.</entry><entry>Steroid external drugs are not effective for erythema, infiltrative erythema and scales on the face and neck.</entry><entry>Not reduced even by "very strong" steroid external therapy.</entry><entry>Upon discontinuation of steroid external therapy, he is in a state of erythroderma with appearance of skin flush and desquamation over the whole body.</entry></row><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry></row></tbody></tgroup></table></tables></p><p id="p0164" num="0164"><tables id="tabl0006" num="0006"><table frame="all"><title>[Table 6]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 6 (<figref idrefs="f0002">Fig. 2</figref>)</entry><entry align="center" valign="top">Subject 7 (<figref idrefs="f0002">Fig. 3</figref>)</entry><entry align="center" valign="top">Subject 8</entry><entry align="center" valign="top">Subject 9</entry><entry align="center" valign="top">Subject 10</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 2</entry><entry align="center">Case 7</entry><entry align="center">Case 8</entry><entry align="center">Case 3</entry><entry align="center">Case 4</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">41 years old</entry><entry align="center">29 years old</entry><entry align="center">36 years old</entry><entry align="center">38 years old</entry><entry align="center">32 years old</entry></row><row><entry>Dosage form</entry><entry>CNP aqueous-solution preparation</entry><entry>CNP aqueous-solution preparation</entry><entry>CNP aqueous-solution preparation</entry><entry>CNP aqueous-solution preparation</entry><entry>CNP aqueous-solution preparation</entry></row><row><entry>Dosage</entry><entry>100 µg/ml</entry><entry>100 µg/ml</entry><entry>100 µg/ml</entry><entry>100 µg/ml</entry><entry>100 µg/ml</entry></row><row><entry>Number of administrations</entry><entry>Twice a day</entry><entry>Twice a day</entry><entry>Twice a day</entry><entry>Twice a day</entry><entry>3 times at 20-min interval</entry></row><row><entry>Days of administration</entry><entry>4 days</entry><entry>4 days</entry><entry>10 days</entry><entry>4 days</entry><entry>Only 1 day when visiting the clinic.</entry></row><!-- EPO <DP n="77"> --><row><entry>Application regions</entry><entry>Face and neck</entry><entry>Face</entry><entry>Face and neck</entry><entry>Face</entry><entry>None</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild</entry><entry>After: moderate</entry><entry>After: minor</entry><entry>After: minor</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry></row><row><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry></row><row><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry></row><row><entry>Lichenification:3</entry><entry>Lichenification:2</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry></row><row><entry>Total: 14/18</entry><entry>Total: 14/18</entry><entry>Total: 15/18</entry><entry>Total: 14/18</entry><entry>Total: 13/18</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 0</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 0</entry></row><row><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry></row><row><entry>Lichenification: 1</entry><entry>Lichenification:0</entry><entry>Lichenification:2</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 2/18</entry><entry>Total: 4/18</entry><entry>Total: 6/18</entry><entry>Total: 3/18</entry><entry>Total: 2/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 4 days of application of 100 µg/ml CNP aqueous-solution preparation to both sides of the face and neck twice a day, erythema was markedly reduced and scales disappeared, and the skin texture became fine.</entry><entry>On 4th day of application of 100 µg/ml CNP aqueous-solution preparation, all of the infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations on the face were markedly improved.</entry><entry>After 3 days of application of 100-µg/ml CNP aqueous-solution preparation to both sides of the face and neck twice a day, erythema and infiltration were reduced and erosions were alleviated.</entry><entry>After 4 days of application of 100-µg/ml CNP aqueous-solution preparation, all of the infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations were markedly improved.</entry><entry>Sixty (60) min after the application of 100 µg/ml CNP aqueous-solution preparation 3 times at 20 min interval, subjective itching sensation on the right forearm was reduced and erythema was markedly improved, and inflammation and dryness symptoms almost disappeared.</entry></row><!-- EPO <DP n="78"> --><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 1</entry><entry align="center">After: 0</entry><entry align="center">After: 4</entry><entry align="center">After: 0</entry><entry align="center">After: 1</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">5 days</entry><entry align="center">2 weeks or more</entry><entry align="center">5 days</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="79"> --></p><heading id="h0034"><b>Example 6</b></heading><p id="p0165" num="0165">Details of the test examples of the CNP gel preparation and CNP aqueous-solution preparation summarized in Tables 3 to 6 are as follows.</p><heading id="h0035"><u>CNP gel preparation, test-example 1 (Case 1; Subject 1; see Tables 3 and 4):</u></heading><heading id="h0036"><u>Preliminary test:</u></heading><p id="p0166" num="0166">In the subject of Case 1, erythema, infiltrative erythema, and scales were observed on the face and neck. Steroid external drugs did not show any effects on these erythema, infiltrative erythema, and scales.</p><p id="p0167" num="0167">Therefore, the CNP gel preparation was applied only to the right side of the face and neck of the subject, and a gel without CNP as the active ingredient was applied to the left side, twice a day, and symptoms were observed. The CNP gel preparation used was the CNP gel preparation (30 µg/g) obtained in Example 2.</p><heading id="h0037"><u>Preliminary test results:</u></heading><p id="p0168" num="0168">Ten min after the application, as a subjective symptom, a burning sensation subsided on the right side on which the CNP gel preparation was applied, and 30 min later, erythema also began to become less severe to a certain degree. In addition, there were no irritation symptoms due to the application of the CNP gel preparation.</p><heading id="h0038"><u>Treatment and its outcome:</u></heading><p id="p0169" num="0169">From the above findings of the preliminary test, the CNP gel preparation was judged to be effective in this case without side effects; therefore<!-- EPO <DP n="80"> --> its application to both sides of the face and neck twice a day was started. As a result, erythema clearly improved by 4 days after the start of the treatment, while scales disappeared, and the skin was softened and its texture became finer. Furthermore, given that the itching sensation level before the application of the CNP gel preparation is rated as 10, then the itching sensation level after the application was 0, i.e., it is completely disappeared. Here, evaluation of the itching sensation level was performed by the visual analogue scale method.</p><p id="p0170" num="0170">Clinical follow-up after this revealed that, when the application of the CNP gel preparation was discontinued for 4 or 5 days, recurrence of minor erythema and scales was observed, but the symptoms did not worsen acutely, and the symptoms were improved without prolongation by the application of the CNP gel preparation for several days. It was also effective for the exacerbation before the start of a menstrual period, and symptoms were improved to almost normal conditions with little inflammatory symptom by the next morning, by the application twice a day in the morning and evening.</p><heading id="h0039"><u>CNP gel preparation, test example 2 (Case 6; Subject 2; see Tables 3 and 4):</u></heading><heading id="h0040"><u>Treatment and its outcome:</u></heading><p id="p0171" num="0171">The subject of Case 6 presented with infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema over the whole body, and also infiltrative erythema with severe scales and a strong burning sensation on the face. In addition, the subject<!-- EPO <DP n="81"> --> was in a state of erythroderma posteczematosa presumably due to the long-term steroid external therapy, presenting with skin flush and desquamation over the whole body. The severity level of the rash on the face was characterized mainly by severe infiltration, erythema and numerous excoriations.</p><p id="p0172" num="0172">Under such conditions, using the right/left comparative method, initially, the CNP gel preparation with a concentration of 30 µg/g obtained in Example 2 was applied only to the right side of the face, and a gel alone was applied to the left side of the face. As a result, immediately after the application of the CNP gel preparation, a burning sensation on the right side subjectively subsided, and erythema began to improve. Moreover, no symptoms of irritation due to the application of the CNP gel preparation were observed.</p><p id="p0173" num="0173">Subsequently, the CNP gel preparation with a concentration of 30 µg/g was applied to both sides of the face and the neck twice a day. As a result, significant effects were observed; erythema almost disappeared after 3 days, and scales disappeared and the texture of the skin became finer.</p><p id="p0174" num="0174">The severity level of the rash on the face was improved by the application of the CNP gel preparation from severe to mild, according to the classification based on the Dermatological Association Guideline. Furthermore, by the application of the CNP gel preparation of the present invention, the itching sensation level was improved from 10 to 1 according to the visual analogue scale method.<!-- EPO <DP n="82"> --></p><p id="p0175" num="0175">Clinical follow-up after this revealed that, around 3 days after the discontinuation of the present CNP gel preparation, mild erythema recurred but did not worsen any further. In this case, when the present CNP gel preparation was re-applied, these symptoms disappeared after 3 or 4 days</p><heading id="h0041"><u>CNP gel preparation, test example 3 (Case 5; Subject 3; see Tables 3 and 4):</u></heading><heading id="h0042"><u>Treatment and its outcome:</u></heading><p id="p0176" num="0176">This test mainly aimed at evaluation of absorbability of the CNP gel preparation at the dorsal region.</p><p id="p0177" num="0177">The subject of Case 5 had moderate to severe erythema, scales, and excoriations over the whole body, and the severity level of the rash on the back was characterized mainly by severe swelling, erythema with edema, and scales.</p><p id="p0178" num="0178">Under such condition, using the right/left comparative method, the CNP gel preparation with a concentration of 30 µg/g obtained in Example 2 was applied only to the left side of the back of the subject twice at an interval of 20 min, and a gel alone was applied to the right side of the back. As a result, erythema with swelling improved markedly on the left side after 45 min, to a mild symptom characterized mainly by mild erythema. The description in Table 4 shows the results of evaluation of the therapeutic effects of the CNP gel preparation at this point.</p><p id="p0179" num="0179">The above gel preparation (concentration of 30 µg/g) was applied to the face and neck of the same subject without right/left comparisons, twice a day for 3 days. As a result, erythema and scales on the face and neck markedly<!-- EPO <DP n="83"> --> improved to be diagnosed as being a mild degree. Namely, the severity level on the face and neck was improved from severe to mild, according to the classification based on the Dermatological Association Guideline.</p><p id="p0180" num="0180">These test results demonstrated that the CNP gel preparation has excellent transdermal absorbability not only on the face, neck and forearms, but also on the dorsal region.</p><heading id="h0043"><u>CNP gel preparation, test example 4 (Case 9; Subject 4; see Tables 3 and 4):</u></heading><heading id="h0044"><u>Treatment and its outcome:</u></heading><p id="p0181" num="0181">The subject of Case 9 was a female infant suffering from recurrent eczema with itching over the whole body, and erythema, papules, scales and numerous excoriations were observed over the whole body. In addition, erythema, papules, scales and numerous excoriations were observed on both forearms.</p><p id="p0182" num="0182">Under such condition, the CNP gel preparation with a concentration of 30 µg/g obtained in Example 2 was applied only to the right forearm of the subject. The application was performed twice at an interval of 20 min. As a result, desquamative erythema and infiltration on the right cubital fossa were reduced, and erythema, papules and scales on the forearm were also improved.</p><p id="p0183" num="0183">Of particular note in this case is that improved condition was maintained for 2 weeks or longer after application only twice at the time of visiting the clinic. The result of this test showed that scales disappeared, and<!-- EPO <DP n="84"> --> skin texture became finer and softened, thus the effectiveness in infant were also evident.</p><heading id="h0045"><u>CNP gel preparation, test example 5 (Case 10; Subject 5; see Tables 3 and 4):</u></heading><heading id="h0046"><u>Treatment and its outcome:</u></heading><p id="p0184" num="0184">The subject of Case 10 developed atopic dermatitis in infancy; suffering from recurrent eczema with itching; presenting with infiltrative erythema with itching associated with sleep disturbance, lichenified lesions and scales over the whole body; being associated chilly sensation; and the subject was diagnosed as erythroderma posteczematosa. Particularly on the upper limbs, infiltrative erythema with a strong burning sensation was observed, signifying its intractable nature. The rash on both upper limbs was mainly characterized by severe swelling, infiltration, erythema and erosions, with numerous excoriations.</p><p id="p0185" num="0185">To this subject, using the right/left comparative method, the CNP gel preparation with a concentration of 30 µg/g obtained in Example 2 was applied only to the right upper limb at an interval of 20 min, and a gel alone was applied to the left upper limb. As a result, the burning sensation on the right side, where the CNP gel preparation was applied, subsided after 60 min as a subjective symptom, and the infiltration, scales and erythema on the right side were markedly improved compared to the right arm prior to the application, and compared to the left arm where the gel preparation without CNP was applied three times at 20 min interval. <figref idrefs="f0001">Figure 1</figref> is a photograph showing the result of<!-- EPO <DP n="85"> --> application of the CNP gel preparation to the subject.</p><heading id="h0047"><u>CNP aqueous-solution preparation, test example 1 (Case 2; Subject 6; see Tables 5 and 6):</u></heading><heading id="h0048"><u>Preliminary test:</u></heading><p id="p0186" num="0186">In the subject of Case 2, the rash on the face was characterized mainly by erythema with severe swelling, infiltration and lichenification, papules, erosions, and numerous excoriations. The subject had a burning sensation as a subjective symptom. In addition, the subject had a history of recurring herpes virus infections, thus this is a case for which tacrolimus external therapy cannot be used.</p><p id="p0187" num="0187">As in the case of the test example 1, the CNP aqueous-solution preparation with a concentration of 100 µg/ml obtained in Example 3 was applied only to the right side of the face of the subject, and saline alone was applied to the left side.</p><heading id="h0049"><u>Preliminary test results:</u></heading><p id="p0188" num="0188">Ten min after the application, the burning sensation subsided on the right side of the face on which the CNP aqueous-solution preparation had been applied, and erythema on the right side of the face also began to be slightly improved 30 min later. In addition, irritation symptoms attributed to the application of the CNP aqueous-solution preparation were completely absent. Since the subject felt that the burning sensation and heaviness on the skin were reduced and that the preparation permeated into the skin, the preparation was considered to be effective for reducing subjective symptoms. Moreover,<!-- EPO <DP n="86"> --> apparent improvement in infiltration and erythema was observed.</p><heading id="h0050"><u>Treatment and its outcome:</u></heading><p id="p0189" num="0189">From the findings of the preliminary test above, the CNP aqueous-solution preparation was judged to be effective without side effects in this case; therefore, its application to both sides of the face and neck twice a day was initiated. As a result, erythema was clearly improved after 4 days, while the scales disappeared and the texture of the skin became finer. Furthermore, while the itching sensation level before application of the CNP aqueous-solution preparation was scored 10 based on the visual analogue scale method, it was markedly improved to 1 after the application.</p><p id="p0190" num="0190">Clinical follow-up after this revealed that, when the application of the CNP aqueous-solution preparation was discontinued for 4 or 5 days, mild erythema recurred, but the symptoms did not worsen any further. In addition, this recurrence of mild erythema was improved again by further application of the CNP aqueous-solution preparation for a period of 3-4 days. <figref idrefs="f0002">Figure 2</figref> is a photograph showing the results of application of the CNP aqueous-solution preparation of the present invention to the subject.</p><p id="p0191" num="0191">Moreover, the symptoms of this subject were markedly improved by continuous application of the CNP aqueous-solution preparation; accordingly, the subject became able to wear makeup. Furthermore, the safety and efficacy of the present preparation as an externally applicable preparation to the patients with herpes virus infection<!-- EPO <DP n="87"> --> complications, to whom tacrolimus external therapy cannot be applied, has been demonstrated by this test.</p><heading id="h0051"><u>Dosage-finding study:</u></heading><p id="p0192" num="0192">A dose-finding study was performed with the same subject. With the CNP solution preparation with a CNP concentration of 50 µg/ml, the healing process of the skin was slightly slower compared to that with the concentration of 100 µg/ml, and the treated skin was slightly rough to the touch. Although the CNP aqueous-solution preparation with a CNP concentration of 200 µg/ml remained to cause no irritation, this did not double its effectiveness.</p><heading id="h0052"><u>CNP aqueous-solution preparation, test example 2 (Case 7; Subject 7; see Tables 5 and 6):</u></heading><heading id="h0053"><u>Treatment and its outcome:</u></heading><p id="p0193" num="0193">The subject of Case 7 presented with infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts and numerous excoriations on the four limbs and face, and the rash on the face was characterized mainly by erythema with lichenification, papules, erosions, scales and numerous excoriations.</p><p id="p0194" num="0194">Under such conditions, using the right/left comparative method, initially, the CNP aqueous-solution preparation with a concentration of 100 µg/ml obtained in Example 3 was applied only to the right side of the face, and saline alone was applied to the left side of the face.</p><p id="p0195" num="0195">As a result, 20 min after application, a the subjective symptom of burning sensation on the right side of the face subsided, and erythema began to be slightly improved. No irritation symptom attributable to the<!-- EPO <DP n="88"> --> application of the CNP aqueous-solution preparation was observed at all. On the 4th day from the start of the application of the CNP aqueous-solution preparation, all of the infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts and numerous excoriations on the face were markedly improved. By the application of the CNP aqueous-solution preparation, the itching sensation level was improved from 10 to 0, the absence of subjective itching, based on the visual analogue scale method. In addition, the severity level of the rash on the face was improved from severe to mild by the application of the CNP aqueous-solution preparation, in accordance with the classification by the Dermatological Association Guideline. Subsequently, follow-up showed no recurrence of erythema even after discontinuation of the administration of the CNP aqueous-solution preparation. <figref idrefs="f0002">Figure 3</figref> is a photograph showing the application of the CNP aqueous-solution preparation to the subject.</p><heading id="h0054"><u>CNP aqueous-solution preparation, test example 3 (Case 8; Subject 8; see Tables 5 and 6):</u></heading><heading id="h0055"><u>Treatment and its outcome:</u></heading><p id="p0196" num="0196">The subject of Case 8 presented with infiltrative erythema with itching associated with sleep disturbance, lichenified lesions, and erythema over the whole body; had severe infiltration and erythema due to recurrence of eczema with itching over the whole body, and was in a state in which exudate would come out if not treated by the application of "the strongest" steroid external drugs.<!-- EPO <DP n="89"> --></p><p id="p0197" num="0197">Under such conditions, we attempted to apply the CNP aqueous-solution preparation with a concentration of 100 µg/ml obtained in Example 3 to the erythema, infiltrative erythema and scales on the face and neck, the areas in which no therapeutic effect was observed with steroid external drugs. The number of application was twice a day.</p><p id="p0198" num="0198">Using the right/left comparative method, the CNP aqueous-solution preparation was first applied to the right side of the face and neck twice at 20 min interval, and saline alone was applied to the left side. As a result, infiltration and erythema began to be slightly improved on the right side. No irritation symptom attributable to the CNP aqueous-solution preparation was observed at all.</p><p id="p0199" num="0199">Subsequently, the CNP aqueous-solution preparation was applied to both sides of the face and neck twice a day. As a result, erythema and infiltration were improved and erosions were also reduced after 3 days. The application of the CNP aqueous-solution preparation reduced itching, and the itching sensation level was improved from 10 to 4 based on the visual analogue scale method. The severity level of the rash 3 days after the start of the application was improved from most severe to moderate by the standards of the Guideline 2005. Subsequent further continuous application of the CNP aqueous-solution preparation twice a day for 7 days further improved the rash, and moderate infiltrative erythema was improved to mild erythema.</p><heading id="h0056"><u>CNP aqueous-solution preparation, test example 4 (Case 3; Subject 9; see Tables 5 and 6):</u></heading><heading id="h0057"><u>Treatment and its outcome:</u></heading><!-- EPO <DP n="90"> --><p id="p0200" num="0200">The subject of Case 3 presented with infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations over the whole body, and the rash on the face was characterized mainly by erythema with lichenification, papules, erosions, scales, and numerous excoriations.</p><p id="p0201" num="0201">The CNP aqueous-solution preparation with a concentration of 100 µg/ml was applied to both sides of the face of the subject. As a result, the subjective symptom of sensation of tight-stretched skin was improved after 10 min. Then erythema was improved and the skin became soft to the touch with a finer texture from after 30 min. No irritation symptoms were observed with the external application, and the efficacy for epithelization of erosion and excoriation also became evident. Furthermore, findings about some beneficial changes such as reduction of scales and becoming finer skin texture were obtained. After 4 days from the application of the CNP aqueous-solution preparation of 100 µg/ml, all of the infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations were markedly improved. While the itching sensation level before application was rated as 10, subjective itching completely disappeared after the application to a level of 0.</p><p id="p0202" num="0202">Regarding the severity of erythema on the face after application of the CNP aqueous-solution preparation, there were a little inflammatory symptoms with almost no dryness, and the severity level of the rash based on the Dermatological Association Guideline was markedly improved from severe to minor.<!-- EPO <DP n="91"> --></p><p id="p0203" num="0203">From the above findings, the CNP aqueous-solution preparation was concluded to be very effective in this case. Subsequent follow-up showed no recurrence of erythema after discontinuation of the application of the present preparation.</p><heading id="h0058"><u>CNP aqueous-solution preparation, test example 5 (Case 4; Subject 10; see Tables 5 and 6):</u></heading><heading id="h0059"><u>Treatment and its outcome:</u></heading><p id="p0204" num="0204">This test mainly aimed at evaluation of absorbability of the CNP preparations on the forearms, on which absorbability is presumed to be inferior to that on the face.</p><p id="p0205" num="0205">The subject of Case 4 presented with moderate erythema, scales and excoriation over the whole body, and the rash on the forearms was characterized mainly by erythema with severe swelling, scales, and excoriations.</p><p id="p0206" num="0206">Under such conditions, 100 µl of the CNP aqueous-solution preparation with a concentration of 100 µg/ml was applied to the right forearm 3 times at 20 min interval, and saline alone was applied to the left forearm. As a result, 60 min later, subjective itching was reduced on the right forearm to which the CNP aqueous-solution preparation was applied; and erythema was also markedly improved; and inflammation and dryness symptoms mostly disappeared as well. No irritation symptom associated with the application of the aqueous-solution preparation was observed at all. Thus, the CNP aqueous-solution preparation exhibited remarkable effects on the forearms of the subject of this case as well.<!-- EPO <DP n="92"> --> These findings indicated that the preparation is also effective to the regions other than the face where the drug absorbability is presumed to be relatively high, namely the disorders on forearms. The rash on the forearms was improved by the administration of the CNP aqueous-solution preparation, from severe to minor level according to the classification based on the Dermatological Association Guideline. In addition, application of the CNP aqueous-solution preparation improved the itching sensation level from 10 to 1 based on the visual analogue scale method.</p><p id="p0207" num="0207">Next, CNP gel-base preparations were tested. "Gel-base preparation" differs from "gel preparation" in that the former does not comprise dipotassium glycyrrhizinate, allantoin, pyridoxine hydrochloride, xanthan gum and vitamin E. The effects of CNP preparations would be more clearly demonstrated to be due to the effects of CNP itself by confirming the effects of CNP in a preparation without these components, which could have some efficacy potentially.</p><heading id="h0060"><b>Example 7</b></heading><heading id="h0061"><b>1. Production of CNP gel-base preparation:</b></heading><heading id="h0062">Preparation of the gel was performed as follows.</heading><p id="p0208" num="0208">0.1 g of methyl parahydroxybenzoate (product name: Mekkins M, Ueno Fine Chemicals Industry), 0.2 g of phenoxyethanol, and 3.0 g of 1,2-pentanediol were measured in the same container, dissolved at 60-70°C, and introduced into a mixing kettle. The, 6.0 g of concentrated glycerin<!-- EPO <DP n="93"> --> was introduced and a mixture of 0.44 g of carboxy vinyl polymer (product name: Carbopol 940, Lubrisol Advanced Materials, Inc.) and 0.08 g of xanthan gum (product name: Keltrol T, CP Kelco) were added, and stirred with a paddle at 15 rpm to be sufficiently dispersed. Next, while stirring with a paddle at 15 rpm, 83.95 g of purified water was gradually introduced and the mixture was dissolved by stirring at a kettle temperature of 70-80°C, with a paddle at 20 rpm and a disperser at 1500-2000 rpm. After stopping the disperser, dissolution was confirmed and cooling was immediately started; when the kettle temperature approached around 40°C, 6.0 g of Lubrajel NP from ISP Japan, Ltd. (2.7 g of Glycerin, 0.06 g of carboxy vinyl polymer, 0.018 g of sodium polyacrylate, 3.222 g of water) was added and mixed homogeneously with a paddle at 20 rpm, then 0.230 g of potassium hydroxide was added for neutralization, and when the kettle temperature reached 25°C, the rotation of the paddle was terminated to obtain a gel-base.</p><p id="p0209" num="0209">Then, 3 mg of human CNP-22 (Peptide Institute, Inc.) as a principal agent was dissolved in 3 ml of saline to obtain the CNP solution with a concentration of 1000 µg/ml, and 1 ml of this CNP solution was homogeneously stirred and mixed in 19 g of the gel-base obtained as above, to produce the gel-base preparation with a concentration of 50 µg/g.</p><p id="p0210" num="0210">Similarly, 600 µl of the above CNP solution with a concentration of 1000 µg/ml was diluted with 400 µl of saline to prepare the concentration of 600 µg/ml, then the 1 ml of resulting solution was homogeneously stirred and mixed in 19 g of the gel-base obtained as above, to produce the gel-base preparation with a concentration of 30 µg/g.<!-- EPO <DP n="94"> --></p><heading id="h0063"><b>Example 8</b></heading><heading id="h0064"><b>2. Diagnosis of subjects:</b></heading><p id="p0211" num="0211">Prior to administration of the CNP gel-base preparation, history taking from the subjects, scratch tests for allergens and a diagnosis were conducted. Table 7 (subjects 11-15) and Table 9 (subjects 16-20) show the results of the subjects' history taking and diagnosis, i.e., sex, age, onset and disease course, family history, past history, scratch test results, diagnostic findings, and symptom evaluations based on "Guideline 2005" of the subject in each case.</p><heading id="h0065"><b>Example 9</b></heading><heading id="h0066"><b>3. Therapeutic effects on subjects:</b></heading><p id="p0212" num="0212">Therapeutic effects of the CNP gel-base preparation are shown in Table 8 (subjects 11-15) and Table 10 (subjects 16-20). In Tables 8 and 10, "itching sensation" represents a comparison of the itching sensation evaluated using the visual analogue scale method before and after treatment. Similarly, "non-recurrence period" refers to the period after discontinuation of the treatment by the preparation subsequent to the improvement of symptoms, in which relapse of the symptoms did not occur. In order to evaluate objectively, photographs were taken before and after application of CNP preparations for all cases. Of these, photographs of some cases are shown in the figures.</p><p id="p0213" num="0213">As shown in Tables 7 to 10, simply applying the CNP gel-base preparations to affected<!-- EPO <DP n="95"> --> areas of atopic dermatitis twice a day for 2-4 days, resulted in itching sensation to be mostly disappeared, and the severity levels of the rash in terms of external appearance was markedly improved in accordance with the Dermatological Association Guideline and with the SCORAD method.</p><p id="p0214" num="0214">The CNP gel-base preparations are almost identically effective with both concentrations of 30 µg/g and 50 µg/g, and the preparations showed their efficacy regardless of sex over a broad range of ages from 21 to 39 years old. In addition, the preparations were effective for any regions including the face, neck and upper limbs. Furthermore, atopic dermatitis was improved in the patients who have immunoreactivity for a wide range of allergens, from patients with immunoreactivity to house dust and mites, to patients with immunoreactivity for all of house dust, mites, cedar, orchard grass, and ragweed.</p><p id="p0215" num="0215">The CNP gel-base preparations markedly improved atopic dermatitis of patients with a familial allergic diathesis. In addition, the CNP gel-base preparations markedly improved the symptoms of atopic dermatitis in subjects 11-18, who had developed the disease in their infancy and had recurrence repeatedly. Additionally, the CNP gel-base preparations markedly improved the symptoms of intractable, frequently-recurrent atopic dermatitis. Moreover, it is surprising that the CNP gel-base preparations markedly improved symptoms of atopic dermatitis which steroid external therapy had failed to alleviate. Furthermore, it deserves<!-- EPO <DP n="96"> --> a special note that the recurrence of atopic dermatitis was not observed for at least 5 days, and for longer cases 2 weeks or more, after discontinuation of the application of the CNP gel-base preparations.</p><p id="p0216" num="0216">Here, the above therapeutic effects on atopic dermatitis were more clearly demonstrated to be attributable to the efficacy of CNP itself since the CNP gel-base preparation of the present invention differs from "gel preparation" in that the former does not comprise dipotassium glycyrrhizinate, allantoin, pyridoxine hydrochloride, xanthan gum, and vitamin E.<!-- EPO <DP n="97"> --></p><p id="p0217" num="0217"><tables id="tabl0007" num="0007"><table frame="all"><title>[Table 7]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="29mm"/><colspec colnum="5" colname="col5" colwidth="29mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 11</entry><entry align="center" valign="top">Subject 12</entry><entry align="center" valign="top">Subject 13</entry><entry align="center" valign="top">Subject 14</entry><entry align="center" valign="top">Subject 15</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">31 years old</entry><entry align="center">23 years old</entry><entry align="center">39 years old</entry><entry align="center">39 years old</entry><entry align="center">21 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed in infancy, having recurrent eczema with itching; infiltrative erythema on the face appeared since he started to work, and it has recurred frequently.</entry><entry>Developed in infancy, having recurrent eczema with itching; eczema also developed and frequently recurred on the face starting several years ago.</entry><entry>Developed on the face in infancy; since around 20 years of age, dry eczema extended to almost whole body including the face. The face in particular has repeatedly become red with fever as if it got burned, and has also been severely dry for many years.</entry><entry>Developed in infancy, having recurrent eczema with itching; in particular infiltrative erythema on the neck induces strong itching, and the region is always wrapped in bandages, with complication of intractable atopic alopecia.</entry><entry>Developed at the age of 4, having recurrent eczema with itching; recently, erythema on the face and neck began to show intractable nature.</entry></row><row><entry>Family history</entry><entry>Child; Atopic dermatitis</entry><entry>Mother; Atopic dermatitis</entry><entry>Mother; Atopic dermatitis</entry><entry>Father; Atopic dermatitis</entry><entry>Mother and grandmother; Atopic dermatitis</entry></row><row><entry>Past history</entry><entry/><entry>Allergic rhinitis</entry><entry>Allergic rhinitis, Bronchial asthma</entry><entry>Bronchial asthma</entry><entry>Allergic rhinitis</entry></row><!-- EPO <DP n="98"> --><row><entry morerows="4">Scratch tests</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 2+</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 2+</entry><entry>Cedar: 1+</entry><entry>Cedar: 1+</entry><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry></row><row><entry>Orchard grass:2+</entry><entry>Orchard grass:3+</entry><entry/><entry>Orchard grass:2+</entry><entry>Orchard grass:1+</entry></row><row><entry>Ragweed: 1+</entry><entry>Ragweed: 1+</entry><entry/><entry>Ragweed: 1+</entry><entry/></row><row><entry>Diagnostic findings</entry><entry>Erythema with severe swelling/ edema/ infiltration/ lichenification, as well as many papules, severe scales, adhesion of crusts, vesicles, and erosions are observed on the face.</entry><entry>Up to moderate erythema, scales, a small number of papules, and excoriations are observed on the face.</entry><entry>Infiltrative erythema, lichenified lesions, erythema are observed on the face, neck and back, accompanied by strong itching with sleep disturbance..</entry><entry>Erythema with lichenification, severe scales, adhesion of crusts, and erosions are observed on the face, neck, four limbs and body trunk.</entry><entry>Infiltrative erythema, erythema, scales, and lichenification are observed on the face and neck.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face are associated with erythema with severe swelling/ edema/ infiltration/ or lichenification, adhesion of crusts and vesicles.</entry><entry>Rash on the face is mainly characterized by erythema, edema, papules, erosions, and excoriations.</entry><entry>Rash on the face is mainly characterized by erythema with lichenification, and scales.</entry><entry>Rash on the face and neck are associated with erythema with infiltration or lichenification, as well as severe scales, and adhesion of crusts.</entry><entry>Rash on the face and neck is erythema with lichenification/ infiltration.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Relapsed on discontinuation of steroid external therapy</entry><entry>No improvement even by "very strong" steroid external therapy.</entry><entry>Relapsed on discontinuation of steroid external therapy; in particular intractable nature is shown on the face.</entry><entry>Relapsed on discontinuation of steroid external therapy.</entry><entry>Relapsed on discontinuation of steroid external therapy.</entry></row><!-- EPO <DP n="99"> --><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Severe</entry><entry align="center">Moderate</entry><entry align="center">Severe</entry><entry align="center">Severe</entry><entry align="center">Severe</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="100"> --></p><p id="p0218" num="0218"><tables id="tabl0008" num="0008"><table frame="all"><title>[Table 8]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 11</entry><entry align="center" valign="top">Subject 12</entry><entry align="center" valign="top">Subject 13</entry><entry align="center" valign="top">Subject 14</entry><entry align="center" valign="top">Subject 15</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">31 years old</entry><entry align="center">23 years old</entry><entry align="center">39 years old</entry><entry align="center">39 years old</entry><entry align="center">21 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face</entry><entry align="center">Face</entry><entry align="center">Face</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: minor</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry></row><row><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 1</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification:2</entry><entry>Lichenification: 1</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry></row><row><entry>Total: 13/18</entry><entry>Total: 12/18</entry><entry>Total: 13/18</entry><entry>Total: 13/18</entry><entry>Total: 10/18</entry></row><!-- EPO <DP n="101"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 0</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry></row><row><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry></row><row><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 3/18</entry><entry>Total: 2/18</entry><entry>Total: 2/18</entry><entry>Total: 4/18</entry><entry>Total: 2/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 3 days of application of 30-µg/g CNP gel-base preparation to the face twice a day, erythema, infiltration and itching markedly improved and the skin textures became fine.</entry><entry>After 3 days of application of 30 µg/g CNP gel-base preparation to the face twice a day, erythema, infiltration, scales and itching were markedly improved.</entry><entry>By the application of 30 µg/g CNP gel-base preparation to the face twice a day, after 2 days erythema was reduced, and infiltration and itching were markedly improved, and burning sensation disappearedon day 3.</entry><entry>After 3 days of application of 30-µg/g CNP gel-base preparation to the face twice a day, erythema, infiltration, scales and itching were markedly improved.</entry><entry>After 3 days of application of 30-µg/g CNP gel-base preparation to the face and neck twice a day, erythema, infiltration, and itching were markedly improved.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 0</entry><entry align="center">After: 0</entry><entry align="center">After: 1</entry><entry align="center">After: 0</entry><entry align="center">After: 0</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks or more</entry><entry align="center">5 days</entry><entry align="center">2 weeks</entry></row></tbody></tgroup></table></tables></p><p id="p0219" num="0219"><tables id="tabl0009" num="0009"><table frame="all"><title>[Table 9]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="32mm"/><colspec colnum="3" colname="col3" colwidth="27mm"/><colspec colnum="4" colname="col4" colwidth="29mm"/><colspec colnum="5" colname="col5" colwidth="29mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 16</entry><entry align="center" valign="top">Subject 17 (<figref idrefs="f0003">Fig. 4</figref>)</entry><entry align="center" valign="top">Subject 18</entry><entry align="center" valign="top">Subject 19</entry><entry align="center" valign="top">Subject 20 (<figref idrefs="f0004">Fig. 5</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">25 years old</entry><entry align="center">36 years old</entry><entry align="center">22 years old</entry><entry align="center">31 years old</entry><entry align="center">35 years old</entry></row><!-- EPO <DP n="102"> --><row><entry>Onset and course of disease</entry><entry>Had recurrent eczema with itching since infancy, and symptoms worsened due to psychological stress during these last several years; by the application of steroid external drugs every day, skin flush, scales and infiltrative erythema became observed over the whole body.</entry><entry>Developed in infancy, and symptoms worsen due to change of seasons and sweating. Application of various external preparations did not stop the inflammation at all, and sleep disturbance due to itching continued; severe swelling prohibits bending of the arms.</entry><entry>Developed in infancy; symptoms were initially only on the body trunk, but rapidly worsened to extend to almost the whole body including the face. In particular, symptoms worsen when he is in dusty conditions.</entry><entry>She had eczema at cubital fossae and popliteal fossae that worsened by sweating, and which was reduced temporarily by steroid external application but relapsed repeatedly. Since around 2002 when she started to work, erythema appeared on the face due to leisureless life and stress caused by interpersonal relationships.</entry><entry>Recurrent erythema appeared since 21 years of age when she began to work a night shift, and extended to the whole body.</entry></row><row><entry>Family history</entry><entry>Father; Atopic dermatitis</entry><entry>Father; Allergic rhinitis, conjunctivitis</entry><entry>Mother; Atopic dermatitis</entry><entry>Mother; Bronchial asthma</entry><entry>Elder brother; Bronchial asthma</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis, Bronchial asthma</entry><entry>Allergic rhinitis, Conjunctivitis</entry><entry>Allergic rhinitis, Conjunctivitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 3+</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry><entry>House dust: 3+</entry><entry>House dust: 3+</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry><entry/><entry>Cedar: 3+</entry><entry>Cedar: 2+</entry></row><row><entry>Orchard grass:3+</entry><entry/><entry/><entry>Orchard grass:1+</entry><entry/></row><row><entry>Ragweed: 1+</entry><entry/><entry/><entry>Ragweed: 2+</entry><entry/></row><!-- EPO <DP n="103"> --><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body. He is in a state of erythroderma posteczematosa.</entry><entry>Erythema with lichenification, infiltrative erythema, severe scales, adhesion of crusts, vesicles, and erosions are observed over the whole body.</entry><entry>Infiltrative erythema with strong itching associated with sleep disturbance, erythema, and excoriations are observed on almost whole body including face and neck.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, and numerous excoriations are observed over the whole body. Have strong itching associated with sleep disturbance.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts and numerous excoriations are observed over the whole body.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face and neck includes erythema with severe swelling/ infiltration/ or lichenification.</entry><entry>Rash on the face, neck and four limbs are associated with erythema with infiltration or lichenification, severe scales, and numerous excoriations.</entry><entry>Rash on the face is mainly characterized by erythema with lichenification, erosions, scales, and numerous excoriations.</entry><entry>Rash on the face and neck consists of severe swelling/ edema/ infiltration/ erythema, vesicles and erosions.</entry><entry>Rash on the upper limbs are associated with severe swelling/ edema/ infiltration/ erythema.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Skin flush and desquamation appear over the whole body after discontinuation of steroid external application, resulting in a state of erythroderma.</entry><entry>Symptoms are not alleviated by steroid external therapy at all.</entry><entry>Recurrence occurred soon after discontinuation of steroid external therapy.</entry><entry>Skin flush and desquamation appear after discontinuation of steroid external application.</entry><entry>Skin flush and desquamation appear after discontinuation of steroid external application.</entry></row><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="104"> --></p><p id="p0220" num="0220"><tables id="tabl0010" num="0010"><table frame="all"><title>[Table 10]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 16</entry><entry align="center" valign="top">Subject 17 (<figref idrefs="f0003">Fig. 4</figref>)</entry><entry align="center" valign="top">Subject 18</entry><entry align="center" valign="top">Subject 19</entry><entry align="center" valign="top">Subject 20 (<figref idrefs="f0004">Fig. 5</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">25 years old</entry><entry align="center">36 years old</entry><entry align="center">22 years old</entry><entry align="center">31 years old</entry><entry align="center">35 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry><entry align="center">CNP gel-base preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">3 days</entry><entry align="center">2 days</entry><entry align="center">3 days</entry><entry align="center">2 days</entry><entry align="center">4 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face and neck</entry><entry align="center">Face, neck and upper limbs</entry><entry align="center">Face</entry><entry align="center">Face and neck</entry><entry align="center">Forearms</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild-moderate</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: minor</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry></row><row><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 3</entry></row><row><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 1</entry></row><row><entry>Excoriation: 2</entry><entry>Excoriation: 3</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification:3</entry><entry>Lichenification:3</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry><entry>Lichenification:1</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry></row><row><entry>Total: 17/18</entry><entry>Total: 17/18</entry><entry>Total: 14/18</entry><entry>Total: 16/18</entry><entry>Total: 12/18</entry></row><!-- EPO <DP n="105"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 0</entry></row><row><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry></row><row><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 2</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 5/18</entry><entry>Total: 7/18</entry><entry>Total: 7/18</entry><entry>Total: 4/18</entry><entry>Total: 1/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 2 or 3 days of application of 30 µg/g CNP gel-base preparation to the face and neck twice a day, tingling sensation disappeared, and erythema, infiltration and itching were markedly improved.</entry><entry>After 2 days of application of 30 µg/g CNP gel-base preparation to the face, neck and upper limbs twice a day, erythema, infiltration, scales and itching were markedly improved, and she was able to sleep.</entry><entry>After application of 50 µg/g CNP gel-base preparation twice a day, dryness and itching were markedly improved on the next day. 2 days later, erythema was reduced, and only slight scales remained on the 3rd day.</entry><entry>After 2 days of application of 50 µg/g CNP gel-base preparation to the face and neck twice a day, erythema was reduced, and itching disappeared. Slight dryness and erythema remained.</entry><entry>After 3 days of application of 50 µg/g CNP gel-base preparation twice a day, erythema was markedly reduced, and the skin texture became fine on the 4thday.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 2</entry><entry align="center">After: 2</entry><entry align="center">After: 3</entry><entry align="center">After: 0</entry><entry align="center">After: 0</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">7 days</entry><entry align="center">5 days</entry><entry align="center">5 days</entry><entry align="center">5 days</entry><entry align="center">7 days</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="106"> --></p><heading id="h0067"><b>Example 10</b></heading><heading id="h0068"><b>1. Production of CNP ointment preparation:</b></heading><p id="p0221" num="0221">Ointments were prepared as follows: 3 mg of human CNP-22 (Peptide Institute, Inc.) as a principal agent was dissolved in 3 ml of saline to obtain the CNP solution with a concentration of 1000 µg/ml; 1 ml of this CNP solution was homogeneously mixed in 9 g of white vaseline of Japanese Pharmacopoeia by high-speed stirring, to adjust its concentration to 100 µg/g.</p><p id="p0222" num="0222">Similarly, 500 µl of the above CNP solution with a concentration of 1000 µg/ml was diluted with 500 µl of saline to adjust its concentration at 500 µg/ml, and 1 ml of this solution was homogeneously mixed in 9 g of white vaseline of the Japanese Pharmacopoeia by high-speed stirring, to adjust its concentration at 50 µg/g.</p><p id="p0223" num="0223">In addition, 300 µl of the above CNP solution with a concentration of 1000 µg/ml was diluted with 700 µl of saline to adjust its the concentration at 300 µg/ml, and 1 ml of this solution was homogeneously mixed in 9 g of white vaseline of the Japanese Pharmacopoeia by high-speed stirring, to adjust its concentration to 30 µg/g.</p><heading id="h0069"><b>Example 11</b></heading><heading id="h0070"><b>2. Diagnosis of subjects:</b></heading><p id="p0224" num="0224">Prior to administration of the CNP ointment preparation, history taking from subjects, scratch tests for allergens and diagnosis were conducted. Table 11 (subjects 21-25), Table 13 (subjects 26-30), and Table 15 (subjects 31-35) show the results of<!-- EPO <DP n="107"> --> the subjects' history taking and diagnosis, i.e., sex, age, onset and course of disease, family history, past history, scratch test results, diagnostic findings, and symptom evaluation based on "Guideline 2005" of the subject in each case.</p><heading id="h0071"><b>Example 12</b></heading><heading id="h0072"><b>3. Therapeutic effect on subjects:</b></heading><p id="p0225" num="0225">Therapeutic effects of the CNP ointment preparation are shown in Table 12 (subjects 21-25), Table 14 (subjects 26-30), and Table 16 (subjects 31-35). In Tables 12, 14 and 16, "itching sensation" represents a comparison of the itching sensation evaluated using the visual analogue scale method before and after treatment. Similarly, the "non-recurrence period" refers to the period after discontinuation of the treatment by the preparation subsequent to the improvement of symptoms, for which relapse of the symptoms did not occur.</p><p id="p0226" num="0226">As shown in Tables 11 through 16, simply applying the CNP ointment preparation to affected areas of atopic dermatitis twice a day for 2-3 days resulted in the itching sensation to disappear mostly, and the severity levels of the rash in terms of external appearance was markedly improved in accordance with the Dermatological Association Guideline or in terms of external appearance according to the SCORAD method. Here, in order to evaluate objectively, photographs were taken before and after the application of CNP preparations for<!-- EPO <DP n="108"> --> all cases. Of these, photographs of some of the cases are shown in the figures.</p><p id="p0227" num="0227">The CNP ointment preparations are almost identically effective with concentrations of 30 µg/g, 50 µg/g, and 100 µg/g, and the preparations showed their efficacy regardless of sex over a broad range of ages from 3 to 56 years old. In addition, the preparations were effective for any regions including the face, neck, back, and upper limbs. Furthermore, atopic dermatitis was improved in the patients who have immunoreactivity for a wide range of allergens, from patients with immunoreactivity to house dust, mites, and orchard grass to patients with immunoreactivity to all of house dust, mites, cedar, orchard grass, and ragweed.</p><p id="p0228" num="0228">The CNP ointment preparations markedly improved atopic dermatitis of the patients with a familial allergic diathesis. In addition, the CNP ointment preparations markedly improved symptoms of atopic dermatitis in the subjects who had developed the disease in their infancy and had recurrence repeatedly. Additionally, the CNP ointment preparations also markedly improved symptoms of intractable, frequently-recurrent atopic dermatitis. Moreover, it is surprising that the CNP ointment preparations markedly improved symptoms of atopic dermatitis steroid external therapy had failed to alleviate. Furthermore, it deserves special note that recurrence of atopic dermatitis was not observed for at least 5 days, and for longer cases, 2 weeks or more,<!-- EPO <DP n="109"> --> after discontinuation of the application of the CNP ointment preparations.</p><p id="p0229" num="0229">Here, since the CNP ointment preparations do not comprise any components, other than CNP, which could potentially have some efficacy, the above therapeutic effects on atopic dermatitis are clearly demonstrated to be the efficacy of the CNP itself.<!-- EPO <DP n="110"> --></p><p id="p0230" num="0230"><tables id="tabl0011" num="0011"><table frame="all"><title>[Table 11]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="24mm"/><colspec colnum="2" colname="col2" colwidth="30mm"/><colspec colnum="3" colname="col3" colwidth="29mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="30mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP ointment preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 21 (<figref idrefs="f0005">Fig. 6</figref>)</entry><entry align="center" valign="top">Subject 22</entry><entry align="center" valign="top">Subject 23 (<figref idrefs="f0005">Fig. 7</figref>)</entry><entry align="center" valign="top">Subject 24</entry><entry align="center" valign="top">Subject 25</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">21 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">33 years old</entry><entry align="center">39 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed in infancy; symptoms worsen in dry seasons, erythema with itching appears mainly on the face, neck, upper limbs and body trunk, and the symptoms recurred repeatedly despite the application of steroid external drugs.</entry><entry>Developed at 3 months of age with eczema mainly on the four limbs; asthma worsened 4 years ago, and dermatitis rapidly expanded due to the stress of examinations and family relationships starting 3 years ago.</entry><entry>Developed at the time of being a junior high school student with symptoms on the face; eczema with itching which worsens with sweating have appeared repeatedly on the cubital fossae and back, etc.; since 3 years ago, erythema has always appeared despite steroid external application.</entry><entry>Developed in infancy, has recurrent eczema with itching; from around starting to work, infiltrative erythema appeared particularly on the face and neck, which extended to the whole body and she claims that she can hardly sleep because of itching.</entry><entry>Eczema appeared on the face since around 17 years of age, and he repeatedly suffers from dry dermatitis that worsens in winter. Thereafter he has continuously visited a dermatologist for treatment, but symptoms show intractable nature even against long-term steroid external therapy.</entry></row><row><entry>Family history</entry><entry>Mother; Atopic dermatitis</entry><entry>Younger sister, Father; Atopic dermatitis Mother: allergic rhinitis</entry><entry>Elder brother; Atopic dermatitis, Allergic rhinitis</entry><entry>Mother and younger brother; Atopic dermatitis</entry><entry>Child; Atopic dermatitis</entry></row><!-- EPO <DP n="111"> --><row><entry>Past history</entry><entry>Allergic rhinitis, Atopic conjunctivitis</entry><entry>Bronchial asthma</entry><entry>Allergic rhinitis, Bronchial asthma</entry><entry>Allergic rhinitis, Conjunctivitis</entry><entry>Bronchial asthma, Allergic rhinitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 1+</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry><entry>House dust: 3+</entry></row><row><entry>Mite: 1+</entry><entry>Mite: 3+</entry><entry>Mite: 2+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry><entry>Cedar: 1+</entry><entry>Cedar: 2+</entry></row><row><entry>Orchard grass:2+</entry><entry>Orchard grass:2+</entry><entry>Orchard grass:3+</entry><entry>Orchard grass:1+</entry><entry>Orchard grass:2+</entry></row><row><entry/><entry>Ragweed: 2+</entry><entry>Ragweed: 2+</entry><entry>Ragweed: 1+</entry><entry/></row><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body, and particularly severe on the face and neck.</entry><entry>Infiltrative erythema, erythema, severe scales, adhesion of crusts, and edema are observed on almost whole body, accompanied by hair loss.</entry><entry>Infiltrative erythema with strong itching associated with sleep disturbance, erythema, and excoriations are observed on the face, neck, four limbs and back.</entry><entry>Infiltrative erythema with strong itching and erythema are observed on the face, neck and body trunk.</entry><entry>Infiltrative erythema with strong itching associated with sleep disturbance, lichenified lesions, and erythema are observed over the whole body.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face and neck is mainly characterized by erythema with infiltration, scales and crusts.</entry><entry>Rash on the face and neck is mainly characterized by erythema with infiltration and lichenification.</entry><entry>Rash on the face and neck is mainly characterized by severe infiltrative erythema, scales and numerous excoriations.</entry><entry>Rash on the face and neck is mainly characterized by erythema with severe infiltration.</entry><entry>Rash on the face and neck is mainly characterized by erythema with infiltration and lichenification.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Since recurrence soon observed by discontinuation of steroid external therapy, non-steroid external preparations were applied, leading to further exacerbation.</entry><entry>Out of control with steroid external therapy.</entry><entry>Sufficient effects are not obtained with steroid external drugs for erythema and infiltrative erythema on the face.</entry><entry>Recurrence occurred soon after discontinuation of steroid external therapy.</entry><entry>Sufficient effects are not obtained with steroid external drugs for lichenified lesions and infiltrative erythema.</entry></row><!-- EPO <DP n="112"> --><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Severe</entry><entry align="center">Severe</entry></row></tbody></tgroup></table></tables></p><p id="p0231" num="0231"><tables id="tabl0012" num="0012"><table frame="all"><title>[Table 12]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP ointment preparation</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 21 (<figref idrefs="f0005">Fig. 6</figref>)</entry><entry align="center" valign="top">Subject 22</entry><entry align="center" valign="top">Subject 23 (<figref idrefs="f0005">Fig. 7</figref>)</entry><entry align="center" valign="top">Subject 24</entry><entry align="center" valign="top">Subject 25</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">21 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">33 years old</entry><entry align="center">39 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">30 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">2 days</entry><entry align="center">2 days</entry><entry align="center">3 days</entry><entry align="center">2 days</entry><entry align="center">3 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry></row><!-- EPO <DP n="113"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 1</entry></row><row><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 15/18</entry><entry>Total: 12/18</entry><entry>Total: 15/18</entry><entry>Total: 12/18</entry><entry>Total: 10/18</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry></row><row><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 6/18</entry><entry>Total: 5/18</entry><entry>Total: 5/18</entry><entry>Total: 4/18</entry><entry>Total: 3/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 2 days of application of 30-µg/g CNP ointment preparation to the face twice a day, erythema, infiltration, scales and itching were markedly improved.</entry><entry>After 2 days of application to the face and neck twice a day, erythema, infiltration, and itching were markedly improved:</entry><entry>After 3 days of application to the face and neck twice a day, erythema, excoriations, infiltration, and itching were markedly improved.</entry><entry>After 2 days of application to the face and neck twice a day, erythema, infiltration, and itching were markedly improved.</entry><entry>After 3 days of application to the face and neck twice a day, erythema, infiltration, and itching were markedly improved.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 0</entry><entry align="center">After: 1</entry><entry align="center">After: 0</entry><entry align="center">After: 0</entry><entry align="center">After: 0</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">5 days</entry><entry align="center">7 days</entry><entry align="center">7 days</entry><entry align="center">10 days</entry><entry align="center">2 weeks</entry></row></tbody></tgroup></table></tables></p><p id="p0232" num="0232"><!-- EPO <DP n="114"> --><tables id="tabl0013" num="0013"><table frame="all"><title>[Table 13]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="31mm"/><colspec colnum="4" colname="col4" colwidth="31mm"/><colspec colnum="5" colname="col5" colwidth="27mm"/><colspec colnum="6" colname="col6" colwidth="31mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP ointment preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 26</entry><entry align="center" valign="top">Subject 27 (<figref idrefs="f0007">Fig. 10</figref>)</entry><entry align="center" valign="top">Subject 28 (<figref idrefs="f0007">Fig. 11</figref>)</entry><entry align="center" valign="top">Subject 29 (<figref idrefs="f0006">Fig. 8</figref>)</entry><entry align="center" valign="top">Subject 30 (<figref idrefs="f0006">Fig. 9</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">32 years old</entry><entry align="center">3 years old</entry><entry align="center">22 years old</entry><entry align="center">44 years old</entry><entry align="center">36 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Erythema began to appear on the face at the age of 20; erythema and papules appeared on the back and four limbs, which worsened by sweating; they have recurred repeatedly.</entry><entry>Developed at 2 months of age, having erythema over the whole body. In particular, the face is sometimes full of excoriations due to scratching all the time.</entry><entry>Developed in infancy, having recurrent eczema with itching; due to steroid external application every day, skin flush, scales, and infiltrative erythema become observed over the whole body. She is complicated with intractable alopecia.</entry><entry>Starting 10 years ago, chronic recurrent dermatitis with itching repeatedly appeared due to the stress caused by professional responsibility.</entry><entry>Developed in infancy, having recurrent eczema with itching; due to steroid external application every day starting 10 years ago, skin flush, scales and infiltrated erythema appeared over the whole body.</entry></row><row><entry>Family history</entry><entry>Elder brother; Atopic dermatitis</entry><entry>Father; Atopic dermatitis Elder brother: Atopic dermatitis</entry><entry>Mother; Allergic rhinitis</entry><entry>Child; Atopic dermatitis</entry><entry/></row><row><entry>Past history</entry><entry>Allergic rhinitis, Conjunctivitis</entry><entry/><entry>Allergic rhinitis,</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 2+</entry><entry>House dust: 1+</entry><entry>House dust: 2+</entry><entry>House dust: 1+</entry><entry>House dust: 2+</entry></row><row><entry>Mite: 2+</entry><entry>Mite: 2+</entry><entry>Mite : 3+</entry><entry>Mite: 3+</entry><entry>Mite: 1+</entry></row><row><entry>Cedar: 2+</entry><entry>Egg white: 2+</entry><entry>Cedar: 3+</entry><entry>Cedar: 1+</entry><entry>Cedar: 2+</entry></row><row><entry rowsep="0">Orchard grass:3+</entry><entry rowsep="0"/><entry rowsep="0"/><entry rowsep="0">Ragweed: 1+</entry><entry rowsep="0">Orchard grass:1+</entry></row><row><entry>Ragweed: 2+</entry><entry/><entry/><entry/><entry/></row><!-- EPO <DP n="115"> --><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema and swelling of the face and neck are observed, and erythema, scales, adhesion of crusts, and numerous excoriations are observed on the four limbs and body trunk.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body. She is in a state of erythroderma posteczematosa.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, and adhesion of crusts are observed over the whole body. She is in a state of erythroderma posteczematosa.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, adhesion of crusts and numerous excoriations are observed on the body trunk.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts and numerous excoriations are observed over the whole body. He is in a state of erythroderma posteczematosa.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face and neck is mainly characterized by erythema with swelling.</entry><entry>Rash on the face consists of infiltration/ severe scales, adhesion of crusts, erosions, and numerous excoriations.</entry><entry>Rash on the face and neck is mainly characterized by infiltrative erythema with swelling.</entry><entry>Rash on the back forms a plaque accompanied by erythema with infiltration/ lichenification, scales, and adhesion of crusts.</entry><entry>Rash on the face and upper limbs is mainly characterized by erythema with severe swelling and infiltration.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Symptoms recur soon after discontinuation of steroid external therapy.</entry><entry>After discontinuation of steroid external application, skin flush and desquamation appear over the whole body, and she becomes a state of erythroderma.</entry><entry>Not improved even by "very strong" steroid external therapy.</entry><entry>Recurrence appears soon with "very strong" steroid external therapy.</entry><entry>Not improved even by steroid external therapy.</entry></row><!-- EPO <DP n="116"> --><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables></p><p id="p0233" num="0233"><tables id="tabl0014" num="0014"><table frame="all"><title>[Table 14]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP ointment preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 26</entry><entry align="center" valign="top">Subject 27 (<figref idrefs="f0007">Fig. 10</figref>)</entry><entry align="center" valign="top">Subject 28 (<figref idrefs="f0007">Fig. 11</figref>)</entry><entry align="center" valign="top">Subject 29 (<figref idrefs="f0006">Fig. 8</figref>)</entry><entry align="center" valign="top">Subject 30 (<figref idrefs="f0006">Fig. 9</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">32 years old</entry><entry align="center">3 years old</entry><entry align="center">22 years old</entry><entry align="center">44 years old</entry><entry align="center">36 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">2 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">2 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face and neck</entry><entry align="center">Face</entry><entry align="center">Face, neck, head</entry><entry align="center">Neck and back</entry><entry align="center">Face and upper limbs</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild</entry><entry>After: minor</entry><entry>After: mild</entry><entry>After: mild</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema:3</entry><entry>Erythema:3</entry><entry>Erythema:3</entry><entry>Erythema:3</entry><entry>Erythema:3</entry></row><row><entry>Edema/papulation:2</entry><entry>Edema/papulation:2</entry><entry>Edema/papulation:3</entry><entry>Edema/papulation:2</entry><entry>Edema/papulation:3</entry></row><row><entry>Oozing/crusting:1</entry><entry>Oozing/crusting:3</entry><entry>Oozing/crusting:3</entry><entry>Oozing/crusting:3</entry><entry>Oozing/crusting:3</entry></row><row><entry>Excoriation:1</entry><entry>Excoriation:3</entry><entry>Excoriation:2</entry><entry>Excoriation:2</entry><entry>Excoriation:3</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:3</entry><entry>Lichenification:3</entry></row><row><entry>Dryness:2</entry><entry>Dryness:3</entry><entry>Dryness:3</entry><entry>Dryness:3</entry><entry>Dryness:3</entry></row><row><entry>Total: 10/18</entry><entry>Total: 16/18</entry><entry>Total: 16/18</entry><entry>Total: 16/18</entry><entry>Total: 18/18</entry></row><!-- EPO <DP n="117"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema:1</entry><entry>Erythema:1</entry><entry>Erythema:0</entry><entry>Erythema:1</entry><entry>Erythema:1</entry></row><row><entry>Edema/papulation:1</entry><entry>Edema/papulation:1</entry><entry>Edema/papulation:0</entry><entry>Edema/papulation:1</entry><entry>Edema/papulation:0</entry></row><row><entry>Oozing/crusting:1</entry><entry>Oozing/crusting:1</entry><entry>Oozing/crusting:1</entry><entry>Oozing/crusting:1</entry><entry>Oozing/crusting:1</entry></row><row><entry>Excoriation:0</entry><entry>Excoriation:1</entry><entry>Excoriation:0</entry><entry>Excoriation:1</entry><entry>Excoriation:1</entry></row><row><entry>Lichenification:0</entry><entry>Lichenification:1</entry><entry>Lichenification:0</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry></row><row><entry>Dryness:1</entry><entry>Dryness:1</entry><entry>Dryness:1</entry><entry>Dryness:1</entry><entry>Dryness:1</entry></row><row><entry>Total: 4/18</entry><entry>Total: 6/18</entry><entry>Total: 2/18</entry><entry>Total: 6/18</entry><entry>Total: 5/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 2 days of application to the face and neck twice a day, erythema, swelling and itching were improved.</entry><entry>After 3 days of application to the face twice a day, erythema, infiltration, scales, and itching were markedly improved.</entry><entry>After 7 days of application to the face, neck and head twice a day, erythema, infiltration, and itching were improved, and remarkable hair growth was observed in the hair-loss regions.</entry><entry>After 3 days of application to the neck and back twice a day, lichenification, erythema, infiltration, scales and itching were markedly improved.</entry><entry>After 2 days of application to the face and upper limbs twice a day, erythema, excoriations, infiltration and itching were markedly improved.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 2</entry><entry align="center">After: 1</entry><entry align="center">After: 1</entry><entry align="center">After: 1</entry><entry align="center">After: 1</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">5 days</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks or more</entry><entry align="center">5 days</entry></row></tbody></tgroup></table></tables></p><p id="p0234" num="0234"><tables id="tabl0015" num="0015"><table frame="all"><title>[Table 15]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="22mm"/><colspec colnum="2" colname="col2" colwidth="26mm"/><colspec colnum="3" colname="col3" colwidth="31mm"/><colspec colnum="4" colname="col4" colwidth="26mm"/><colspec colnum="5" colname="col5" colwidth="31mm"/><colspec colnum="6" colname="col6" colwidth="30mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of CNP ointment preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 31</entry><entry align="center" valign="top">Subject 32</entry><entry align="center" valign="top">Subject 33</entry><entry align="center" valign="top">Subject 34</entry><entry align="center" valign="top">Subject 35</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">38 years old</entry><entry align="center">24 years old</entry><entry align="center">56 years old</entry><entry align="center">36 years old</entry><entry align="center">25 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed in infancy; worsening of symptoms was triggered by delivery 7 years ago, and erythema with itching appeared mainly on the face, upper limbs and body trunk; despite application of steroid external drugs, recurrence persisted.</entry><entry>Chronic recurrent dermatitis with itching occurred repeatedly since kindergarten; due to external application of strong steroid ointments, she has erythroderma posteczematosa; she has had cataract surgery and retinal detachment 6 times , and she uses eye-drops to decrease eye pressure.</entry><entry>Skin flush with a burning sensation erythema, and scales appeared on the face since several years ago, and they recurred repeatedly.</entry><entry>Developed in infancy, having recurrent eczema with itching; since 4 years ago, steroid external drugs have been applied every day, resulting in skin flush, scales and infiltrative erythema over the whole body.</entry><entry>Diagnosed to have atopic dermatitis at 2 months of age; since then he has continued to visit dermatology department for treatment, but symptoms worsened starting 2 years ago; he has erythroderma posteczematosa presumably due to long-term steroid external therapy.</entry></row><!-- EPO <DP n="118"> --><row><entry>Family history</entry><entry>Child; Atopic dermatitis</entry><entry>Father, mother; Allergic rhinitis Younger sister; Atopic dermatitis</entry><entry/><entry>Elder brother; Atopic dermatitis, Bronchial asthma</entry><entry>Mother; Atopic dermatitis</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis, Allergic conjunctivitis</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry><entry>Child asthma, Allergic rhinitis, Allergic conjunctivitis</entry></row><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 2+</entry><entry>House dust: 3+</entry><entry>House dust: 1+</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry></row><row><entry>Mite: 2+</entry><entry>Mite: 3+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 1+</entry><entry>Cedar: 3+</entry><entry>Orchard grass:1+</entry><entry>Cedar: 1+</entry><entry>Orchard grass:2+</entry></row><row><entry>Orchard grass:2+</entry><entry>Orchard grass:1+</entry><entry/><entry>Orchard grass:3+</entry><entry/></row><row><entry>Ragweed: 2+</entry><entry>Ragweed: 2+</entry><entry/><entry>Ragweed: 1+</entry><entry/></row><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema with itching associated with sleep disturbance, and erythema are observed on almost whole body.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body. She has erythroderma posteczematosa.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed on the four limbs and face.</entry><entry>Infiltrative erythema, lichenified lesions, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body. He has erythroderma posteczematosa.</entry><entry>Strong itching with sleep disturbance, infiltrative erythema, lichenified lesions and erythema are observed over the whole body; and severe scales, infiltrative erythema, adhesion of crusts, and numerous excoriations are observed on the face.</entry></row><!-- EPO <DP n="119"> --><row><entry>Symptoms of application regions</entry><entry>Rash on the face is mainly characterized by erythema with severe infiltration and edema.</entry><entry>Rash on the face includes erythema with severe swelling/ edema/ infiltration/ or lichenification, as well as severe scales, adhesion of crusts, vesicles, erosions, and numerous excoriations.</entry><entry>Rash on the face is mainly characterized by erythema, erosions, crusts, and excoriations.</entry><entry>Rash on the face is mainly characterized by erythema with lichenification, erosions, scales, and numerous excoriations.</entry><entry>Rash on the face is mainly characterized by severe infiltration, erythema, exudate, crusts, and numerous excoriations.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Steroid external drug is not sufficiently effective against erythema, infiltrative erythema and scales on the face, upper limbs and body trunk, which show an intractable nature.</entry><entry>Skin flush and desquamation appear over the whole body upon discontinuation of steroid external application, leading to the state of erythroderma.</entry><entry>Infiltrative erythema on the face is temporarily reduced by steroid external therapy, but symptoms soon recur with a worsening tendency.</entry><entry>Not improved even by "very strong" steroid external therapy.</entry><entry>He has erythroderma posteczematosa presumably due to steroid external therapy.</entry></row><!-- EPO <DP n="120"> --><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Moderate</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables></p><p id="p0235" num="0235"><tables id="tabl0016" num="0016"><table frame="all"><title>[Table 16]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of CNP ointment preparation</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 31</entry><entry align="center" valign="top">Subject 32</entry><entry align="center" valign="top">Subject 33</entry><entry align="center" valign="top">Subject 34</entry><entry align="center" valign="top">Subject 35</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">38 years old</entry><entry align="center">24 years old</entry><entry align="center">56 years old</entry><entry align="center">36 years old</entry><entry align="center">25 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry><entry align="center">CNP ointment preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">100 µg/g</entry><entry align="center">100 µg/g</entry><entry align="center">100 µg/g</entry><entry align="center">100 µg/g</entry><entry align="center">100 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face</entry><entry align="center">Face</entry><entry align="center">Face</entry><entry align="center">Face and back</entry><entry align="center">Face</entry></row><!-- EPO <DP n="121"> --><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry rowsep="0">Before: moderate</entry><entry rowsep="0">Before: severe</entry><entry rowsep="0">Before: severe</entry><entry rowsep="0">Before: severe</entry><entry rowsep="0">Before: severe</entry></row><row><entry>After: minor</entry><entry>After: moderate</entry><entry>After: minor</entry><entry>After: mild</entry><entry>After: mild</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 2</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 2</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 3</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 3</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:3</entry><entry>Lichenification:1</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 3</entry><entry>Dryness: 1</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry></row><row><entry>Total: 8/18</entry><entry>Total: 17/18</entry><entry>Total: 11/18</entry><entry>Total: 13/18</entry><entry>Total: 14/18</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 0</entry><entry>Erythema: 1</entry><entry>Erythema: 0</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry></row><row><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification:0</entry><entry>Lichenification:2</entry><entry>Lichenification:0</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry></row><row><entry>Dryness: 0</entry><entry>Dryness: 2</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 1/18</entry><entry>Total: 8/18</entry><entry>Total: 1/18</entry><entry>Total: 4/18</entry><entry>Total: 6/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 3 days of application to the face twice a day, erythema and infiltration were markedly improved to the best condition since 20 years ago.</entry><entry>After 3 days of application to the face twice a day, erythema, infiltration, scales, and itching were markedly improved.</entry><entry>After 3 days of application to the face twice a day, erythema, infiltration, crusts, itching, and burning sensation were markedly improved.</entry><entry>After 3 days of application to the face and neck twice a day, erythema, infiltration, scales, and itching were markedly improved.</entry><entry>After 3 days of application to the face twice a day, erythema, infiltration, scales, and itching were markedly improved.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 2</entry><entry align="center">After: 1</entry><entry align="center">After: 0</entry><entry align="center">After: 1</entry><entry align="center">After: 1</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">10 days</entry><entry align="center">7 days</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks or more</entry><entry align="center">5 days</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="122"> --></p><heading id="h0073"><u>Summary of therapeutic effects of CNP gel preparation, CNP aqueous-solution preparation, CNP gel-base preparation, and CNP ointment preparation:</u></heading><p id="p0236" num="0236">The above case studies clarified the following.</p><p id="p0237" num="0237">By administering skin external preparations comprising CNP, erythema with severe swelling/edema/infiltration, erythema with lichenification, papules, and scales were markedly improved, or they were improved to the mild symptoms that are characterized mainly by dryness, mild erythema, scales, etc., or to the minor rash characterized mainly by dryness with less inflammation. In particular, by administering skin external preparations comprising CNP, skin flush, infiltration, scales lichenification and burning sensation of on the face of adult patients, which are difficult to cure and can disrupt the patients' social lives, could be dramatically improved to a condition without any irritation symptoms. Moreover, remarkable improvement was observed in other regions such as the upper limbs and back, and similar effects were observed for infants as well, and were not limited to adults. Any of these skin external preparations comprising CNP such as CNP gel preparation, CNP aqueous-solution preparation, CNP gel-base preparation and CNP ointment preparation demonstrated almost identical therapeutic effects.</p><p id="p0238" num="0238">Manifestation of these effects of the skin external preparations comprising CNP is as follows: approximately 10 min after the application, a subjective burning sensation subsides, and on and after approximately 30 min after the application, improvements in erythema and infiltration were<!-- EPO <DP n="123"> --> objectively observed. Furthermore, continuation of the application for 3 or 4 days apparently reduced erythema and infiltration, resulting in near-normal skin with fine texture. This could be a great relief for patients with severe atopic dermatitis.</p><p id="p0239" num="0239">In addition, by administering skin external preparations comprising CNP, beneficial changes in vasodilation and inflammatory erythema was observed by the findings in the upper dermis of the skin by dermoscopy. Furthermore, by administering skin external preparations comprising CNP, it was demonstrated that the texture of the skin surface becomes finer, scales decrease, and the skin become soft to the touch. These findings were also confirmed by the findings in the upper dermis of the skin by dermoscopy. The fact that "the texture of the skin surface becomes finer, scales decrease, and the skin become soft to the touch" is important in compensating for skin dryness and deterioration of barrier functions, as well as preventing recurrence of inflammation. Such effects were also observed in psoriasis; disappearance of scales and reduction of infiltration were observed. Neither local irritation symptoms nor systemic side effects were observed at all by the CNP application. Likewise in rosacea, improvements in capillary dilation and erythema were achieved by the CNP application.</p><p id="p0240" num="0240">These therapeutic effects of good skin conditions were maintained for between 5 days to approximately 2 weeks after discontinuation of the application. Thereafter, even when erythema relapsed, it did not worsen as was observed<!-- EPO <DP n="124"> --> before the application, and symptoms were merely mild, and this demonstrates that stable conditions could be maintained. This deserves a special note since these effects could not have been obtained by conventional therapy, i.e., steroid external application. In addition, even when symptoms relapsed, it was evident that re-application to the rash could lead to mild or minor rash by a smaller number of applications than the initial application.</p><p id="p0241" num="0241">The primary goal of treatment of atopic dermatitis is to achieve the following conditions in patients.
<ol><li>(1) No symptoms; if any, minor symptoms without any problems caused in daily life, with a requirement of a low degree of drug therapy.</li><li>(2) While minor or mild symptoms persist, there is a small possibility of acute worsening; even when the symptoms worsen, they will not persist for a long time.</li></ol></p><p id="p0242" num="0242">The above case studies clearly demonstrated that the skin external preparations comprising CNP of the present invention are able to achieve these conditions in patients.</p><p id="p0243" num="0243">Next, skin external preparations comprising BNP were examined.</p><heading id="h0074"><b>Example 13</b></heading><heading id="h0075"><b>1. Production of BNP gel-base preparation:</b></heading><p id="p0244" num="0244">Preparation of the BNP gel-base preparations was performed as follows.</p><p id="p0245" num="0245">0.1 g of methyl parahydroxybenzoate (product name: Mekkins M, Ueno Fine Chemicals Industry), 0.2 g of phenoxyethanol, and 3.0 g of 1,2-pentanediol were measured<!-- EPO <DP n="125"> --> in the same container, dissolved at 60-70°C, and introduced into a mixing kettle. 6.0 g of concentrated glycerin was introduced, and a mixture of 0.44 g of carboxy vinyl polymer (product name: Carbopol 940, Lubrisol Advanced Materials, Inc.) and 0.08 g of xanthan gum (product name: Keltrol T, CP Kelco) was added to this solution and stirred thoroughly with a paddle at 15 rpm for dispersion. Then, while stirring with a paddle at 15 rpm, 83.95 g of purified water was gradually introduced, and the mixture was dissolved by stirring at a kettle temperature of 70-80°C using a paddle at 20 rpm and a disperser at 1500-2000 rpm. After stopping the disperser, dissolution was confirmed and cooling was immediately started; when the kettle temperature approached around 40°C, 6.0 g of Lubrajel NP from ISP Japan, Ltd. (2.7 g of glycerin, 0.06 g of carboxy vinyl polymer, 0.018 g of sodium polyacrylate, 3.222 g of water) was added and mixed homogeneously with a paddle at 20 rpm, then 0.230 g of potassium hydroxide was added for neutralization, and when the kettle temperature reached 25°C, the rotation of the paddle was terminated to obtain a gel-base.</p><p id="p0246" num="0246">Then, 3 mg of human BNP-32 (Peptide Institute, Inc.) as a principal agent was dissolved in 3 ml of saline to obtain the BNP solution with a concentration of 1000 µg/ml, and 1 ml of this BNP solution was homogeneously stirred and mixed in 19 g of the gel-base obtained as above, to produce the gel-base preparation with a concentration of 50 µg/g.</p><p id="p0247" num="0247">Similarly, 600 µl of the above BNP solution with a concentration of 1000 µg/ml was diluted with 400 µl of saline to adjust the concentration at 600 µg/ml, then 1 ml<!-- EPO <DP n="126"> --> of the resulting solution was homogeneously mixed in 19 g of the gel-base obtained as above and stirred, to produce the gel-base preparation with a concentration of 30 µg/g.</p><heading id="h0076"><b>Example 14</b></heading><heading id="h0077"><b>2. Production of BNP aqueous-solution preparation:</b></heading><p id="p0248" num="0248">3 mg of human BNP-32 (Peptide Institute, Inc.) as a principal agent was dissolved in 3 ml of saline to obtain a BNP solution, and 1 ml of this solution was diluted with 19 ml of saline to produce the aqueous-solution preparation with a BNP concentration of 50 µg/ml.</p><heading id="h0078"><b>Example 15</b></heading><heading id="h0079"><b>3. Diagnosis of subjects:</b></heading><p id="p0249" num="0249">The patients' diagnosis, evaluation of symptoms, selection of external therapy, test methods and observation of the skin were performed similarly to the methods of Example 1.</p><p id="p0250" num="0250">In addition, similarly to the methods of Example 1, prior to administration of the BNP gel-base preparation or BNP aqueous-solution preparation of the present invention, history taking from the subjects, scratch tests for allergens and diagnosis were conducted. Table 17 (subjects 36-40) and Table 19 (subjects 41-45) show the results of the subjects' history taking and diagnosis, i.e., sex, age, onset and course of disease, family history, past history, scratch test results, diagnostic findings, and symptom evaluation based on "Guideline 2005" of the subject in each case.</p><heading id="h0080"><b>Example 16</b></heading><!-- EPO <DP n="127"> --><heading id="h0081"><b>4. Therapeutic effects on subjects:</b></heading><p id="p0251" num="0251">Therapeutic effects of the BNP gel-base preparation or BNP aqueous-solution preparation are shown in Table 18 (subjects 36-40) and Table 20 (subjects 41-45). In Tables 18 and 20, "itching sensation" represents a comparison of the itching sensation evaluated using the visual analogue scale method before and after treatment. Similarly, "non-recurrence period" refers to the period after discontinuation of the treatment by the preparation subsequent to improvement of symptoms, for which relapse of the symptoms did not occur. In order to evaluate objectively, photographs before and after the application of BNP preparations were taken for all cases. Of these, photographs of some of the cases are shown in the figures.<!-- EPO <DP n="128"> --></p><p id="p0252" num="0252"><tables id="tabl0017" num="0017"><table frame="all"><title>[Table 17]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="23mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><colspec colnum="3" colname="col3" colwidth="32mm"/><colspec colnum="4" colname="col4" colwidth="29mm"/><colspec colnum="5" colname="col5" colwidth="29mm"/><colspec colnum="6" colname="col6" colwidth="27mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of BNP gel-base preparation or BNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 36</entry><entry align="center" valign="top">Subject 37</entry><entry align="center" valign="top">Subject 38</entry><entry align="center" valign="top">Subject 39</entry><entry align="center" valign="top">Subject 40 (<figref idrefs="f0010">Fig. 14</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 7</entry><entry align="center">Case 6</entry><entry align="center">Case 2</entry><entry align="center">Case 3</entry><entry align="center">Case 5</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">32 years old</entry><entry align="center">22 years old</entry><entry align="center">31 years old</entry><entry align="center">21 years old</entry><entry align="center">36 years old</entry></row><row><entry>Onset and course of disease</entry><entry>She had severe bronchial asthma until about 20 years of age; since then, she has been suffering mainly from erythema on the face.</entry><entry>Developed soon after birth, continuously receiving steroid external therapy; symptoms worsened in junior-high school. Symptoms relapse soon after discontinuation due to steroid rebound, and worsen further.</entry><entry>Developed atopic dermatitis in infancy; infiltrative erythema appeared particularly on the face recently, showing intractable nature.</entry><entry>Developed in infancy; symptoms worsened after entering university 3 years ago and eczema is appearing even on the face.</entry><entry>Developed in infancy, continuously using commercially-available steroid ointments; but the symptoms do not subside at all, and she can hardly sleep because of itching.</entry></row><row><entry>Family history</entry><entry>Elder brother; Atopic dermatitis</entry><entry>Uncle; Allergic rhinitis</entry><entry>Mother; Allergic rhinitis</entry><entry>Father; Bronchial asthma</entry><entry>Father; Atopic dermatitis, Allergic rhinitis</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis, Conjunctivitis</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry><entry>Bronchial asthma</entry><entry>Allergic rhinitis</entry></row><!-- EPO <DP n="129"> --><row><entry morerows="4">Scratch test</entry><entry rowsep="0">House dust: 3+</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 1+</entry><entry rowsep="0">House dust: 2+</entry><entry rowsep="0">House dust: 2+</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 2+</entry><entry>Cedar: 1+</entry><entry>Cedar: 3+</entry><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry></row><row><entry>Orchard grass:2+</entry><entry>Orchard grass:2+</entry><entry/><entry>Orchard grass:3+</entry><entry/></row><row><entry>Ragweed: 1+</entry><entry>Ragweed: 1+</entry><entry/><entry>Ragweed: 2+</entry><entry/></row><row><entry>Diagnostic findings</entry><entry>Infiltrative erythema, edema, and erythema are disseminated on the face and neck; papules and erythema are disseminated on the four limbs.</entry><entry>Edema, infiltrative erythema, erythema, scales, and numerous excoriations are observed over the whole body. She has erythroderma posteczematosa.</entry><entry>Infiltrative erythema, erythema and scales on the face, neck and body trunk.</entry><entry>Infiltrative erythema, erythema, many, adhesion of crusts, and excoriations are observed on the face, four limbs, and back.</entry><entry>Infiltrative erythema, erythema, edema, scales, adhesion of crusts, and numerous excoriations are observed on the face, neck, four limbs and body trunk.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the face and neck is mainly characterized by severe infiltration, erythema and swelling.</entry><entry>Rash on the face and neck is mainly characterized by severe edema, infiltration, erythema, erosions, scales and numerous excoriations.</entry><entry>Rash on the face and neck is mainly characterized by severe infiltration, erythema and scales.</entry><entry>Rash on the face is mainly characterized by infiltrative erythema, many papules, and excoriations.</entry><entry>Rash on the face and neck is mainly characterized by erythema with edema, erosions, scales and numerous excoriations.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Symptoms relapse soon after discontinuation of steroid external therapy.</entry><entry>Symptoms cannot be improved by steroid external therapy.</entry><entry>Symptoms relapse soon after discontinuation of steroid external therapy.</entry><entry>Symptoms relapse soon after discontinuation of steroid external therapy.</entry><entry>Symptoms are not reduced by steroid external therapy.</entry></row><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="130"> --></p><p id="p0253" num="0253"><tables id="tabl0018" num="0018"><table frame="all"><title>[Table 18]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of BNP gel-base preparation or BNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 36</entry><entry align="center" valign="top">Subject 37</entry><entry align="center" valign="top">Subject 38</entry><entry align="center" valign="top">Subject 39</entry><entry align="center" valign="top">Subject 40 (<figref idrefs="f0010">Fig. 14</figref>)</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 7</entry><entry align="center">Case 6</entry><entry align="center">Case 2</entry><entry align="center">Case 3</entry><entry align="center">Case 5</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">32 years old</entry><entry align="center">22 years old</entry><entry align="center">31 years old</entry><entry align="center">21 years old</entry><entry align="center">36 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP gel-base preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">30 µg/g</entry><entry align="center">30 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">3 days</entry><entry align="center">5 days</entry><entry align="center">3 days</entry><entry align="center">3 days</entry><entry align="center">2 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face</entry><entry align="center">Face and neck</entry><entry align="center">Face</entry><entry align="center">Face</entry><entry align="center">Face and neck</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: minor</entry><entry>After: mild</entry><entry>After: minor</entry><entry>After: mild</entry><entry>After: mild</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry></row><row><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 3</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 1</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:2</entry><entry>Lichenification:1</entry><entry>Lichenification:1</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 2</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 11/18</entry><entry>Total: 15/18</entry><entry>Total: 12/18</entry><entry>Total: 12/18</entry><entry>Total: 14/18</entry></row><!-- EPO <DP n="131"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry></row><row><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry></row><row><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry></row><row><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry></row><row><entry>Dryness: 0</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry></row><row><entry>Total: 1/18</entry><entry>Total: 4/18</entry><entry>Total: 2/18</entry><entry>Total: 4/18</entry><entry>Total: 3/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 2 to 3 days of application of 30 µg/g BNP gel-base preparation, erythema, edema, dryness and itching were markedly improved.</entry><entry>After 5 days of application of 30 µg/g BNP gel-base preparation to the face and neck twice a day, edema, erythema, excoriations, infiltration, scales, burning sensation and itching were markedly improved.</entry><entry>After 3 days of application of 50 µg/g BNP gel-base preparation to the face twice a day, erythema, infiltration, burning sensation and itching were markedly improved. Symptoms are mainly characterized by dryness with less inflammatory symptoms.</entry><entry>After 3 days of application of 50 µg/g BNP gel-base preparation to the face twice a day, erythema, infiltration, and itching were markedly improved.</entry><entry>By application of 50 µg/g BNP gel-base preparation twice a day, erosions were improved in 1 day, and 2 days later, erythema, infiltration, excoriations and itching were markedly improved.</entry></row><row><entry align="center">Itching</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center"/><entry align="center">After: 0</entry><entry align="center">After: 2</entry><entry align="center">After: 0</entry><entry align="center">After: 3</entry><entry align="center">After: 1</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">10 days</entry><entry align="center">5 days</entry><entry align="center">2 weeks</entry><entry align="center">2 weeks</entry><entry align="center">7 days</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="132"> --></p><p id="p0254" num="0254"><tables id="tabl0019" num="0019"><table frame="all"><title>[Table 19]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="25mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="26mm"/><colspec colnum="4" colname="col4" colwidth="30mm"/><colspec colnum="5" colname="col5" colwidth="26mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of BNP gel-base preparation or BNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 41 (<figref idrefs="f0008">Fig. 12</figref>)</entry><entry align="center" valign="top">Subject 42 (<figref idrefs="f0009">Fig. 13</figref>)</entry><entry align="center" valign="top">Subject 43 (<figref idrefs="f0011">Fig. 15</figref>)</entry><entry align="center" valign="top">Subject 44</entry><entry align="center" valign="top">Subject 45</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 1</entry><entry align="center">Case 4</entry><entry align="center">Case 8</entry><entry align="center">Case 9</entry><entry align="center">Case 10</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">11 years old</entry><entry align="center">23 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">48 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed in infancy; having recurrent eczema that worsens as seasons change; it developed into erythroderma recently.</entry><entry>Developed at around 3 years of age; symptoms worsened after transferring jobs last year. In particular erythema on the face shows intractable nature.</entry><entry>Symptoms worsened since last autumn, and he has eczema over the whole body including the face, and he claims that he can hardly sleep because of itching.</entry><entry>Developed when he was in elementary school. In recent years intractable recurrent erythema became obvious mainly on the face.</entry><entry>Developed at 3 months of age; symptoms worsen as seasons change. Recently the rash worsened due to leisureless life, and she is in a state of erythroderma.</entry></row><row><entry>Family history</entry><entry>Mother; Atopic dermatitis</entry><entry/><entry>Mother; Allergic rhinitis</entry><entry>Mother; Bronchial asthma</entry><entry>Elder brother; Atopic dermatitis</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis</entry><entry>Bronchial asthma</entry><entry/><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry></row><row><entry morerows="1">Scratch test</entry><entry>House dust: 2+</entry><entry>House dust: 2+</entry><entry>House dust: 3+</entry><entry>House dust: 1+</entry><entry>House dust: 3+</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 1+</entry><entry>Mite: 3+</entry></row><row><entry/><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry><entry>Cedar: 2+</entry><entry>Cedar: 1+</entry><entry>Cedar: 2+</entry></row><row><entry/><entry>Orchard grass:2+</entry><entry>Orchard grass:2+</entry><entry>Orchard grass:2+</entry><entry>Orchard grass:2+</entry><entry>Orchard grass:3+</entry></row><row><entry/><entry>Ragweed: 1+</entry><entry>Ragweed: 1+</entry><entry>Ragweed: 3+</entry><entry/><entry/></row><!-- EPO <DP n="133"> --><row><entry>Diagnostic findings</entry><entry>Edema, infiltrative erythema, erythema, severe scales, and numerous excoriations are observed over the whole body. She has erythroderma posteczematosa.</entry><entry>Infiltrative erythema, erythema, edema, scales, and adhesion of crusts are observed on the four limbs, body trunk, neck and face.</entry><entry>Infiltrative erythema with lichenification, erythema, many papules and excoriations are observed on the body; and infiltrative erythema, erythema and many papules are observed on the face.</entry><entry>Infiltrative erythema, erythema, edema, scales, and numerous excoriations are observed on the four limbs, body trunk, neck and face.</entry><entry>Skin flush with chills, edema, and infiltrative erythema are observed on the almost whole body.</entry></row><row><entry>Symptoms of application regions</entry><entry>Rash on the neck is mainly characterized by severe edema, infiltration, erythema, erosions, scales, and numerous excoriations.</entry><entry>Rash on the upper limbs consists of infiltrative erythema, erythema, papules, scales and crusts.</entry><entry>Rash on the face is mainly characterized by infiltrative erythema, many papules, scales and excoriations.</entry><entry>Rash on the face consists of infiltration, erythema, severe scales and crusts.</entry><entry>Rash on the face, neck, and four limbs consist of severe swelling, skin flush and edema.</entry></row><row><entry>Effects of steroid external drug</entry><entry>Symptoms cannot be improved by steroid external therapy.</entry><entry>Symptoms cannot be controlled by steroid external application.</entry><entry>Symptoms relapse soon after discontinuation of steroid external therapy.</entry><entry>Symptoms soon relapse with steroid external therapy.</entry><entry>She is in a state of erythroderma due to side effects of long-term and excessive steroid external application.</entry></row><row><entry align="center">Evaluation of symptoms</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="134"> --></p><p id="p0255" num="0255"><tables id="tabl0020" num="0020"><table frame="all"><title>[Table 20]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of BNP gel-base preparation or BNP aqueous-solution preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 41 (<figref idrefs="f0008">Fig. 12</figref>)</entry><entry align="center" valign="top">Subject 42 (<figref idrefs="f0009">Fig. 13</figref>)</entry><entry align="center" valign="top">Subject 43 (<figref idrefs="f0011">Fig. 15</figref>)</entry><entry align="center" valign="top">Subject 44</entry><entry align="center" valign="top">Subject 45</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 1</entry><entry align="center">Case 4</entry><entry align="center">Case 8</entry><entry align="center">Case 9</entry><entry align="center">Case 10</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Male</entry><entry align="center">Female</entry></row><row><entry align="center">Age</entry><entry align="center">11 years old</entry><entry align="center">23 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">48 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP gel-base preparation</entry><entry align="center">BNP aqueous-solution preparation</entry><entry align="center">BNP aqueous-solution preparation</entry><entry align="center">BNP aqueous-solution preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/ml</entry><entry align="center">50 µg/ml</entry><entry align="center">50 µg/ml</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">5 days</entry><entry align="center">5 days</entry><entry align="center">5 days</entry><entry align="center">1 day</entry><entry align="center">3 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Neck</entry><entry align="center">Upper limbs</entry><entry align="center">Face</entry><entry align="center">Face and neck</entry><entry align="center">Face and neck</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: mild</entry><entry>After: mild</entry><entry>After: mild</entry><entry>After: minor</entry><entry>After: moderate</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry></row><row><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 3</entry></row><row><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 3</entry></row><row><entry>Excoriation: 3</entry><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 2</entry></row><row><entry>Lichenification:3</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:3</entry></row><row><entry>Dryness: 2</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 17/18</entry><entry>Total: 13/18</entry><entry>Total: 12/18</entry><entry>Total: 14/18</entry><entry>Total: 17/18</entry></row><!-- EPO <DP n="135"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 1</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 1</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 0</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 0</entry><entry>Oozing/crusting: 2</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 0</entry><entry>Excoriation: 1</entry></row><row><entry>Lichenification:1</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:0</entry><entry>Lichenification:1</entry></row><row><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 1</entry><entry>Dryness: 2</entry></row><row><entry>Total: 6/18</entry><entry>Total: 3/18</entry><entry>Total: 3/18</entry><entry>Total: 2/18</entry><entry>Total: 9/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>After 5 days of application of 50 µg/g BNP gel-base preparation to the neck twice a day, edema, erythema, excoriations, infiltration, scales, burning sensation and itching were markedly improved. Symptoms are mainly characterized by dryness, mild erythema, and scales.</entry><entry>After 3 days of application of 50 µg/g BNP gel-base preparation twice a day, erythema, infiltration, and itching were markedly improved although the skin was slightly dry.</entry><entry>After 2 days of application of 50 µg/ml BNP saline-solution preparation twice a day, erythema, infiltration, scales and itching were markedly improved.</entry><entry>By the application of 50 µg/ml BNP saline-solution preparation twice a day, on the next day, erythema, itching and dryness were markedly improved.</entry><entry>By the application of 50 µg/ml BNP saline-solution preparation twice a day, swelling, erythema, itching sensation and tight-stretched sensation were fairly improved in 1 day, and infiltrative erythema, swelling, excoriations and itching were markedly improved 3 days later; however, scales and dryness still remained.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 2</entry><entry align="center">After: 1</entry><entry align="center">After: 3</entry><entry align="center">After: 0</entry><entry align="center">After: 1</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">5 days</entry><entry align="center">2 weeks</entry><entry align="center">10 days</entry><entry align="center">7 days</entry><entry align="center">5 days</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="136"> --></p><heading id="h0082">Example 17</heading><p id="p0256" num="0256">Details of the test examples of the BNP gel-base preparations and BNP aqueous-solution preparations shown in Tables 17-20 are described below. For reference, photographs of Case 1 (subject 41), Case 4 (subject 42), and Case 5 (subject 40) as examples of most severe patients before and after the application are shown in <figref idrefs="f0008">Figs. 12</figref>, <figref idrefs="f0009">13</figref> and <figref idrefs="f0010">14</figref>, respectively.</p><heading id="h0083"><u>BNP test example 1 (Case 1; subject 41):</u></heading><p id="p0257" num="0257">The subject of Case 1 presented with edema, infiltrative erythema, erythema, severe scales, and numerous excoriations over the whole body, and was diagnosed to be in the state of erythroderma posteczematosa. Furthermore, the rash on the neck was characterized mainly by severe edema, infiltration, erythema, erosions, scales and numerous excoriations, and the severity level based on "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation according to "Guideline 2005" was most severe. The symptoms of this subject did not improve by the use of steroid external preparations.</p><heading id="h0084"><u>Treatment and its outcome:</u></heading><p id="p0258" num="0258">To the subject of Case 1, the BNP gel-base preparation with a concentration of 50 µg/g obtained in Example 13 was applied to the neck twice a day; 5 days later, edema, erythema, excoriations, infiltration, scales, burning sensation and itching were markedly improved. Itching sensation level was improved from 10 prior to the<!-- EPO <DP n="137"> --> application to 2 after the application. <figref idrefs="f0008">Figure 12</figref> shows photographs before and after 5 days of application; A shows the state before application, and B shows the state after application.</p><heading id="h0085"><u>BNP test example 2 (Case 2; subject 38)</u></heading><p id="p0259" num="0259">The subject of case 2 presented with infiltrative erythema, erythema and scales on the face, neck and body trunk; and the rash on the face and neck was mainly characterized by severe infiltration, erythema and scales. The rash on the face and neck was mainly characterized by severe infiltration, erythema and scales, and the severity level based on "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation according to "Guideline 2005" was severe. Steroid external therapy was applied to this subject, but the subject had recurrence soon after discontinuation of the external application.</p><heading id="h0086"><u>Treatment and its outcome:</u></heading><p id="p0260" num="0260">To the subject of Case 2, the BNP gel-base preparation with a concentration of 50 µg/g obtained in Example 13 was applied to the face twice a day; 3 days later, erythema, infiltration, burning sensation and itching were markedly improved. Itching sensation level was improved from 10 prior to the application to 0 after the application.</p><heading id="h0087"><u>BNP test example 3 (Case 3; subject 39):</u></heading><p id="p0261" num="0261">The subject of Case 3 presented with infiltrative erythema, erythema, many papules, adhesion of crusts and excoriations on the face, four limbs and back, and the rash on the face was mainly characterized by infiltrative<!-- EPO <DP n="138"> --> erythema, many papules and excoriations. In addition, the rash on the face and neck was mainly characterized by severe infiltration, erythema and scales, and the severity level based on "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation based on "Guideline 2005" was severe. Steroid external therapy was applied to this subject; but the subject had recurrence soon after discontinuation of the external application.</p><heading id="h0088"><u>Treatment and its outcome:</u></heading><p id="p0262" num="0262">To the subject of Case 3, the BNP gel-base preparation with a concentration of 50 µg/g obtained in Example 13 was applied to the face twice a day; 3 days later, erythema, infiltration, and itching markedly improved. Itching level improved from 10 prior to the application to 0 after the application for 3 days.</p><heading id="h0089"><u>BNP test example 4 (Case 4; subject 42):</u></heading><p id="p0263" num="0263">The subject of Case 4 presented with infiltrative erythema, erythema, edema, scales and adhesion of crusts on the four limbs, body trunk, neck and face, and the rash on the upper limbs consists of infiltrative erythema, erythema, papules, severe scales and crusts. In addition, the rash on the upper limbs consists of infiltration, erythema, edema, severe scales and crusts, and the severity level based on the "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation based on the "Guideline 2005" was most severe, and the symptoms were not improved by steroid external preparations.</p><heading id="h0090"><u>Treatment and its outcome:</u></heading><!-- EPO <DP n="139"> --><p id="p0264" num="0264">The BNP gel-base preparation with a concentration of 50 µg/g obtained in Example 13 was applied to the upper limbs of the subject of Case 4 twice a day; 3 days later, although mild erythema remained, infiltration, papules, scales, crusts and itching were markedly improved. Itching sensation level was improved from 10 prior to the application to 1 after the application for 3 days. <figref idrefs="f0009">Figure 13</figref> shows photographs before and after 5 days of application. A shows the state before application, and B shows the state after application.</p><heading id="h0091"><u>BNP test example 5 (Case 5; subject 40):</u></heading><p id="p0265" num="0265">The subject of Case 5 presented with infiltrative erythema, erythema, edema, scales, adhesion of crusts and numerous excoriations on the face, neck, four limbs and body trunk, and the rash on the face and neck was mainly characterized by erythema with edema, erosions, scales, and numerous excoriations. In addition, the rash on the face and neck was mainly characterized by erythema with edema, erosions, scales, and numerous excoriations, and the severity level based on the "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation based on the "Guideline 2005" was most severe, and the symptoms were not improved by steroid external preparations.</p><heading id="h0092"><u>Treatment and its outcome:</u></heading><p id="p0266" num="0266">The BNP gel-base preparation with a concentration of 50 µg/g obtained in Example 13 was applied to the face and neck of the subject of Case 5 twice a day; erosions were improved 1 day later, and erythema, infiltration, excoriations and itching were markedly improved 2 days<!-- EPO <DP n="140"> --> later. Itching sensation level was improved from 10 prior to the application to 1 after the application of 2 days. <figref idrefs="f0010">Figure 14</figref> shows photographs before and after 1 day of application. A shows the state before application, and B shows the state after application.</p><heading id="h0093"><u>BNP test example 6 (Case 6; subject 37):</u></heading><p id="p0267" num="0267">The subject of Case 6 presented with edema, infiltrative erythema, erythema, severe scales, and numerous excoriations over the whole body, and the subject was in a state of erythroderma posteczematosa. The rash on the face and neck was mainly characterized by severe edema, infiltration, erythema, erosions, scales and numerous excoriations, and the severity level based on the "Dermatological Association Guideline" was severe. Meanwhile, symptom evaluation based on the "Guideline 2005" was most severe, and the symptoms of this subject were not improved by steroid external therapy.</p><heading id="h0094"><u>Treatment and its outcome:</u></heading><p id="p0268" num="0268">The BNP gel-base preparation with a concentration of 30 µg/g obtained in Example 13 was applied to the face and neck of the subject of Case 6 twice a day; 5 days later, edema, erythema, excoriations, infiltration, scales, burning sensation and itching were markedly improved. Itching sensation level was improved from 10 prior to the application to 2.</p><heading id="h0095"><u>BNP test example 7 (Case 7; subject 36):</u></heading><p id="p0269" num="0269">The subject of Case 7 presented with infiltrative erythema, edema and erythema on the face and neck, and<!-- EPO <DP n="141"> --> papules and erythema were disseminated on the four limbs. The rash on the face and neck was mainly characterized by severe infiltration, erythema and swelling. The severity level based on the "Dermatological Association Guideline" was severe, and symptom evaluation based on the "Guideline 2005" was severe. Steroid external therapy was applied to this subject, but the subject had recurrence soon after its discontinuation.</p><heading id="h0096"><u>Treatment and its outcome:</u></heading><p id="p0270" num="0270">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the subject of Case 7, but both erythema and itching worsened by drying. Therefore, the BNP gel-base preparation with a concentration of 30 µg/g obtained in Example 13 was applied to the face twice a day; after 2 to 3 days, erythema, edema, dryness, and itching were markedly improved. Itching sensation level was improved from 10 prior to the application to 0.</p><heading id="h0097"><u>BNP test example 8 (Case 8; subject 43):</u></heading><p id="p0271" num="0271">The subject of Case 8 presented with infiltrative erythema with lichenification, erythema, many papules, and excoriations on the body, and infiltrative erythema, erythema and many papules on the face; the rash on the face was mainly characterized by infiltrative erythema, many papules, scales and excoriations. The severity level based on the "Dermatological Association Guideline" was severe, and symptom evaluation based on the "Guideline 2005" was most severe. Steroid external therapy was applied to this<!-- EPO <DP n="142"> --> subject, but the subject had recurrence soon after its discontinuation.</p><heading id="h0098"><u>Treatment and its outcome:</u></heading><p id="p0272" num="0272">The BNP aqueous-solution preparation with a concentration of 50 µg/ml obtained in Example 14 was applied to the subject of Case 8 twice a day; after 2 days, erythema, infiltration, scales, and itching were markedly improved. Itching sensation level was improved from 10 prior to the application to 3. <figref idrefs="f0011">Figure 15</figref> shows photographs before and after 5 days of application. A shows the state before application, and B shows the state after application.</p><heading id="h0099"><u>BNP test example 9 (Case 9; subject 44):</u></heading><p id="p0273" num="0273">The subject of Case 9 presented with infiltrative erythema, erythema, edema, scales and numerous excoriations on the four limbs, body trunk, neck and face, and the rash on the face consisted of infiltration, erythema, severe scales and crusts. The severity level based on the "Dermatological Association Guideline" was severe, and symptom evaluation based on the "Guideline 2005" was severe. Steroid external therapy was applied to this subject, but the subject had recurrence soon after its discontinuation.</p><heading id="h0100"><u>Treatment and its outcome:</u></heading><p id="p0274" num="0274">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the subject of Case 9; while redness of the skin slightly disappeared after approximately 3 days, erythema did not fade away any more even after 7 days of further application, and scales also remained. Therefore, the BNP aqueous-solution preparation with a concentration of 50 µg/ml obtained in<!-- EPO <DP n="143"> --> Example 14 was applied to the face and neck twice a day; then erythema, itching, and dryness were markedly improved on the next day. Itching sensation level was improved from 10 prior to the application to 0.</p><heading id="h0101"><u>BNP test example 10 (Case 10; subject 45):</u></heading><p id="p0275" num="0275">The subject of Case 10 presented with skin flush with chills, edema, and infiltrative erythema on almost the whole body, and the rash on the face, neck and four limbs consisted of severe swelling, skin flush, and edema. The severity level based on the "Dermatological Association Guideline" was severe, and symptom evaluation based on the "Guideline 2005" was most severe. Due to side effects caused by a long period of steroid external therapy and its excessive application, the subject was in a state of erythroderma.</p><heading id="h0102"><u>Treatment and its outcome:</u></heading><p id="p0276" num="0276">The subject of Case 10 is the subject of Comparative case 3 in the comparative test example in which the later-described ANP gel-base preparation has been applied. The BNP aqueous-solution preparation with a concentration of 50 µg/ml obtained in Example 14 was applied to the face and neck of this subject twice a day; swelling, erythema, itching, and the sensation of tight-stretched skin were fairly improved the next day, and 3 days later, infiltrative erythema, swelling, excoriations, and itching were markedly improved, but scales and dryness still remained. Itching sensation level was improved from 10 prior to the application to 1.<!-- EPO <DP n="144"> --></p><p id="p0277" num="0277">Subsequently, the ANP aqueous solution with a concentration of 50 µg/g was applied twice a day, then the areas of erythema extended in one day, and itching worsened to a level that could be clearly perceived subjectively.</p><heading id="h0103"><u>Summary of therapeutic effects of BNP gel-base preparation and BNP aqueous-solution preparation:</u></heading><p id="p0278" num="0278">The above case studies clarified the following.</p><p id="p0279" num="0279">By administering skin external preparations comprising BNP, erythema with severe swelling/edema/infiltration, erythema with lichenification, papules, and scales were markedly improved, or they were improved to the mild symptoms mainly characterized by dryness, mild erythema, scales, etc., or to the minor rash mainly characterized by dryness with less inflammation. In particular, by administering skin external preparations comprising BNP, skin flush, infiltration, scales lichenification and burning sensation on the face of adult patients, which are hardly curable and can disrupt the patients' social lives, could be dramatically improved to a condition without any irritation symptoms. Any of these skin external preparations comprising BNP such as BNP aqueous-solution preparation and BNP gel-base preparation demonstrated almost identical therapeutic effects.</p><p id="p0280" num="0280">Due to such effects of the skin external preparations comprising BNP, continuation of application for 3 to 4 days apparently reduced erythema and infiltration, resulting in almost normal skin with fine texture in some cases. This could be a great relief for patients with severe atopic dermatitis.<!-- EPO <DP n="145"> --></p><p id="p0281" num="0281">In addition, by administering skin external preparations comprising BNP, improvement of vasodilation and inflammatory erythema was confirmed from findings in the upper dermis of the skin by dermoscopy. Furthermore, by administering skin external preparations comprising BNP, it was confirmed that the texture of the skin surface becomes finer, scales decrease, and the skin becomes soft to the touch. These findings were also confirmed by the findings in the upper dermis of the skin by dermoscopy. The fact that "the texture of the skin surface becomes finer, scales decrease, and the skin become soft to the touch" is important in compensating for skin dryness and deterioration of barrier functions as well as preventing recurrence of inflammation. Such effects were also observed in psoriasis; disappearance of scales and improvement of infiltration were confirmed. Neither local irritation symptom nor systemic side effect was observed at all by the BNP application. In rosacea as well, improvement in capillary dilation and erythema was observed by the BNP application.</p><p id="p0282" num="0282">These effects of BNP therapeutic preparations for dermatitis were almost similar to those of CNP claimed in the priority application, which include the following: subjective burning sensation and sensation of heaviness were improved at approximately 20 min after the application, and at approximately 40 min after the application, improvement of erythema, infiltration and swelling were objectively observed. Moreover, after 2 to 3 days of application, erythema with severe infiltration/edema/swelling, erythema with lichenification,<!-- EPO <DP n="146"> --> papules and scales were markedly improved to symptoms mainly characterized by dryness, mild to minor erythema and scales, etc. The continuation of the effects was also observed, and good skin conditions were maintained for 5 days to around 2 weeks after discontinuation of the application.</p><p id="p0283" num="0283">Thereafter, even when erythema relapsed, it did not worsen as was observed before the application, and symptoms were merely mild, and it was confirmed that stable conditions could be maintained. This deserves a special note since these effects could not have been obtained by conventional therapy, i.e., steroid external application. In addition, even when symptoms relapsed, it was confirmed that re-application to the rash could lead to mild or minor rash by a smaller number of application than the initial application.</p><p id="p0284" num="0284">Regarding the degree of improvement of the rash, the severity level of the rash based on the "Dermatological Association Guideline" were improved from severe to mild or minor. According to the severity level of local symptoms based on the globally used "SCORAD index: Clinical Evaluation", severity levels for most of the items "Erythema", "Edema/population", "Oozing/crusting", "Excoriation" and "Lichenification" were improved from stage 3 to stage 1, i.e., the most mild state.</p><p id="p0285" num="0285">In the first place, the goal of treatment of atopic dermatitis is to achieve the following conditions in patients.<!-- EPO <DP n="147"> -->
<ol><li>(1) No symptoms; if any, minor symptoms without any problem in daily life, with a requirement of a low degree of drug therapy.</li><li>(2) While minor or mild symptoms persist, there is low possibility of acute worsening; even when the symptoms worsen, they will not persist for a long time.</li></ol></p><p id="p0286" num="0286">The above case studies clearly confirmed that the skin external preparations comprising BNP are able to achieve these conditions in patients.</p><heading id="h0104"><b>Example 18</b></heading><heading id="h0105"><b>Comparative test:</b></heading><heading id="h0106">1. Production of ANP gel-base preparation:</heading><p id="p0287" num="0287">For comparative testing, ANP gel-base preparations were prepared as follows.</p><p id="p0288" num="0288">0.1 g of methyl parahydroxybenzoate (product name: Mekkins M, Ueno Fine Chemicals Industry), 0.2 g of phenoxyethanol, and 3.0 g of 1,2-pentanediol were measured in the same container, dissolved at 60-70°C, and introduced into a mixing kettle. 6.0 g of concentrated glycerin was introduced and a mixture of 0.44 g of carboxy vinyl polymer (product name: Carbopol 940, Lubrisol Advanced Materials, Inc.) and 0.08 g of xanthan gum (product name: Keltrol T, CP Kelco) was added to this solution and stirred thoroughly with a paddle at 15 rpm for dispersion. Then, while stirring with a paddle at 15 rpm, 83.95 g of purified water was gradually introduced, and the mixture was dissolved by stirring at a kettle temperature of 70-80°C using a paddle at 20 rpm and a disperser at 1500-2000 rpm. After stopping the disperser, dissolution was confirmed and cooling was<!-- EPO <DP n="148"> --> immediately started; when the kettle temperature approached around 40°C, 6.0 g of Lubrajel NP from ISP Japan, Ltd. (2.7 g of glycerin, 0.06 g of carboxy vinyl polymer, 0.018 g of sodium polyacrylate, 3.222 g of water) was added and mixed homogeneously with a paddle at 20 rpm, then 0.230 g of potassium hydroxide was added for neutralization, and when the kettle temperature reached 25°C, the rotation of the paddle was terminated to obtain a gel base.</p><p id="p0289" num="0289">Then, 1000 µg of HANP injection 1000 (carperitide for injection; α-atrial natriuretic peptide preparation) as a principal agent was dissolved in 10 ml of an injection solvent to obtain the ANP solution with a concentration of 100 µg/ml, and 10 ml of this ANP solution was diluted with 10 g of the gel-base obtained as above, to produce a gel-base preparation with an ANP concentration of 50 µg/g.</p><p id="p0290" num="0290">In addition, in order to conduct the comparison under the same condition as BNP, human ANP-28 (Peptide Institute, Inc.) was also used for the examination. In this case, 0.5 mg of human ANP-28 was dissolved in 1 ml of purified water to obtain an ANP solution with a concentration of 500 µg/ml, then 1.0 ml of this solution was homogeneously mixed and stirred in 9 g of the above gel-base to obtain the ANP gel-base preparation. The ANP concentration of this gel-base preparation is 50 µg/g.</p><heading id="h0107"><b>Example 19</b></heading><heading id="h0108">2. Production of ANP aqueous-solution preparation:</heading><p id="p0291" num="0291">0.5 mg of human ANP-28 (Peptide Institute, Inc.) as a principal agent was dissolved in 1 ml of purified water to obtain an ANP solution, and 1.0 ml of this solution was<!-- EPO <DP n="149"> --> diluted with 9 ml of purified water to produce the aqueous-solution preparation with an ANP concentration of 50 µg/ml.</p><heading id="h0109"><b>Example 20</b></heading><heading id="h0110"><b>3. Diagnosis of subjects:</b></heading><p id="p0292" num="0292">Patients' diagnosis, evaluation of symptoms, selection of external therapy, test method and observation of the skin were performed similarly to the methods of Example 1.</p><p id="p0293" num="0293">In addition, similarly to the methods of Example 1, prior to administration of the ANP gel-base preparation of the present invention, history taking from subjects, scratch tests for allergens, and diagnosis were conducted. Table 21 (subjects 45-49) shows the results of the subjects' history taking and diagnosis, i.e., sex, age, onset and course of disease, family history, past history, scratch test result, diagnostic findings, and symptom evaluation based on the "Guideline 2005" of the subject in each case.</p><heading id="h0111"><b>Example 21</b></heading><heading id="h0112"><b>4. Therapeutic effects on subjects:</b></heading><p id="p0294" num="0294">Therapeutic effects of the ANP gel-base preparation are shown in Table 22 (subjects 45-49). In Table 22, "itching sensation" represents comparison of the itching sensation evaluated using visual analogue scale method before and after treatment. Similarly, "non-recurrence period" refers to the period after discontinuation of the treatment by the preparation of the present invention subsequent to improvement of symptoms, for which relapse of the symptoms did not occur.<!-- EPO <DP n="150"> --> In order to evaluate the results objectively, photographs before and after the application of ANP preparations were taken for all cases. Of these, photographs of some of the cases are shown in the figures.<!-- EPO <DP n="151"> --></p><p id="p0295" num="0295"><tables id="tabl0021" num="0021"><table frame="all"><title>[Table 21]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="29mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="27mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="29mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Diagnosis prior to application of ANP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 45 (<figref idrefs="f0013">Fig. 17</figref>)</entry><entry align="center" valign="top">Subject 46 (<figref idrefs="f0012">Fig. 16</figref>)</entry><entry align="center" valign="top">Subject 47</entry><entry align="center" valign="top">Subject 48 (<figref idrefs="f0014">Fig. 18</figref>)</entry><entry align="center" valign="top">Subject 49</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 3</entry><entry align="center">Case 2</entry><entry align="center">Case 4</entry><entry align="center">Case 5</entry><entry align="center">Case 1</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">48 years old</entry><entry align="center">27 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">14 years old</entry></row><row><entry>Onset and course of disease</entry><entry>Developed at 3 months of age; symptoms worsen as seasons change. Recently the rash worsened due to leisureless life, and she is in a sate of erythroderma.</entry><entry>Developed in infancy; symptoms worsened since the start of menstruation in the junior high school, and they were alleviated during pregnancy, but relapsed after birth, extending to the whole body.</entry><entry>Developed in infancy; symptoms worsen in dry seasons, and erythema with itching appeared mainly on the face, neck, upper limbs and trunk; they relapse and worsen due to steroids.</entry><entry>Developed in infancy; symptoms were mainly on the body trunk and four limbs; they extended to the face and neck after he reached adulthood. In particular, the rash on the back shows intractable nature.</entry><entry>Developed in infancy; symptoms worsened since around the 2nd grade of elementary school, and he visited many clinics but they were not improved; starting 5 years ago, dryness has become particularly severe.</entry></row><row><entry>Family history</entry><entry>Elder brother; Atopic dermatitis,</entry><entry>Younger brother; Bronchial asthma, Mother; Allergic rhinitis</entry><entry>Mother; Atopic dermatitis</entry><entry/><entry>Mother; Allergic rhinitis, Allergic conjunctivitis</entry></row><row><entry>Past history</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis</entry><entry>Allergic rhinitis, Allergic conjunctivitis</entry><entry>Allergic rhinitis</entry><entry>Bronchial asthma, Allergic rhinitis, Allergic conjunctivitis</entry></row><!-- EPO <DP n="152"> --><row><entry morerows="4" rowsep="1">Scratch test</entry><entry>House dust: 3+</entry><entry>House dust: 2+</entry><entry>House dust: 1+</entry><entry>House dust: 1+</entry><entry>House dust:3 +</entry></row><row><entry>Mite: 3+</entry><entry>Mite: 3+</entry><entry>Mite: 1+</entry><entry>Mite: 2+</entry><entry>Mite: 3+</entry></row><row><entry>Cedar: 2+</entry><entry/><entry>Cedar: 2+</entry><entry>Cedar: 1+</entry><entry>Cedar: 3+</entry></row><row><entry>Orchard grass:3+</entry><entry/><entry>Orchard grass:2+</entry><entry>Orchard grass:3+</entry><entry>Orchard grass:2+</entry></row><row><entry/><entry/><entry/><entry>Ragweed: 1+</entry><entry/></row><row><entry>Diagnosti c findings</entry><entry>Skin flush with chills, edema, and infiltrative erythema are observed on the almost whole body.</entry><entry>Infiltrative erythema with lichenification, erythema, and severe scales are observed on the face and neck, infiltrated erythema is observed on the four limbs and body trunk.</entry><entry>Infiltrative erythema, erythema, severe scales, adhesion of crusts, and numerous excoriations are observed over the whole body, and they are particularly severe on the face and neck.</entry><entry>Infiltrative erythema, erythema, numerous excoriations, and papules are particularly severely observed on the back.</entry><entry>Erythema with strong itching associated with sleep disturbance, severe scales, and numerous excoriations are observed over the whole body.</entry></row><row><entry>Symptoms of applicati on regions</entry><entry>Rash on the face, neck, and four limbs consist of severe swelling, skin flush and edema.</entry><entry>Rash on the face is mainly characterized by severe lichenified infiltration, erythema, and scales.</entry><entry>Rash on the face is mainly characterized by severe infiltration, edema, erythema, scales, crusts and excoriations.</entry><entry>Rash on the back consists of severe infiltration, erythema, numerous excoriations, papules and lichenification.</entry><entry>Rash on the back is mainly characterized by severe scales, erythema, and numerous excoriations.</entry></row><row><entry>Effects of steroid external drug</entry><entry>She is in a state of erythroderma due to the side effects by long-term steroid external therapy and excessive application.</entry><entry>Steroid external therapy is not sufficiently effective to infiltrative erythema on the face.</entry><entry>Symptoms on the face soon relapse with the use of steroid, and further worsen compared to the condition before the use.</entry><entry>Sufficient effects cannot be obtained with steroid external application, and symptoms soon relapse strong itching does not subside.</entry><entry>Symptoms are temporarily reduced with steroid external therapy, but soon relapse and dryness occurs.</entry></row><!-- EPO <DP n="153"> --><row><entry align="center">Evaluatio n of symptoms</entry><entry align="center">Most severe</entry><entry align="center">Most severe</entry><entry align="center">Severe</entry><entry align="center">Severe</entry><entry align="center">Most severe</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="154"> --><tables id="tabl0022" num="0022"><table frame="all"><title>[Table 22]</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="28mm"/><colspec colnum="2" colname="col2" colwidth="28mm"/><colspec colnum="3" colname="col3" colwidth="28mm"/><colspec colnum="4" colname="col4" colwidth="28mm"/><colspec colnum="5" colname="col5" colwidth="28mm"/><colspec colnum="6" colname="col6" colwidth="28mm"/><thead><row><entry namest="col1" nameend="col6" align="left" valign="top">Therapeutic effects of ANP gel-base preparation.</entry></row><row><entry align="center" valign="top">Subject</entry><entry align="center" valign="top">Subject 45 (<figref idrefs="f0013">Fig. 17</figref>)</entry><entry align="center" valign="top">Subject 46 (<figref idrefs="f0012">Fig. 16</figref>)</entry><entry align="center" valign="top">Subject 47</entry><entry align="center" valign="top">Subject 48 (<figref idrefs="f0014">Fig. 18</figref>)</entry><entry align="center" valign="top">Subject 49</entry></row></thead><tbody><row><entry align="center">Case</entry><entry align="center">Case 3</entry><entry align="center">Case 2</entry><entry align="center">Case 4</entry><entry align="center">Case 5</entry><entry align="center">Case 1</entry></row><row><entry align="center">Sex</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Female</entry><entry align="center">Male</entry><entry align="center">Male</entry></row><row><entry align="center">Age</entry><entry align="center">48 years old</entry><entry align="center">27 years old</entry><entry align="center">21 years old</entry><entry align="center">28 years old</entry><entry align="center">14 years old</entry></row><row><entry align="center">Dosage form</entry><entry align="center">ANP gel-base preparation</entry><entry align="center">ANP gel-base preparation</entry><entry align="center">ANP gel-base preparation</entry><entry align="center">ANP gel-base preparation</entry><entry align="center">ANP gel-base preparation</entry></row><row><entry align="center">Dosage</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry><entry align="center">50 µg/g</entry></row><row><entry align="center">Number of administration</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry><entry align="center">Twice a day</entry></row><row><entry align="center">Days of administration</entry><entry align="center">7 days</entry><entry align="center">7 days</entry><entry align="center">5 days</entry><entry align="center">5 days</entry><entry align="center">7 days</entry></row><row><entry align="center">Applied region</entry><entry align="center">Face and upper limbs</entry><entry align="center">Face and neck</entry><entry align="center">Face</entry><entry align="center">Back</entry><entry align="center">Back</entry></row><row><entry morerows="1">Severity level of rash by Dermatological Association Guideline</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry><entry>Before: severe</entry></row><row><entry>After: severe</entry><entry>After: severe</entry><entry>After: severe</entry><entry>After: severe</entry><entry>After: severe</entry></row><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (before application)</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 1</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry></row><row><entry>Excoriation: 1</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 3</entry><entry>Excoriation: 2</entry></row><row><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 15/18</entry><entry>Total: 11/18</entry><entry>Total: 14/18</entry><entry>Total: 16/18</entry><entry>Total: 12/18</entry></row><!-- EPO <DP n="155"> --><row><entry morerows="6">Severity level evaluation of the rash region by SCORAD (after application)</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 3</entry><entry>Erythema: 2</entry></row><row><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 2</entry><entry>Edema/papulation: 3</entry><entry>Edema/papulation: 1</entry></row><row><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 2</entry><entry>Oozing/crusting: 3</entry><entry>Oozing/crusting: 2</entry></row><row><entry>Excoriation: 2</entry><entry>Excoriation: 1</entry><entry>Excoriation: 2</entry><entry>Excoriation: 3</entry><entry>Excoriation: 2</entry></row><row><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:2</entry><entry>Lichenification:3</entry><entry>Lichenification:2</entry></row><row><entry>Dryness: 3</entry><entry>Dryness: 3</entry><entry>Dryness: 2</entry><entry>Dryness: 2</entry><entry>Dryness: 3</entry></row><row><entry>Total: 15/18</entry><entry>Total: 13/18</entry><entry>Total: 13/18</entry><entry>Total: 17/18</entry><entry>Total: 12/18</entry></row><row><entry>Detailed description of improvement status of symptoms</entry><entry>By the application of 50 µg/g ANP gel-base preparation twice a day, edema was slightly reduced, but skin flush and erythema were not improved even after 7 days.</entry><entry>Despite the application of 50 µg/g ANP gel-base preparation twice a day for 7 days, redness did not disappear and erythema and scales worsened.</entry><entry>Despite the application of 50 µg/g ANP gel-base preparation twice a day, erythema and infiltration were not reduced at all even after 5 days.</entry><entry>Despite the application of 50 µg/g ANP gel-base preparation twice a day for 3 days, erythema and itching were not improved and edema even worsened.</entry><entry>Despite the application of 50 µg/g ANP gel-base preparation twice a day for 7 days, severe scales, erythema and numerous excoriations still remained just as the condition before application.</entry></row><row><entry morerows="1" rowsep="1" align="center">Itching sensation</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry><entry align="center">Before: 10</entry></row><row><entry align="center">After: 10</entry><entry align="center">After: 10</entry><entry align="center">After: 10</entry><entry align="center">After: 10</entry><entry align="center">After: 10</entry></row><row><entry align="center">Non-recurrence period</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry><entry align="center">-</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="156"> --></p><heading id="h0113"><b>Example 22</b></heading><p id="p0296" num="0296">For comparison, a test was performed using the ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18. For reference, as photographs before and after application, <figref idrefs="f0012">Fig. 16</figref> shows photographs of Comparative test example 2 (Case 2; subject 46), <figref idrefs="f0013">Fig. 17</figref> shows photographs of Comparative test example 3 (Case 3; subject 45), and <figref idrefs="f0014">Fig. 18</figref> shows photographs of Comparative test example 5 (Case 5; subject 48).</p><heading id="h0114"><u>Comparative test example 1 (Case 1; subject 49):</u></heading><p id="p0297" num="0297">The subject of Comparative case 1 presented with erythema with strong itching associated with sleep disturbance, severe scales and numerous excoriations over the whole body. In addition, the rash on the back was mainly characterized by severe scales, erythema and numerous excoriations, and the severity level based on the "Dermatological Association Guideline" was severe. The symptom evaluation of this subject based on the "Guideline 2005" was most severe, and the symptoms were reduced temporarily by steroid external therapy, but they relapsed immediately and the skin dried.</p><heading id="h0115"><u>Treatment and its outcome:</u></heading><p id="p0298" num="0298">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the back of the subject of Comparative case 1 twice a day for 7 days, but the severe scales, erythema and numerous excoriations remained unchanged compared to the condition before the application. The itching sensation level before<!-- EPO <DP n="157"> --> application was 10, and it was still 10 after application; the severity level remained severe after application.</p><heading id="h0116"><u>Comparative test example 2 (Case 2; subject 46):</u></heading><p id="p0299" num="0299">The subject of Comparative case 2 presented with infiltrative erythema with lichenification, erythema, and severe scales on the face and neck, and infiltrative erythema on the four limbs and body trunk. The rash on the face was mainly characterized by severe lichenified infiltration, erythema and scales, and the severity level based on the "Dermatological Association Guideline" was severe. The symptom evaluation of this subject based on the "Guideline 2005" was most severe, and sufficient effects of steroid external therapy were not observed for the infiltrative erythema on the face.</p><heading id="h0117"><u>Treatment and its outcome:</u></heading><p id="p0300" num="0300">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the face and neck of the subject of Comparative case 2 twice a day for 7 days, but redness did not disappear, and both erythema and scales worsened. <figref idrefs="f0012">Figure 16</figref> shows photographs before and after 5 days of application. A shows the state before application, and B shows the state after application. The itching sensation level before application was 10, and it was still 10 after application; the severity level remained severe after application.</p><heading id="h0118"><u>Comparative test example 3 (Case 3; subject 45):</u></heading><p id="p0301" num="0301">The subject of Comparative case 3 presented with skin flush with chills, edema, and infiltrative erythema on the<!-- EPO <DP n="158"> --> almost whole body. The rash on the face, neck, and four limbs consists of severe swelling, skin flush, and edema, and the severity level based on the "Dermatological Association Guideline" was severe. The symptom evaluation of this subject based on the "Guideline 2005" was most severe, and due to the side effects caused by a long period of steroid external therapy and its excessive application, the subject was in a state of erythroderma.</p><heading id="h0119"><u>Treatment and its outcome:</u></heading><p id="p0302" num="0302">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the face and upper limbs of the subject of Comparative case 3 twice a day, then edema was slightly reduced, but both skin flush and erythema was not improved even after 7 days of application. <figref idrefs="f0013">Figure 17</figref> shows photographs before and after 7 days of application. A shows the state before application, and B shows the state after application. The itching sensation level before application was 10, and it was still 10 after application; the severity level remained severe after application.</p><heading id="h0120"><u>Comparative test example 4 (Case 4; subject 47):</u></heading><p id="p0303" num="0303">The subject of Comparative case 4 presented with infiltrative erythema, erythema, severe scales, adhesion of crusts, and numerous excoriations over the whole body, and they are particularly severe on the face and neck. The rash on the face was mainly characterized by severe infiltration, edema, erythema, papules, scales, crusts and excoriations, and the severity level based on the "Dermatological Association Guideline" was severe. The<!-- EPO <DP n="159"> --> symptom evaluation of this subject based on the "Guideline 2005" was severe; and despite the use of steroids, symptoms on the face soon relapsed and they tended to worsen compared to those before the application.</p><heading id="h0121"><u>Treatment and its outcome:</u></heading><p id="p0304" num="0304">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the face of the subject of Comparative case 4 twice a day, but both erythema and infiltration was not reduced even after 5 days of application. The itching sensation level before application was 10, and it was still approximately 10 after application; the severity level remained severe after application.</p><heading id="h0122"><u>Comparative test example 5 (Case 5; subject 48):</u></heading><p id="p0305" num="0305">The subject of Comparative case 5 presented with infiltrative erythema, erythema, numerous excoriations and papules particularly on the back. The rash on the back consists of severe infiltration, erythema, numerous excoriations, papules and lichenification, and the severity level based on the "Dermatological Association Guideline" was severe. The symptom evaluation of this subject based on the "Guideline 2005" was severe, and sufficient effects were not observed by steroid external application, the symptoms relapsed soon, and strong itching was not reduced.</p><heading id="h0123"><u>Treatment and its outcome:</u></heading><p id="p0306" num="0306">The ANP gel-base preparation with a concentration of 50 µg/g obtained in Example 18 was applied to the back of the subject of Comparative case 5 twice a day, but no effect was observed for both erythema and itching after 3<!-- EPO <DP n="160"> --> days of application. <figref idrefs="f0014">Figure 18</figref> shows photographs before and after 5 days of application. A shows the state before application, and B shows the state after application. The itching sensation level before application was 10, and it was still 10 after application; the severity level remained severe after application.</p><heading id="h0124"><u>Summary of the comparative test examples:</u></heading><p id="p0307" num="0307">The above comparative case studies clarified the following.</p><p id="p0308" num="0308">According to the comparative tests using external preparations comprising ANP, the ANP external preparations with the same concentration as CNP or BNP exhibited marginal effects in a certain cases; however, onset of the effects required approximately 3 days of application, and erythema did not disappear completely; even when application was continued for 7 days or more, erythema did not disappear as in the cases of therapeutic agents for dermatitis comprising CNP or BNP, and erythema even worsened in some cases. Furthermore, when the external application was discontinued, symptoms soon relapsed and dryness increased, with enhanced itching. Apparently, these effects were inferior to those of the therapeutic agents for dermatitis comprising CNP or BNP. In many cases, ANP external preparations did not improve the conditions or even worsened the conditions, and improvement of the rash was, in terms of the severity level of the rash by the "Dermatological Association Guideline", from severe to severe, remaining at the same level. According to the severity level of local symptoms based on the globally used<!-- EPO <DP n="161"> --> "SCORAD index: Clinical Evaluation" including the items "Erythema", "Edema/papulation", "Oozing/crusting", "Excoriation" and "Lichenification", severity levels for "Edema/papulation" and "Oozing/crusting" were improved from stage 3 to stage 2 in some of the cases; however, those for "Excoriation," "Lichenification" and "Erythema" remained at the same level of stage 3.</p><p id="p0309" num="0309">In the first place, the goal of treatment of atopic dermatitis is to achieve the following conditions in patients.
<ol><li>(1) No symptoms; if any, minor symptoms without any problem in daily life, with a requirement of a low degree of drug therapy.</li><li>(2) While minor or mild symptoms persist, there is low possibility of acute worsening; even when the symptoms worsen, they will not persist for a long time.</li></ol></p><p id="p0310" num="0310">The above comparative case studies confirmed that the skin external preparation comprising ANP was unable to achieve these conditions in patients.</p><heading id="h0125"><u>Comprehensive summary of the effects of the invention:</u></heading><p id="p0311" num="0311">In order to confirm the effects of the skin external-preparation composition in overview, composite indices made by severity evaluation of rash regions based on SCORAD for each preparation were compared between before and after application, and the result of the comparison was expressed with a bar graph as shown in <figref idrefs="f0015">Fig. 19</figref>.</p><p id="p0312" num="0312">Severity levels of rash regions based on SCORAD compared between before and after application of the ANP<!-- EPO <DP n="162"> --> gel-base preparations as comparative test examples showed almost no difference. In contrast, when the skin external-preparation compositions comprising CNP or BNP were used, the severity level of rash regions based on SCORAD was dramatically improved after application.</p><p id="p0313" num="0313">Similarly, in order to confirm the effects of the skin external-preparation compositions in a panoramic manner, itching sensation evaluated using visual analogue scale method for each preparation were compared between before and after application, and the result of the comparison was expressed with a bar graph, as shown in <figref idrefs="f0016">Fig. 20</figref>.</p><p id="p0314" num="0314">There was no change in the itching sensation before and after application of the ANP gel-base preparations as comparative test examples. In contrast, when the skin external-preparation compositions comprising CNP or BNP were used, the itching sensation level was dramatically improved after application.</p><p id="p0315" num="0315">Thus, the results shown in <figref idrefs="f0015">Figs. 19</figref> and <figref idrefs="f0016">20</figref> demonstrated that the skin external-preparation compositions comprising CNP or BNP dramatically improved symptoms of atopic dermatitis.</p><heading id="h0126"><b>Industrial applicability</b></heading><p id="p0316" num="0316">The skin external-preparation compositions comprising CNP or BNP, in particular the therapeutic preparations for dermatitis, are extremely effective in the treatment of atopic dermatitis, which is recognized to have particularly-intractable nature. And the preparations are capable of<!-- EPO <DP n="163"> --> wide application. In addition, there is little concern of systemic side effects since CNP and BNP are originally intrinsic hormones, since the number of days of external application is only approximately 3 days, since an amount taken into the body through absorption from the skin upon being used as a topical medication is extremely small, and since a concentration used in the present invention is merely around 30 µg/g. The preparations dramatically reduce subjective itching sensation without causing local irritation symptoms. Hence, the preparations can be applied to patients in whom conventional steroids and tacrolimus were ineffective, as well as to patients and young subjects in whom steroids and tacrolimus cannot be used due to the concern of side effects. Moreover, the QOL of psoriasis patients who suffer from many scales can be improved.</p><p id="p0317" num="0317">Therefore, research and development as well as practical application as therapeutic preparations for use in treating dermatitis can be greatly expected.</p><p id="p0318" num="0318">Furthermore, the preparations improve texture of the skin, since the effects with the preparations of the present invention that "the texture of the skin surface becomes finer, scales decrease, and the skin become soft to the touch" is important in compensating for skin dryness and the deterioration of barrier functions as well as preventing recurrence of inflammation, and since the preparations of the present invention exert the effects regardless of dosage form.<!-- EPO <DP n="164"> --></p><p id="p0319" num="0319">Namely, effects of anti-inflammation, horny cell layer care, epidermis care, and basal membrane care are observed, and in terms of clinical effects, improvement of elasticity and wrinkles of the skin, and moisturizing the skin are observed.</p></description><claims mxw-id="PCLM56985155" lang="DE" load-source="patent-office"><!-- EPO <DP n="168"> --><claim id="c-de-01-0001" num="0001"><claim-text>Therapeutisches Präparat, umfassend 1 - 500 µg/g natriuretisches Peptid Typ C (CNP) oder natriuretisches Peptid Typ B (BNP) zur Verwendung bei der Behandlung von<br/>
Dermatitis, die eine Immunreaktion auf mindestens ein Allergen zeigt, das aus der Gruppe ausgewählt ist, die aus Hausstaub, Milben, Zedern, Knaulgras, Ambrosie, Eiweiß und Eidotter besteht,<br/>
atopischer Dermatitis,<br/>
Ekzemen,<br/>
Dermatitis, die zu Steroid-Dermatitis führte,<br/>
rosacea-artiger Dermatitis,<br/>
steroidresistenter Dermatitis,<br/>
Erythrodermie,<br/>
post-ekzematöser Erythrodermie,<br/>
Rosacea oder<br/>
irgendeiner der vorstehenden Dermatitiserscheinungen, auf die sich Tacrolimus nicht anwenden lässt.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Therapeutisches Präparat zur Verwendung nach Anspruch 1, wobei es sich bei dem natriuretischen Peptid Typ C (CNP) oder dem natriuretischen Peptid Typ B (BNP) um ein chimäres Peptid von CNP und BNP handelt, das durch eine intramolekulare Disulfidbindung eine Ringstruktur bildet,<br/>
worin CNP CNP-22, CNP-53 oder ein Peptid ist, das irgendeine Aminosäuresequenz mit 5 oder mehr aufeinander folgenden Aminosäuren in der Aminosäuresequenz von CNP-22 oder CNP-53 umfasst, die eine Deletion(en), Substitution(en) oder Addition(en) irgendeiner/irgendwelcher Aminosäure(n) aufweisen,<br/>
und worin BNP BNP-26, BNP-32, BNP-45 oder ein Peptid ist, das irgendeine Aminosäuresequenz mit 5 oder mehr aufeinander folgenden Aminosäuren in der Aminosäuresequenz von BNP-26, BNP-32 oder BNP-45 umfasst, die eine Deletion(en), Substitution(en) oder Addition(en) irgendeiner/irgendwelcher Aminosäure(n) aufweisen,<br/>
und wobei das chimäre Peptid eine CNP-Aktivität oder BNP-Aktivität aufweist;<br/>
oder es sich um ein Derivat des chimären Peptids handelt.<!-- EPO <DP n="169"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Therapeutisches Präparat zur Verwendung nach Anspruch 1 oder 2, wobei es sich bei dem natriuretischen Peptid Typ C (CNP) um CNP-22, CNP-53 oder ein CNP-Derivat handelt, bei dem irgendeine/irgendwelche Aminosäure(n) in der Aminosäuresequenz von CNP-22 oder CNP-53 deletiert, substituiert oder addiert ist/sind, und das CNP-Aktivität aufweist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Therapeutisches Präparat zur Verwendung nach Anspruch 1, wobei es sich bei dem natriuretischen Peptid Typ C (CNP) um CNP-22 handelt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Therapeutisches Präparat zur Verwendung nach Anspruch 1, wobei es sich bei dem natriuretischen Peptid Typ B (BNP) um BNP-26, BNP-32, BNP-45 oder ein BNP-Derivat handelt, bei dem irgendeine/irgendwelche Aminosäure(n) in der Aminosäuresequenz von BNP-26, BNP-32 oder BNP-45 deletiert, substituiert oder addiert ist/sind, und das BNP-Aktivität aufweist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Therapeutisches Präparat zur Verwendung nach Anspruch 1, wobei es sich bei dem natriuretischen Peptid Typ B (BNP) um BNP-32 handelt.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 6, umfassend 20 - 200 µg/g natriuretisches Peptid Typ C (CNP) oder natriuretisches Peptid Typ B (BNP).</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 7, umfassend 30 - 100 µg/g natriuretisches Peptid Typ C (CNP) oder natriuretisches Peptid Typ B (BNP).</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 8, das die Hauttextur verbessert.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 9, wobei es sich bei der Dermatitis um eine Entzündung handelt, die mit mindestens einem Ausschlagsymptom verbunden ist, das aus der Gruppe ausgewählt ist, die aus Erythem, infiltrativem Erythem, lichenifizierter Läsion, Schuppen, Krustenadhäsion,<!-- EPO <DP n="170"> --> Ekzemen, Abrasion, Exkoriation, Prurigo nodularis, Papeln, Erosionen, Infiltration, Vesikeln und Ödemen besteht.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 10, wobei es sich bei der Dermatitis um Dermatitis in mindestens einem Bereich handelt, der aus der Gruppe ausgewählt ist, die aus Gesicht, Hals, Rücken und Arm(en) besteht.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Therapeutisches Präparat zur Verwendung nach einem der Ansprüche 1 bis 11, wobei es sich bei der Verabreichungsform um ein äußerliches Präparat handelt, das aus der Gruppe ausgewählt ist, die aus einem Salbenpräparat, einem Gelpräparat, einem Cremepräparat, einem Lotionpräparat, einem Flüssigpräparat, einem Spraypräparat und einem Pflasterpräparat besteht.</claim-text></claim></claims><claims mxw-id="PCLM56985156" lang="EN" load-source="patent-office"><!-- EPO <DP n="165"> --><claim id="c-en-01-0001" num="0001"><claim-text>A therapeutic preparation comprising 1-500 µg/g C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) for use in the treatment of<br/>
dermatitis which shows an immune reaction to at least one allergen selected from the group consisting of house dust, mites, cedar, orchard grass, ragweed, egg white, and egg yolk,<br/>
atopic dermatitis,<br/>
eczema,<br/>
dermatitis that led up to steroid dermatitis,<br/>
rosacea-like dermatitis,<br/>
steroid-resistant dermatitis,<br/>
erythroderma,<br/>
erythroderma post-eczematosa,<br/>
rosacea or<br/>
any one of the foregoing dermatitises, to which tacrolimus is not applicable.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The therapeutic preparation for the use according to claim 1, wherein the C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) is a chimeric peptide of CNP and BNP forming a ring structure by an intramolecular disulfide bond,<br/>
in which CNP is CNP-22, CNP-53, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence of CNP-22 or CNP-53, having deletion(s), substitution(s), or addition(s) of any amino acid(s),<br/>
<!-- EPO <DP n="166"> -->and in which BNP is BNP-26, BNP-32, BNP-45, or a peptide comprising any amino acid sequence with 5 or more consecutive amino acids in the amino acid sequence of BNP-26, BNP-32 or BNP-45, having deletion(s), substitution(s), or addition(s) of any amino acid(s),<br/>
and wherein the chimeric peptide has CNP activity or BNP activity;<br/>
or a derivative of the chimeric peptide.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The therapeutic preparation for the use according to claim 1 or 2, wherein the C-type natriuretic peptide (CNP) is CNP-22, CNP-53, or a CNP derivative in which any amino acid(s) in the amino acid sequence of CNP-22 or CNP-53 is/are deleted, substituted or added, and which has CNP activity.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The therapeutic preparation for the use according to claim 1, wherein the C-type natriuretic peptide (CNP) is CNP-22.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The therapeutic preparation for the use according to claim 1, wherein the B-type natriuretic peptide (BNP) is BNP-26, BNP-32, BNP-45, or a BNP derivative in which any amino acid(s) in the amino acid sequence of BNP-26, BNP-32, or BNP-45 is/are deleted, substituted or added, and which has BNP activity.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The therapeutic preparation for the use according to claim 1, wherein the B-type natriuretic peptide (BNP) is BNP-32.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The therapeutic preparation for the use according to any one of claims 1-6 comprising 20-200 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The therapeutic preparation for the use according to any one of claims 1-7 comprising 30-100 µg/g of C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP).</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The therapeutic preparation for the use according to any one of claims 1-8, which improves skin texture.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The therapeutic preparation for the use according to any one of claims 1-9, wherein the dermatitis is an inflammation associated with at least one rash symptom selected from the group consisting of erythema, infiltrative<!-- EPO <DP n="167"> --> erythema, lichenified lesion, scales, adhesion of crusts, eczema, abrasion, excoriation, prurigo nodularis, papule, erosions, infiltration, vesicle, and edema.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The therapeutic preparation for the use according to any one of claims 1-10, wherein the dermatitis is dermatitis in at least one region selected from the group consisting of face, neck, back, and arm(s).</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The therapeutic preparation for the use according to any one of claims 1-11, wherein the dosage form is the external preparation selected from the group consisting of ointment preparation, gel preparation, cream preparation, lotion preparation, liquid preparation, spray preparation, and patch preparation.</claim-text></claim></claims><claims mxw-id="PCLM56985157" lang="FR" load-source="patent-office"><!-- EPO <DP n="171"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Préparation thérapeutique comprenant 1 à 500 µg/g de peptide natriurétique de type C (CNP) ou de peptide natriurétique de type B (BNP) à usage dans le traitement de<br/>
la dermatite présentant une réaction immune à au moins un allergène sélectionné dans le groupe constitué par la poussière domestique, les acariens, le cèdre, le dactyle, l'ambroisie, le blanc d'oeuf, et le jaune d'oeuf,<br/>
la dermatite atopique,<br/>
l'eczéma,<br/>
la dermatite engendrant la dermatite stéroïdienne,<br/>
la dermatite rosacéiforme,<br/>
la dermatite résistante aux stéroïdes,<br/>
l'érythrodermie,<br/>
l'érythrodermie post-eczématose,<br/>
la rosacée ou<br/>
l'une quelconque des dermatites précitées, auxquelles le tacrolimus n'est pas applicable.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>La préparation thérapeutique pour l'usage selon la revendication 1, dans laquelle le peptide natriurétique de type C (CNP) ou le peptide natriurétique de type B (BNP) est un peptide chimérique de CNP et de BNP formant une structure cyclique via une liaison disulfure intramoléculaire,<br/>
dans laquelle CNP est CNP-22, CNP-53, ou un peptide comprenant n'importe quelle séquence d'acides aminés ayant 5 ou plus acides aminés consécutifs dans la séquence d'acides aminés de CNP-22 ou CNP-53, présentant une (des) suppression(s), une (des) substitution(s), ou une (des) addition(s) de n'importe quel(s) acide(s) aminé(s),<br/>
et dans laquelle BNP est BNP-26, BNP-32, BNP-45, ou un peptide comprenant n'importe quelle séquence d'acides aminés ayant 5 ou plus acides aminés consécutifs dans la séquence d'acides aminés de BNP-26, BNP-32 ou BNP-45, présentant une (des) suppression(s), une (des) substitution(s), ou une (des) addition(s) de n'importe quel(s) acide(s) aminé(s),<br/>
et dans laquelle le peptide chimérique a une activité CNP ou une activité BNP ;<br/>
ou un dérivé du peptide chimérique.<!-- EPO <DP n="172"> --></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>La préparation thérapeutique pour l'usage selon la revendication 1 ou 2, dans laquelle le peptide natriurétique de type C (CNP) est CNP-22, CNP-53, ou un dérivé de CNP dans lequel n'importe quel(s) acide(s) aminé(s) dans la séquence d'acides aminés de CNP-22 ou CNP-53 est (sont) supprimé(s), substitué(s) ou ajouté(s), et qui a une activité CNP.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>La préparation thérapeutique pour l'usage selon la revendication 1, dans laquelle le peptide natriurétique de type C (CNP) est CNP-22.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>La préparation thérapeutique pour l'usage selon la revendication 1, dans laquelle le peptide natriurétique de type B (BNP) est BNP-26, BNP-32, BNP-45, ou un dérivé de BNP dans lequel n'importe quel(s) acide(s) aminé(s) dans la séquence d'acides aminés de BNP-26, BNP-32, ou BNP-45 est (sont) supprimé(s), substitué(s) ou ajouté(s), et qui a une activité BNP.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>La préparation thérapeutique pour l'usage selon la revendication 1, dans laquelle le peptide natriurétique de type B (BNP) est BNP-32.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 6, comprenant 20 à 200 µg/g de peptide natriurétique de type C (CNP) ou de peptide natriurétique de type B (BNP).</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 7, comprenant 30 à 100 µg/g de peptide natriurétique de type C (CNP) ou de peptide natriurétique de type B (BNP).</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 8, qui améliore le grain de la peau.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 9, dans laquelle la dermatite est une inflammation associée à au moins un symptôme d'éruption sélectionné dans le groupe constitué par l'érythème, l'érythème infiltratif, la lésion lichénifiée, les squames, l'adhésion de croûtes,<!-- EPO <DP n="173"> --> l'eczéma, l'abrasion, l'excoriation, le prurigo nodularis, la papule, les érosions, l'infiltration, la cloque, et l'oedème.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 10, dans laquelle la dermatite est une dermatite dans au moins une région sélectionnée dans le groupe constitué par le visage, le cou, le dos, et le(s) bras.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>La préparation thérapeutique pour l'usage selon l'une quelconque des revendications 1 à 11, dans laquelle la forme galénique est la préparation externe sélectionnée dans le groupe constitué par la préparation en onguent, la préparation en gel, la préparation en crème, la préparation en lotion, la préparation en liquide, la préparation en vaporisant, et la préparation en pansement.</claim-text></claim></claims><drawings mxw-id="PDW16672076" load-source="patent-office"><!-- EPO <DP n="174"> --><figure id="f0001" num="1A,1B,1C,1D"><img id="if0001" file="imgf0001.tif" wi="159" he="223" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="175"> --><figure id="f0002" num="2A,2B,3A,3B"><img id="if0002" file="imgf0002.tif" wi="165" he="218" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="176"> --><figure id="f0003" num="4A,4B"><img id="if0003" file="imgf0003.tif" wi="165" he="161" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="177"> --><figure id="f0004" num="5A,5B"><img id="if0004" file="imgf0004.tif" wi="165" he="116" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="178"> --><figure id="f0005" num="6A,6B,7A,7B"><img id="if0005" file="imgf0005.tif" wi="165" he="219" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="179"> --><figure id="f0006" num="8A,8B,9A,9B"><img id="if0006" file="imgf0006.tif" wi="165" he="158" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="180"> --><figure id="f0007" num="10A,10B,11A,11B"><img id="if0007" file="imgf0007.tif" wi="165" he="203" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="181"> --><figure id="f0008" num="12A,12B"><img id="if0008" file="imgf0008.tif" wi="162" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="182"> --><figure id="f0009" num="13A,13B"><img id="if0009" file="imgf0009.tif" wi="165" he="193" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="183"> --><figure id="f0010" num="14A,14B"><img id="if0010" file="imgf0010.tif" wi="124" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="184"> --><figure id="f0011" num="15A,15B"><img id="if0011" file="imgf0011.tif" wi="110" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="185"> --><figure id="f0012" num="16A,16B"><img id="if0012" file="imgf0012.tif" wi="110" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="186"> --><figure id="f0013" num="17A,17B"><img id="if0013" file="imgf0013.tif" wi="110" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="187"> --><figure id="f0014" num="18A,18B"><img id="if0014" file="imgf0014.tif" wi="103" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="188"> --><figure id="f0015" num="19"><img id="if0015" file="imgf0015.tif" wi="143" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="189"> --><figure id="f0016" num="20"><img id="if0016" file="imgf0016.tif" wi="139" he="233" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
